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ABSTRACT 
Background  
Huntington’s disease (HD) is a chronic neurodegenerative disorder characterised by a 
progressive loss of cognitive function, motor control and psychiatric features. Individuals 
also display a variety of systemic features. Progressive neuronal dysfunction and neuronal 
cell death are thought to underlie the onset and progression of many clinical features of HD.  
Despite scientific progress, there is still no cure or disease modifying therapy for HD, and 
available pharmaceutical agents only provide partial relief of motor and psychiatric features. 
An emerging body of evidence indicates that lifestyle enrichment may delay the onset and 
progression of clinical features, and exert favourable effects on neuropathological aspects of 
HD. Few studies have evaluated the effects of lifestyle enrichment strategies like 
multidisciplinary rehabilitation on the clinical features of HD. Moreover, no study has 
evaluated the effects of multidisciplinary rehabilitation on neuropathological aspects of HD. 
Aims 
The initial aim of this thesis was to determine factors that contribute to features of the disease 
that negatively impact on activities of daily living such as mobility and balance (Chapter 2), 
and to identify, using a literature review, a rehabilitation strategy that could positively impact 
on these features of HD (Chapter 3).  These studies informed our ultimate aim which was to 
investigate the clinical utility of multidisciplinary rehabilitation on clinical and 
neuropathological features of HD (Chapters 4, 5 and 6) 
Methods 
In study 1 (Chapter 2), 22 participants were assessed using a battery of balance, mobility, 
cognitive tests, assessments of muscle strength and body composition measures. Data was 
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then statistically examined using stepwise linear regression to identify factors that contribute 
to balance and mobility impairments in individuals with manifest HD. In study 2 (Chapter 3), 
a systematic search of journal databases was made from inception to July 2014 for studies 
reporting on resistance exercise in patients with neurodegenerative disorders. Selected studies 
were abstracted and critically appraised using a quality control checklist.  
For the intervention studies, (3 and 4 Chapters 4 and 5), 20 participants with manifest HD 
were randomly assigned to either a control or training group. Individuals randomised to the 
intervention group were provided with a nine month multidisciplinary intervention 
comprising once weekly supervised clinical exercise, thrice weekly home based exercise and 
fortnightly occupational therapy, while those randomised to the control group were asked to 
continue with their standard care and daily activities. Participants were assessed using motor, 
cognitive, psychological, body composition and quality of life measures at baseline and at the 
completion of the intervention. In study 5 (Chapter 6), 15 participants with manifest HD were  
assessed using magnetic resonance imaging and a battery of cognitive assessments after nine 
months of multidisciplinary rehabilitation to see whether such a therapy is capable of 
inducing favourable changes in brain structure and cognitive function. 
Results 
The main factors that contribute to mobility and balance impairments in patients with 
manifest HD were found to be lower limb muscle weakness and a loss of cognitive function 
(Study 1). Systematic evaluation of the effects of resistance exercise for neurodegenerative 
disorders showed that it is beneficial for multiple sclerosis and Parkinson’s disease. In 
particular, improvements in muscle strength, mobility, balance, clinical disease progression, 
fatigue, functional capacity, quality of life, disease biology, electromyography activity, mood, 
skeletal muscle volume and architecture were reported in individuals with multiple sclerosis 
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or Parkinson’s disease (PD) after resistance exercise. The most robust effects of resistance 
exercise were found for muscle strength outcomes, and were more pronounced in individuals 
with PD (Study 2). 
The multidisciplinary rehabilitation intervention studies conducted as part of this thesis 
significantly improved isometric and isokinetic muscle strength, self-perceived balance, body 
mass, lean tissue mass and fat mass in patients with HD (Studies 3 and 4).  Moreover, 
multidisciplinary rehabilitation also increased grey matter (GM) volume in the caudate 
nucleus and dorsolateral prefrontal cortex of patients. The significant increases in GM 
volume were accompanied by, and correlated to, a significant improvement in performance in 
verbal learning and memory.  
Conclusions 
The work presented here shows that lower extremity muscle weakness and a loss of cognitive 
function significantly contribute to impairments in mobility and balance. This work also 
shows that strength training has favourable effects on motor function, including strength, 
mobility and balance, as well as other clinical features in similar neurodegenerative disorders, 
and thus should be integrated into multidisciplinary rehabilitation interventions for HD. In 
addition, this study provides evidence that multidisciplinary rehabilitation can significantly 
improve aspects of motor control, cognitive function and body composition. Finally we show, 
for the first time, that multidisciplinary rehabilitation can increase GM volume in structures 
known to degenerate in HD, and that such increases are functionally related to changes in 
verbal learning and memory. Future work is urgently required to confirm and expand on 
these exciting findings, particularly with respect to the neurorestorative properties of 
multidisciplinary rehabilitation. 
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CHAPTER 1 -  GENERAL INTRODUCTION 
1.1 HISTORY OF HD 
Huntington’s disease (HD), formerly known as ‘Huntington’s 
chorea’, was first comprehensively described by George 
Sumner Huntington in his self-titled publication ‘On Chorea’ 
in 1872 (Figure 1.1) (Huntington, 1872). This landmark 
publication vividly described the autosomal dominant 
inheritance, adult-onset and central features of HD. 
Huntington’s description laid the foundation for future 
genetic investigations, which over a century later mapped the 
Huntington gene (HTT) to chromosome 4 (Gusella et al., 1983). The ensuing decade led to 
the isolation of the HTT gene (4p16.3) and identification of the expanded cytosine-adenine-
guanine (CAG) sequence responsible for HD (MacDonald et al., 1993). In the years that 
followed, many scientific advances were made, including the genetic engineering of 
transgenic HD mice (Carter et al., 1999; Mangiarini et al., 1996). These mouse models have, 
over the last two decades, enabled the investigation of pathological mechanisms involved in 
HD, as well as genetic manipulation and pharmacological/molecular interventions.  
1.2 EPIDEMIOLOGY OF HD 
The exact worldwide prevalence of HD is unknown, however recent estimates suggest a 
prevalence of 5-8 per 100,000 (Kumar et al., 2010). Countries of European ancestry display a 
higher prevalence of HD (3-10 per 100,000) than countries of non-European ancestry (0.11-
0.45 per 100,000) (Gatto et al., 2014). Recent figures indicate that the prevalence of HD is 
12.3 per 100,000 in the United Kingdom (Evans et al., 2013) and 7 per 100,000 in Australia 
(Harper, 1992; Pridmore, 1990). By contrast, the prevalence of HD within Asia is a mere 0.4 
Figure 1.1 George Huntington 
(1850-1916) 
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per 100,000 (Pringsheim et al., 2012). “Demographic hot spots”, have also been identified, 
such as the Zulia region of Venezuela, where the prevalence of HD is extraordinarily high 
(~50%), owing to a founder effect (Wexler, 2004).  
1.3 CLINICAL VARIANTS OF HD 
Individuals carrying the mutant HTT gene typically present during midlife (4
th
 to 6
th
 decades 
of life) (Tabrizi et al., 2009; 2012; 2011a; 2013), however early and late age of onset variants 
are also well documented (Foroud et al., 1999; James et al., 1994; Lipe and Bird, 2009; 
Mahant et al., 2003; Robertson et al., 2012; Roos et al., 1993). Early onset HD,  termed 
Juvenile HD (JHD) accounts for 4.92% of all HD cases worldwide (Quarrell et al., 2012). 
Often arising through paternal transmission (Merritt et al., 1969), JHD cases typically carry 
60 or more CAG repeats and present before 21 years of age (Cloud et al., 2012; Douglas et 
al., 2013; Quarrell et al., 2013). Typical features of JHD include a progressive rigid-ataxic 
like phenotype, cerebellar signs, chorea, speech and language problems, oropharyngeal 
problems, epilepsy, seizures (tonic-clonic and myoclonic), depression, aggression, weight 
loss and cachexia (Barker and Squitieri, 2009; Cannella et al., 2004; Cloud et al., 2012; 
Gonzalez-Alegre and Afifi, 2006; Nance and Myers, 2001; Quarrell et al., 2013; Ribaï et al., 
2007; Yoon et al., 2006). Late onset HD, in stark contrast to JHD, is characterised by mild 
chorea and more globalised dementia (not too dissimilar to Alzheimer’s disease) (Aziz et al., 
2008; Foroud et al., 1999; James et al., 1994; Lipe and Bird, 2009; Mahant et al., 2003; Roos 
et al., 1993). Interestingly, in late onset HD, individuals typically succumb to age-related 
diseases like cancer, cardiovascular disease and Alzheimer’s disease rather than the disease-
related processes of HD (Bürger et al., 2002; Lipe and Bird, 2009). 
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1.4 HUNTINGTON GENE 
The gene responsible for HD, IT15 (‘interesting transcript’) or HTT, was located on the short 
arm (p) of chromosome 4 by Gusella and colleagues in 1983. Over the next ten years, a 
dedicated group of scientists exhaustively investigated chromosome 4 using emerging gene-
mapping and genomic technology, which in 1993 led to the isolation of HTT (4p16.3) and 
discovery of the mutation responsible for HD. The causative mutation is an expanded 
cytosine-adenine-guanine (CAG) repeat sequence in exon 1 of HTT. Under normal 
circumstances healthy individuals possess between 6 and 35 CAG repeats. While individuals 
with HD typically possess in excess of 39 CAG repeats. Although rare, individuals that 
possess between 36 and 39 CAG repeats are said to have incomplete penetrance, and may 
develop HD at some stage in their lifetime (MacDonald et al., 1993).  
1.5 INTRICATE ROLE OF THE CAG REPEAT 
Robust evidence shows that the length of the expanded CAG sequence is strongly correlated 
with age at onset (Andrew et al., 1993; Claes et al., 1995; Duyao et al., 1993; MacDonald et 
al., 1993; MacMillan et al., 1993; Nørremølle et al., 1993; Snell et al., 1993; Zühlke et al., 
1993).  The length of the CAG expansion is estimated to account for 47% to 72% of the 
variance in age at onset (Brinkman et al., 1997; Craufurd and Dodge, 1993; Ranen et al., 
1995; Rosenblatt et al., 2001; Squitieri et al., 2000). The remainder of the variance in age at 
onset is influenced by environmental and additional genetic factors. In line with this, Wexler 
et al (2004) found that environmental factors accounted for 62% of the remaining variance in 
age at onset in four hundred and fifty eight individuals with HD. Interestingly, Kremer et al 
(1993) has shown that the length of the CAG expansion only accounts for 7% of variation in 
the age of onset of individuals beyond fifty years of age. This indicates that the effect of the 
CAG repeat length on age of onset may diminish with increasing age. 
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1.6 HUNTINGTIN PROTEIN STRUCTURE 
Huntingtin (Htt) is an extremely large protein comprising 3114 amino acids (Johnson and 
Davidson, 2010). The high molecular mass of Htt (348-kDa) has hampered the full 
elucidation of its structure (Zuccato et al., 2010). Structural domains of Htt have nevertheless 
been identified and described in detail. The most recognisable structure within Htt is the 
polyglutamine stretch (PolyQ), which commences at the 18
th
 amino acid (Perutz et al 1994; 
Huntington’s Disease Collaborative Research Group). Immediately following the PolyQ is a 
polyproline domain (PolyP), which is believed to stabilise the PolyQ (Darnell et al., 2007; 
Kim et al., 2009; Steffan et al., 2004). Downstream of the PolyQ and PolyP regions, 16 
Huntingtin, Elongation Factor 3, PR65/A subunit of protein phosphatase 2A and TOR1 the 
target of rapamycin (HEAT) repeat sequences have been identified (Andrade and Bork, 1995; 
Neuwald and Hirano, 2000; Takano and Gusella, 2002). The precise role of these HEAT 
repeat sequences still remains unclear, however increasing evidence indicates an involvement 
in protein-protein interactions (Medicine, 2013; Takano and Gusella, 2002). Htt also 
possesses well-characterised cleavage sites, where proteolytic enzymes such as caspases, 
calpains and aspartyl proteases cleave Htt into smaller fragments (Kim et al., 2001; Zuccato 
et al., 2010). An active nuclear export signal and a less active nuclear localisation signal have 
also been found on Htt, which indicates that Htt may also be involved in the transport of 
molecules from the nucleus to the cytoplasm (Desmond et al., 2013; Xia et al., 2003).  Many 
post-translational modification sites are also present on the Htt protein, particularly in 
polypeptide sequences enriched in proline, glutamate, serine and threonine (PEST domains) 
(Warby et al., 2008), where ubiquitination (Bhat et al., 2014), phosphorylation (Aiken et al., 
2009; Humbert et al., 2002; Khoshnan et al., 2004; Rangone et al., 2004; Schilling et al., 
2006), SUMOylation (Steffan et al., 2004), palmitoylation (Yanai et al., 2006) and 
acetylation (Jeong et al., 2009) of Htt can take place. The exact role of these post-
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translational modifications is not yet clear, however they have been postulated to modulate 
protein-protein interactions as well as influence the stability and localisation of Htt (Bates et 
al., 2014).  
(Q)n indicates the polyglutamine tract, which is followed by the polyproline sequence (P)n; 
the red emptied rectangles indicate the three main HEAT repeats (HEAT group 1, 2, 3). The 
small green rectangles indicate the caspase cleavage sites and their amino acid positions, 
while the small pink triangles indicate the calpain cleavage sites and their amino acid 
positions. Boxes in yellow: B, regions cleaved preferentially in the cerebral cortex; C, regions 
of the protein cleaved mainly in the striatum; A, regions cleaved in both. Posttranslational 
modifications: ubiquitination (UBI) and/or sumoylation (SUMO) sites (green); palmitoylation 
site (orange); phosphorylation at serines 13, 16, 421 and 434 (blue); acetylation at lysine 444 
(yellow). NES is the nuclear export signal while NLS is the nuclear localisation signal. The 
nuclear pore protein translocated promoter region (TPR, azure) is necessary for nuclear 
export. Htt huntingtin. ER, endoplasmic reticulum (Image from Zuccato et al 2010).  
 
 
Figure 1.2 Schematic diagram of the Huntingtin (Htt) amino acid sequence 
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1.7 HUNTINGTIN PROTEIN EXPRESSION 
Htt is ubiquitously expressed throughout neuronal and non-neuronal tissues (Landwehrmeyer 
et al., 1995; Vonsattel and DiFiglia, 1998), with the greatest enrichment in the central 
nervous system and testes (Sapp et al., 1997; Sharp et al., 1995; Wood et al., 1996). Modest 
expression of Htt is also evident in the lungs, heart, kidneys, liver and muscle (Sharp et al., 
1995; Wood et al., 1996). In the cell, Htt co-localises with most organelles, including the 
nucleus, mitochondria, endoplasmic reticulum and golgi apparatus (Atwal and Truant, 2008; 
Choo et al., 2004; DiFiglia et al., 1995; Gutekunst et al., 1998; Milakovic and Johnson, 2005; 
Panov et al., 2002; Velier et al., 1998). Studies using immunolabeling and 
immunoprecipitation have also shown that Htt associates with vesicle membranes and 
microtubules (DiFiglia et al., 1995; Gutekunst et al., 1995; Sharp et al., 1995). Its ubiquitous 
expression and numerous interactions with cellular organelles suggest that Htt is vital for 
normal molecular and cellular function. 
1.8 HUNTINGTIN PROTEIN FUNCTION  
The biological role of Htt is not well understood. Studies in transgenic animal models and 
cell lines have however provided insights into the molecular and cellular roles of Htt.  Early 
investigations in mice showed that constitutive inactivation of Htt causes embryonic lethality 
between embryonic day 8.5 and 10.5 (Duyao et al., 1995; Nasir et al., 1995). Experimental 
reduction of Htt below 50% of resting levels has been shown to cause epiblast defects as well 
as profound cortical and striatal architectural anomalies (Auerbach et al., 2001; White et al., 
1997). These studies clearly implicate wild-type Htt involvement in the formation of the 
central nervous system.  
In vitro and in vivo studies indicate that Htt is also involved in antiapoptotic activities (Ho et 
al., 2001; Leavitt et al., 2006; Sardo et al., 2012). Elegant work by Rigamonti et al (2001; 
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2001) has shown that striatal cells overexpressing wild-type Htt are resistant to lethal 
biological stresses, such as serum deprivation and 3-nitropropionic acid. However depleting 
wild-type Htt using short inhibitory RNA compounds has been found to increase the 
vulnerability of cells to apoptotic events (Zhang et al., 2006). 
Studies in animal models and cell lines have also shown that wild-type Htt stimulates the 
production of brain derived neurotrophic factor (BDNF) by activating BDNF promoter II 
(Benn et al., 2008; Zuccato et al., 2001). BDNF has known roles in synaptogenesis and 
neurogenesis, and is highly expressed in corticostriatal structures, which degenerate in HD. 
These findings indicate that wild-type Htt may mediate the transcription of neuronal genes 
involved in maintaining neuronal homeostasis (Zuccato and Cattaneo, 2007).  
A number of studies also implicate wild-type Htt involvement in axonal and vesicle transport 
(Gunawardena et al., 2003).  Experimentally lowering wild-type Htt to 50% of resting levels 
has been documented to impair fast axonal trafficking of mitochondria as well as BDNF 
transport in mammalian neurons (Gauthier et al., 2004; Trushina et al., 2004).  
Finally, wild-type Htt has been reported to interact with cytoskeletal and synaptic vesicle 
proteins involved in exocytosis and endocytosis, implicating its involvement in synaptic 
activity (Smith et al., 2005). Early investigations showed that wild-type Htt binds to the SH3 
domains of postsynaptic density protein 95 (PSD95) (Sun et al., 2001). PSD95 is a 
multivalent scaffolding protein that colocalises with N-methyl-D-aspartate (NMDA) 
receptors at the postsynaptic density and controls synaptic transmission (Sun et al., 2001). A 
decreased interaction between wild-type Htt and PSD95 leads to an increased interaction 
between PSD95 and NMDA receptors causing an over activation and sensitisation of NMDA 
receptors promoting excitotoxicity (Fan et al., 2009).  
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These findings collectively indicate that a loss of wild-type Htt function at least in part 
contributes to the molecular and cellular pathology witnessed in HD. 
1.9 PATHOLOGICAL MECHANISMS INVOLVED IN HD 
Studies investigating wild-type Htt have shown that it interacts with many proteins involved 
in transcription, synaptic transmission, energy metabolism and protein degradation. Thus a 
loss of wild-type Htt and toxic gain in mutant Htt results in wide scale molecular and cellular 
dysfunction. 
1.9.1 Transcriptional dysregulation in HD  
Transcription anomalies maybe one of the earliest  pathological events in HD (Cha, 2007). In 
situ hybridisation experiments on the post-mortem human HD brain have documented 
decreased expression of preproenkephalin, substance P, dopamine receptors D1 and D2, 
glutamate transporter 1 (GLT-1) and NMDA subunits NR1 and NR2B messenger RNA 
(mRNA) (Arzberger et al., 1997; Augood et al., 1997; Augood et al., 1996). Similar findings 
have also been reported in the R6/2 mouse model (Cha et al., 1999; Cha et al., 1998). A 
number of mechanisms have been proposed through which mutant Htt may disrupt 
transcription regulation (Cha, 2007; Luthi-Carter and Cha, 2003). For instance, mutant Htt 
may perturb the interaction between transcription factors (e.g. Sp1) (Schaffar et al., 2004), 
their transcriptional coactivators (Zhai et al., 2005) and target DNA thereby reducing the 
expression of many important target genes. Mutant Htt may also aberrantly interact with the 
core transcription machinery, such as RNA polymerase II, Transcription Factor II F, 
Transcription Factor II D, TATA-Associated Factor II130 and TATA binding protein, causing 
transcriptional dysregulation (Dunah et al., 2002; Luthi-Carter et al., 2002b; Shimohata et al., 
2000; Zhai et al., 2005).  
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1.9.2 Altered synaptic activity in HD 
Alterations in synaptic activity are well documented and may be responsible for many of the 
clinical features of HD (Gil and Rego, 2008; Milnerwood and Raymond, 2010; Raymond et 
al., 2011; Sepers and Raymond, 2014; Smith et al., 2005). Mutant Htt interacts with a variety 
of cytoskeletal and synaptic vesicle proteins involved in synaptic function (Caviston and 
Holzbaur, 2009; Dominguez and Munoz-Sanjuan, 2014; Li et al., 2003; Qin et al., 2004). 
leading to synaptopathology (Li et al., 2003; Smith et al., 2005).  
Studies in mouse models and postmortem HD brain tissue have reported changes in 
neurotransmitter release, uptake and postsynaptic signalling in corticostriatal pathways 
(Sepers and Raymond, 2014). In particular, elevated glutamate release is evident in early HD, 
followed by a decrease in glutamate release later in HD (Joshi et al., 2009; Miller and 
Bezprozvanny, 2010).  
1.9.3 Impaired energy metabolism in HD 
Impairments in energy metabolism are considered central to the pathogenesis of HD (Aziz et 
al., 2010b). Disruptions in cell metabolism have been reported in central and peripheral 
tissues in human and rodent models of HD (Aziz et al., 2010b; Underwood et al., 2006). 
Investigations using positron emission tomography (PET) have reported decreased glucose 
metabolism in striatal structures in people with manifest HD (Antonini et al., 1996; Kuwert et 
al., 1990; Underwood et al., 2006; Young et al., 1986). There is also evidence of increased 
lactate levels in the cerebral cortex and an elevated lactate-to-pyruvate ratio in the 
cerebrospinal fluid of both manifest and pre-manifest HD patients (Jenkins et al., 1998; 
Jenkins et al., 1993; Koroshetz et al., 1997). Decreased adenosine triphosphate (ATP) levels 
have additionally been observed in the brain and muscle (Ciarmiello et al., 2006; Cross et al., 
1986; Miller and Bezprozvanny, 2010).  
10 
 
Accumulating evidence suggests that mitochondrial dysregulation mediates many of the 
outlined deficits in energy metabolism. For example, impairments in electron transport chain 
(ETC) complexes I, II and III have been reported in HD (Browne et al., 1997; Gu et al., 1996; 
Parker et al., 1990; Stahl and Swanson, 1974). Impaired ETC activity has been found to 
correlate with reduced ATP synthesis and an increase in reactive oxygen species (ROS) in 
HD (Chakraborty et al., 2014; Tabrizi et al., 1999). Impeded axonal transport of mitochondria 
to cellular sites with high energy demands, like neurons, synapses and muscles has also been 
reported (Reddy and Shirendeb, 2012; Shirendeb et al., 2011). Mutant Htt has also been 
found to decrease the expression of peroxisome proliferator-activated receptor-γ (PPAR- γ) 
coactivator-1α (PGC-1α) through cAMP response element-binding protein-dependent 
transcriptional inhibition (Cui et al., 2006). Down-regulation of PGC-1α decreases 
mitochondrial energy metabolism by impairing oxidative phosphorylation (Lin et al., 2005).   
1.9.4 Impaired protein degradation pathways in HD 
Strong evidence indicates that protein degradation pathways are also impaired in HD (Gu et 
al., 1996). Protein degradation pathways are essential for removing dysfunctional and 
damaged proteins, ensuring cellular homeostasis (Labbadia and Morimoto, 2013). Two 
pathways responsible for degrading mutant Htt include the ubiquitin-proteasome system 
(UPS) and autophagy-lysosome pathway (Rubinsztein, 2006). Briefly, the UPS degrades 
short-lived misfolded, oxidized and mutant proteins (Young et al., 1986). In contrast, the 
autophagy-lysosome pathways degrade dysfunctional or damaged cytosolic proteins in 
lysosomes (Jenkins et al., 1993).  
In HD, an accumulation of ubiquitinated mutant Htt  fragments is observed within cells, 
particularly neurons, indicating an impairment in the UPS (Ciarmiello et al., 2006; Jenkins et 
al., 1998). The inability of the UPS to degrade mutant Htt has been proposed to stem from its 
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inability to unfold the stabile β–sheet structure formed by the poly-Q stretch. These 
observations suggest that autophagy degradation pathways may be preferentially used to 
degrade mutant Htt. Like the UPS, autophagy degradation pathways appear impaired in HD 
(Koroshetz et al., 1997). Elegant work by Maria Cuervo’s group has shown that mutant Htt 
impairs the recognition of cytosolic cargo not enabling the degradation of dysfunctional or 
damaged proteins (Martinez-Vicente et al., 2010). Deficient autophagy degradation pathways 
do not enable the recycling of important organelles, like mitochondria, which accumulate in 
cells in HD, facilitating homeostatic distress and proteasome destabilisation (Martinez-
Vicente et al., 2010). 
1.10 NATURAL HISTORY AND DIAGNOSIS OF HD 
The clinical course of HD is incredibly complex but can be simplistically divided into three 
disease stages; asymptomatic, premanifest and manifest HD. Asymptomatic or ‘at risk’ 
terminology is used to describe individuals with an affected parent, who have not undergone 
genetic testing and do not display clinical features of HD. Genetic testing is available to 
individuals at risk of inheriting HD from eighteen years of age, however the uptake of genetic 
testing services remains low worldwide. Individuals that undertake genetic testing and are 
identified as gene positive, but do not possess clinical features by which to make a formal 
diagnosis of HD, are typically termed premanifest. The premanifest disease stage typically 
spans 15-20 years, during which time an individual transitions from completely 
asymptomatic to displaying subtle motor, cognitive and psychological signs. The Unified 
Huntington’s Disease Rating Scale (UHDRS) is currently the preferred clinical tool for 
assessing the onset of HD (Hungtington, 1996). While the scale comprises cognitive, 
behavioural, emotional and functional components, formal diagnosis rests on the presence of 
unmistakable motor features. In particular, clinicians are required to provide a ‘diagnostic 
confidence score’, indicating their level of certainty that any observed motor signs are 
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representative of HD (0-4; where 0 indicates no motor abnormalities suggestive of HD and 4 
indicates motor abnormalities likely to be due to HD with ≥ 99% certainty). Gene positive 
individuals with a score of 4 are said to display manifest HD. This period is marked by the 
presentation and gradual worsening of clinical features, which over time renders the affected 
individual functionally impaired and eventually results in death (Bates et al., 2014; Tabrizi et 
al., 2009; Tabrizi et al., 2012; Tabrizi et al., 2011a; Tabrizi et al., 2013).  
1.11 NEURODEGENERATION IN HD 
1.11.1 Neurodegeneration in HD 
Neuronal cell loss is a pathological hallmark of HD (Georgiou-Karistianis et al., 2013c; Kim 
et al., 2014; Ross et al., 2014; Thu et al., 2010). Studies on the post-mortem HD brain and 
more recent in vivo neuroimaging investigations reveal a striking degeneration of cortical and 
subcortical structures over time in HD (Aylward et al., 2011; Georgiou-Karistianis et al., 
2013a; Guo et al., 2012; Hobbs et al., 2010; Kim et al., 2014; Majid et al., 2011; Nana et al., 
2014; Ross et al., 2014; Tabrizi et al., 2012; Tabrizi et al., 2011a; Tabrizi et al., 2013; Thu et 
al., 2010; Vonsattel et al., 1985). Morphometric investigations of the post-mortem HD human 
brain (n=385) have documented significant whole brain atrophy (mean HD brain weight 
1067g  vs  mean healthy brain weight 1350g) and regional atrophy within the striatum, 
frontal, temporal, parietal and occipital lobes as well as an enlargement of the lateral ventricle 
(Suzanne et al., 1988; Vonsattel et al., 1985; Vonsattel, 2008; Vonsattel and DiFiglia, 1998). 
These macroscopic findings have now been robustly confirmed in vivo using a variety of 
neuroimaging approaches (Aylward et al., 2000; Ginestroni et al., 2010; Harris et al., 1992; 
Peinemann et al., 2005; Ruocco et al., 2006; Tabrizi et al., 2012; Tabrizi et al., 2011a; Tabrizi 
et al., 2013; Vandenberghe et al., 2009) 
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 1.11.2 Striatal degeneration in HD 
Strikingly selective striatal atrophy is evident in HD (Aylward et al., 1997; Ross et al., 2014; 
Suzanne et al., 1988; Tabrizi et al., 2009; Tabrizi et al., 2012; Tabrizi et al., 2011a; Tabrizi et 
al., 2013; Vonsattel, 2008; Vonsattel and DiFiglia, 1998). Striatal degeneration typically 
follows an ordered and topographic pattern over the natural course of the disease (Vonsattel, 
2008; Vonsattel and DiFiglia, 1998). Degeneration typically begins in the tail and body of the 
caudate nucleus and progresses over time in caudorostral, dorsoventral and mediolateral 
directions encompassing the putamen and globus pallidus (Vonsattel, 2008; Vonsattel and 
DiFiglia, 1998). Annual volume losses of 2.9 to 4.9% and 4.5% in the caudate nucleus and 
putamen of individuals with manifest HD are observed in vivo (Aylward et al., 2011; Tabrizi 
et al., 2011a). The most vulnerable neuronal populations within the striatum are GABAergic 
medium spiny neurons, which constitute 90-95% of striatal neurons (Graveland et al., 1985). 
Perplexingly, less common striatal interneurons (5-10%) appear to be relatively spared in HD 
(Albin et al., 1992; Ferrante et al., 1985; 1991; 1987; Reiner et al., 1988; Richfield et al., 
1995). Differences in the neurochemical properties of each neuronal population are thought 
to account for the discrepancy in neuronal vulnerability (Cicchetti et al., 2000).  
The medium spiny neurons of the striatum are involved in direct and indirect striatal 
pathways that modulate motor control through attenuating and facilitating movement 
(Calabresi et al., 2014; Gerfen and Surmeier, 2011). The indirect striatal pathway comprises 
medium spiny neurons that predominantly express dopamine receptor 2 and project to the 
external segment of the globus pallidus (Gerfen and Surmeier, 2011; Gerfen and Wilson, 
1996). In contrast, the direct striatal pathway comprises medium spiny neurons that express 
dopamine receptor 1, dynorphin and substance P and project to the globus pallidus interna 
and substantia nigra reticulata (Gerfen and Surmeier, 2011; Gerfen and Wilson, 1996). 
Disruption of these pathways contributes to the onset and progression of hyperkinetic and 
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dyskinetic movements in HD. Studies investigating the indirect striatal pathway have found 
that a loss of medium spiny neurons coincides with the onset and progression of 
choreoathetoid features (Bates et al., 2014). By contrast, a preferential loss of medium spiny 
neurons in the direct striatal pathway has been shown to be associated with the onset and 
progression of parkinsonism features (André et al., 2011; Galvan et al., 2012).  
1.11.3 Extrastriatal degeneration in HD 
It is becoming increasing clear that extra-striatal structures are also susceptible to the 
neurodegenerative processes involved in HD (Douaud et al., 2006; Forno and Jose, 1973; 
Heinsen et al., 1999; Kassubek et al., 2004; Kremer, 1992; Kremer et al., 1991; Kremer et al., 
1990; Lange et al., 1976; Mühlau et al., 2007; Roizin et al., 1979; Rüb et al., 2013; Suzanne 
et al., 1988; Tellez-Nagel et al., 1974; van den Bogaard et al., 2011). Pathological studies 
have reported significant cortical volume loss in frontal, temporal, parietal and occipital lobes 
of the post-mortem HD human brain  (Halliday et al., 1998). Widespread cortical volume loss 
has also been documented in vivo using MRI (Jernigan et al., 1991; Nopoulos et al., 2011; 
Rosas et al., 2005; Rosas et al., 2002; Rosas et al., 2008; Tabrizi et al., 2011a). For instance, 
Rosas et al (2008) reported significant cortical thinning in primary motor, sensory and visual 
cortical regions, with the most pronounced thinning being found in primary motor and visual 
cortices.   
Pathological and in vivo neuroimaging studies have also reported significant volume loss in 
the globus pallidus (Lange et al., 1976), substantia nigra (Campbell et al., 1961; 
Hallervorden, 1957; Kiferle et al., 2013; Lewy, 1923; Richardson, 1990; Schröder, 1931; 
Spielmeyer, 1926), nucleus accumbens (Lange et al., 1976), subthalamic nucleus (Lange et 
al., 1976; Spielmeyer, 1926), thalamus (Gavazzi et al., 2007; Heinsen et al., 1999; Heinsen et 
al., 1996; Kassubek et al., 2005; Mühlau et al., 2007), hypothalamus (Douaud et al., 2006; 
15 
 
Kassubek et al., 2004; Kremer, 1992; Kremer et al., 1991; Kremer et al., 1990; Politis et al., 
2008; Vogt, 1952), hippocampus (Rosas et al., 2003; Suzanne et al., 1988), cerebellum 
(Fennema-Notestine et al., 2004; Rosas et al., 2003; Rüb et al., 2013) and cingulate gyrus 
(Henley et al., 2009; Kim et al., 2014; Ruocco et al., 2008; Thu et al., 2010) in manifest HD. 
Within the thalamus, significant neuronal loss has been reported in the dorsomedial nucleus 
(23.8%) and centromedial parafascicular nucleus at post-mortem (Grade 3 & 4) (1999; 
Heinsen et al., 1996). Significant neuronal loss has also been reported by Kramer et al (1992; 
1991; 1990) in the lateral tuberal nucleus of the hypothalamus (90%). Lastly, Rosas et al 
(2003) has documented significant volume loss in the hypothalamus (95%) and amygdale 
(24%) in vivo, using MRI.  
1.11.4 Neurodegeneration and clinical expression  
Accumulating evidence suggests that neuronal dysfunction and cell loss mediate the clinical 
expression of HD (Delmaire et al., 2013; Guo et al., 2012; Kim et al., 2014; Nana et al., 2014; 
Scahill et al., 2013; Sprengelmeyer et al., 2014; Thu et al., 2010). In particular, cortical 
interneuron loss in the primary motor cortex and anterior cingulate cortex has been found to 
correlate with the expression of motor features and mood (Kim et al., 2014; Thu et al., 2010). 
Moreover, neuronal cell loss in the striatum, subthalamic nuclei, primary motor, primary 
sensory, secondary visual cortex as well as associational cortices in frontal, temporal and 
parietal lobes has been found to be associated with the expression of motor symptoms (Guo 
et al., 2012; Nana et al., 2014). Lastly, cortical thinning has been found to be associated with 
cognitive and motor performance (Bechtel et al., 2010; Peinemann et al., 2005; Rosas et al., 
2005).  
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1.12 COGNITIVE FUNCTION AND HD 
Cognitive decline is an invariable trait of HD. Cognitive deficits markedly worsen throughout 
the disease in a non-linear pattern (Paulsen, 2011), leading to a severely impaired cognitive 
state, at which point facilitative support is often required (Wheelock et al., 2003). Consistent 
with a frontal-subcortical profile, cognitive features often include cognitive slowing, impaired 
verbal fluency (Eddy and Rickards, 2014), declines in working memory (Bonelli and 
Cummings, 2008; Ho et al., 2003), perceptual and spatial difficulties, impaired construction 
of higher intellectual thoughts and visuoconstructional difficulties (Beglinger et al., 2010). 
Memory problems initially manifest as absent-mindedness, though later develop into more 
debilitative problems including episodic, semantic and nondeclarative memory impairments 
(Knowlton et al., 1996; Rohrer et al., 1999), which greatly impede the affected individual’s 
everyday functioning (Eddy and Rickards, 2014; Hart et al., 2013). Though not consistent 
with frontal-subcortical deficits, features of aphasia, agnosia and anosagnosia may also 
develop in latter stages of the disease, owing to a more cortical profile, as is commonly 
observed in AD (Bonelli and Cummings, 2008). Impairments in executive functioning also 
feature prominently. In particular, deficits in planning, organisation, multi-tasking, attention 
and concentration have been reported previously (Caine et al., 1977). Deficits in attention and 
concentration often manifest early in the disease and likely underpin distractibility in HD 
(Pillon et al., 1991).  
1.13 AFFECTIVE FEATURES AND HD 
Affective disorders vary considerably between affected individuals and progress in an 
unpredictable manner. Typical manifestations include depression (Epping and Paulsen, 
2011), irritability (Craufurd et al., 2001; Kingma et al., 2008), apathy (Baudic et al., 2006; 
Reedeker et al., 2011) and obsessive-compulsive behaviours (Anderson et al., 2001; 
17 
 
Beglinger et al., 2007), though features of aggression (Rosenblatt and Leroi, 2000), 
impulsivity, mania (Mendez, 1994; Shiwach, 1994), psychosis-like states (Paulsen et al., 
2001) and schizophrenia-like delusional states (Folstein et al., 1983a; Folstein et al., 1983b; 
Pflanz et al., 1991) may also present (Thompson et al., 2012). A depressive syndrome has 
long been recognised in HD, even dating back to Huntington’s original  description 
(Huntington, 1872). In fact, major depression is estimated to be present in 30-40% of patients 
during their lifetime and subsyndromal depressive mood is estimated to be present in 35-60% 
of HD patients (Craufurd et al., 2001; Paulsen et al., 2001). Depression is often accompanied 
by suicidal ideation, which coupled with life stressors can lead to impulsive urges to commit 
suicide. Suicide is estimated to be 5-10% higher in HD than in the general population 
(Walker, 2007), and is greatest in individuals presenting with soft neurological features 
awaiting clinical diagnosis (Paulsen and Conybeare, 2005). Apathy is a distressing 
psychiatric feature of HD, regularly reported by spouses, family members and friends. 
Typified by a reduction in purposeful behaviour, apathy was recently shown, in a longitudinal 
study to progressively worsen throughout disease course (Thompson et al., 2013). In addition, 
in the same study, irritability was shown to be very common in HD individuals, with 80% of 
patients exhibiting poor temper control and almost 50% reporting some level of physical 
aggression. Obsessive and compulsive features are also observed in 20 to 50% of HD patients 
(Anderson et al., 2001; Beglinger et al., 2007), while obsessive and compulsive behaviour is 
only present in 5.5% of the general population (Degonda and Angst, 1993).   
1.14 CLINICAL HD MOTOR FEATURES  
Progressive impairments in motor control are a clinical hallmark of HD. Throughout the 
course of the disease, two distinct movement disorders typically emerge, an involuntary 
(hyperkinetic) movement disorder and a loss of voluntary motor control. The temporal 
expression of motor features tends to follow a biphasic pattern, with involuntary movement 
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problems presenting early and voluntary movement problems presenting later on in the 
disease course. 
1.14.1 Hyperkinetic motor features 
Chorea is often the most visible sign of HD. By definition, chorea refers to involuntarily 
abrupt, asynchronistic movement of the limbs, trunk and/or face. For most adult-onset cases 
of HD, chorea is often witnessed early in the disease process. Early manifestations of chorea 
often resemble exaggerated ‘fidgetiness’, with low amplitude (electromyography activity), 
relatively infrequent, choreic manifestations evident, such as finger flicking, eyebrow raising 
and transient facial changes (smiling and grimacing) (Wild and Tabrizi, 2007). In some HD 
cases, early choreic manifestations can be effectively managed with pharmaceutical 
intervention (i.e. Tetrabenazine) (Pidgeon and Rickards, 2013; Venuto et al., 2012). 
However, as the disease progresses, chorea typically worsens (frequency and severity), 
becoming less manageable with pharmaceutical intervention. The magnitude and severity of 
chorea is often exacerbated by life stressors (workplace and family problems), anxiety, 
fatigue and illicit stimulant drugs (Sturrock and Leavitt, 2010). Although disruptive, chorea 
in most cases does not severely impair balance, mobility and upper limb function in HD 
patients (Sturrock and Leavitt, 2010).  
1.14.2 Hypokinetic motor features 
While chorea is inconvenient, impairments in voluntary motor control are often viewed as the 
most disabling motor aspects of HD. Notable features of the voluntary movement disorder 
include impairments in motor learning, motor impersistence, bradykinesia, ataxia and delayed 
postural reflexes. These features contribute to a diversity of clinical problems including, 
pulmonary dysfunction, swallowing problems, speech impairments, mobility and balance 
disturbances and a loss of muscle strength. The onset and progression of these clinical 
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problems are salient predictors of facilitated care, nursing home placement and a reduced 
quality of life (Helder et al., 2001; Ho et al., 2009; Jankovic and Roos, 2014). 
1.14.3 Balance in HD 
Balance impairments are a physically disabling trait of HD (Medina et al., 2013; Panzera et 
al., 2011; Quinn et al., 2013; Salomonczyk et al., 2010; Tian et al., 1992; Tian et al., 1991) 
Clinical and laboratory examinations reveal static and dynamic perturbations in balance in 
people living with manifest HD (Medina et al., 2013; Panzera et al., 2011; Quinn et al., 2013; 
Salomonczyk et al., 2010; Tian et al., 1992; Tian et al., 1991). Common indications of 
balance problems include an increased base of support (Koller and Trimble, 1985; Rao et al., 
2005), excessive postural sway (Reilmann, 2012; Tian et al., 1992; Tian et al., 1991) and 
delayed postural reflexes (Medina et al., 2013; Panzera et al., 2011; Salomonczyk et al., 
2010). Evidence indicates that impairments in static and dynamic balance surface early in the 
disease process and worsen over time increasing the propensity for falls and subsequent 
wheel chair use (Kloos et al., 2012; Rao et al., 2008; Wheelock et al., 2003).  
1.14.4 Mobility in HD 
Evidence indicates that mobility deficits emerge early in the disease process (Rao et al., 
2008) and progressively worsen over time increasing the likelihood of falls (Quinn and Rao, 
2002), assistive aid use (cane, zimmer frame, wheelchair) (Kloos et al., 2012) and nursing 
home placement (Wheelock et al., 2003). Mobility deficits include decreases in gait velocity 
(Churchyard et al., 2001; Delval et al., 2006; Koller and Trimble, 1985; Rao et al., 2005), 
stride length (Bilney et al., 2005; Churchyard et al., 2001; Koller and Trimble, 1985; Rao et 
al., 2005) and frequency (Bilney et al., 2005; Churchyard et al., 2001; Delval et al., 2006; 
Koller and Trimble, 1985; Rao et al., 2005) as well as increased stride-to-stride variability 
(Churchyard et al., 2001; Delval et al., 2006; Rao et al., 2005).  
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1.14.5 Muscle strength in HD 
Evidence, albeit limited, shows that decreases in muscle strength are also evident in people 
with HD (Busse et al., 2008). Busse et al (2008), using hand-held dynamometry, showed 
evidence of significant lower limb muscle weakness in people with HD. The origins of 
muscular weakness are not known, however neuronal degeneration (Tabrizi et al., 2012; 
Tabrizi et al., 2011a; Tabrizi et al., 2013; Vonsattel et al., 1985; Vonsattel, 2008), 
mitochondrial abnormalities, and muscular pathology (Kosinski et al., 2007) as well as 
sedentary behaviour may all contribute to its development. Muscular weakness, particularly 
in the lower limbs contributes to impairments in balance and mobility as well as an increased 
likelihood of falls (Aziz and Roos, 2013; Cruickshank et al., 2014).  
1.15 ADDITIONAL CLINICAL HD FEATURES 
The presence of non-central nervous system abnormalities are increasingly being recognised 
in people with HD. Common peripheral aspects of the disease include weight loss, skeletal 
muscle atrophy, bone mineral density loss, sleep disturbances and cardiac dysfunction 
(Goodman et al., 2008; van der Burg et al., 2009).  
Weight loss is perhaps the most common peripheral feature in HD (Aziz et al., 2008; Aziz 
and Roos, 2013). Clinical investigations of weight loss have shown that it surfaces in 
premanifest HD and worsens over time resulting in profound cachexia by late stage HD 
(Mochel et al., 2007; Robbinsa et al., 2006; Sanberg et al., 1981; Trejo et al., 2005; Trejo et 
al., 2004). Aetiological factors underpinning weight loss are not well understood, however 
several lines of evidence from rodent models of HD implicate changes in metabolism 
(Goodman et al., 2008; Mochel et al., 2007; van der Burg et al., 2008), hormonal 
irregularities (Andreassen et al., 2002; Björkqvist et al., 2005; Boesgaard et al., 2009) and 
malabsorption along the digestive tract (van der Burg et al., 2011). Weight loss has been 
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shown to be associated with a faster rate of disease progression in people with HD (Myers et 
al., 1991), and may therefore represent a useful clinical endpoint for evaluating disease 
modifying strategies.    
Skeletal muscle wasting is also evident in people with HD (Kosinski et al., 2007; Trejo et al., 
2004). Histological examinations of skeletal muscle have shown muscle fibre degeneration 
(Kosinski et al., 2007), abnormal muscle fibre morphology (Arenas et al., 1998) and enlarged 
mitochondria (Kosinski et al., 2007). Histochemical and in vivo imaging studies have 
additionally shown evidence of respiratory chain dysfunction, cytochrome c release, 
increased caspase activity, increased lactate production, decreased adenosine triphosphate 
synthesis and a reduced phosphocreatine to phosphate ratio, implicating mitochondrial 
dysfunction as a potential mediator of skeletal muscle wasting (Arenas et al., 1998; 
Ciammola et al., 2011; Koroshetz et al., 1997; Lodi et al., 2000; Turner et al., 2007). The 
molecular events mediating mitochondrial dysfunction are not currently known. However, 
direct interaction between mitochondria and mutant huntingtin (Bossy-Wetzel et al., 2008; 
Orr et al., 2008) as well as a decrease in the expression of peroxisome proliferator-activated 
receptor-γ (PPARγ) coactivator-1α (PGC-1α) may at least in part underlie mitochondrial 
dysfunction (Chaturvedi et al., 2009).  
Recent evidence also suggests that bone mineral density loss may also be a feature in HD 
(Goodman and Barker, 2011). Using dual-energy x-ray absorptiometry, Goodman and Barker 
(2011) showed that bone mineral density is decreased in people with premanifest HD relative 
to healthy controls. The mechanisms underpinning bone mineral density loss are yet to be 
elucidated. However, it may arise as a side effect of medication, a lack of physical activity or 
hormonal irregularities.  
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1.16 CLINICAL MANAGEMENT OF HD 
Discovery of the CAG mutation in 1993 was met with great excitement and a belief that HD 
could soon be medically solved. Unfortunately, twenty one years on, a cure or disease 
modifying therapy has yet to be unveiled. In the absence of a cure or disease modifying 
therapy, pharmaceutical interventions have been used, and remain the main treatment for 
people suffering with HD.  
1.16.1 Pharmaceutical management of clinical features in HD 
Drug agents are commonly used to treat HD (Ross and Tabrizi, 2011). However there are no 
effective drug agents for treating cognitive symptoms in HD (Mason and Barker, 2009; 
Nance, 2012; Novak and Tabrizi, 2010; Ross and Tabrizi, 2011; Venuto et al., 2012). There 
is also a dearth of peer reviewed evidence indicating that drug agents are effective for treating 
psychiatric symptoms in people with HD (Pidgeon and Rickards, 2013). Evidence does 
however indicate that drug agents are effective in alleviating chorea in HD. In a recent 
guideline document, the American Academy of Neurology found level B evidence for the 
efficacy of tetrabenazine, amantadine and riluzole to treat chorea in people with manifest HD 
(Armstrong and Miyasaki, 2012). 
In summary, there is limited evidence to support the use of drug agents for treating the 
clinical features in HD. In addition, there is no validated evidence showing that drug agents 
are effective for treating pathological mechanisms underpinning HD. Furthermore, many 
drug agents are associated with unwanted side effects such as malaise, sedation and a 
depressive mood state, which may predispose individuals to falls and suicidal ideation. Drug 
agents nevertheless remain the mainstay approach for managing symptoms of HD. 
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1.16.2 Promising neuroprotective therapies for HD 
A number of pharmaceutical compounds with disease-modifying properties have been 
identified over the past twelve years. Unfortunately, none have to date, demonstrated true 
disease-modifying effects in people with HD. There are, however, many promising 
compounds on the horizon (Burgunder, 2013; Dominguez and Munoz-Sanjuan, 2014; 
Schapira et al., 2014).  
The most advanced compounds with potential disease-modifying properties include creatine 
monohydrate, PBT2 (a metal protein-attenuating compound) and cysteamine bitartrate. In a 
recent phase II trial, creatine monohydrate was found to be safe, well tolerated and associated 
with a significant reduction in cortical and striatal atrophy in forty-seven HD gene carriers 
(Rosas et al., 2014). While peer review evidence is not yet available, a recent press release by 
Prana Biotechnology LTD reported benefits in executive function in individuals with 
manifest HD taking PBT2 (Huntington Study Group, 2015). Raptor Pharmaceuticals has also 
recently released intermediate findings from their 36 month phase II trial of cysteamine 
bitartrate (Raptor Pharmaceuticals, 2014). The intermediate findings indicate that cysteamine 
bitartrate has a positive effect on motor function. While positive, subsequent phase III 
investigations are required to recapitulate these findings in larger cohorts of individuals with 
HD.  
A number of alternative pharmaceutical strategies are also being investigated. The most 
promising strategy involves lowering the expression of the mutant Htt protein with antibody 
compounds or by inhibiting gene expression with RNA interference and antisense RNA 
oligonucleotides (Sah and Aronin, 2011). RNA interference has been shown to decrease 
mutant Htt expression and ameliorate the phenotype in mouse models and non-human 
primates (Grondin et al., 2012; Kordasiewicz et al., 2012; McBride et al., 2011). Direct 
infusion of antisense RNA oligonucleotides into the lateral ventricle of mouse models has 
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similarly been shown to repress the expression of mutant Htt (Carroll et al 2011). While 
positive, many challenges still need to be overcome to ensure success in the clinic, such as 
the delivery of these compounds to appropriate sites, assessing the distribution of these 
compounds centrally and determining safe, long term doses of these compounds (Dominguez 
and Munoz-Sanjuan, 2014).  
Another therapeutic approach involves increasing PGC-1α activity via PPARs activators 
thereby restoring metabolic homeostasis (Chandra et al., 2014). PPAR agonist, bezafibrate 
has been shown to reduce striatal atrophy and the loss of medium spiny neurons in the 
striatum, as well as improve survivability and rotarod performance in the R6/2 mouse model 
(Johri et al., 2012). Activation of sirtuin 1 and 3 with nicotinamide riboside has also been 
shown to increase the expression of BDNF and PGC-1α and improve the motor phenotype of 
the R6/1 mouse model of HD (Hathorn et al., 2011). 
Other promising therapeutic approaches include histone deacetylase and kynurenine 3-
monoxygenase inhibitors (Dominguez and Munoz-Sanjuan, 2014). Histone deacetylase 
inhibitors encourage acetyl tagging of histones facilitating normalised gene expression and 
mutant Htt clearance (Bürli et al., 2013). Kynurenine 3-monoxygenase inhibitors increase the 
expression of kynurenic acid, a neuroprotective metabolite, and decrease the expression of 3-
hydroxykynurenine (3-HK) and quinolinic acid (QA) metabolites in the brain. The use of 
such compounds has been shown to improve survivability in R6/2 mice (Zwilling et al., 
2011). 
In summary, there are many promising pharmaceutical compounds with disease modifying 
properties being trialled now. Unfortunately, history has shown that many of these 
compounds will not be successful (futility and/or safety) (Bates et al., 2014). Furthermore, if 
successful, many of these compounds could take up to a decade to become publicly available. 
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Therefore identifying and developing treatments that can be implemented in the short term is 
of paramount importance. 
1.17 LIFESTYLE FACTORS AND HD 
Accumulating evidence indicates that lifestyle factors can have a profound impact on the 
onset and progression of HD. Recent evidence by Bonner-Jackson et al (2013b) showed that 
greater cognitive reserve (composite of premorbid intellectual level, occupational status, and 
years of education) was associated with a slower rate of volume loss in the caudate nucleus 
and putamen in HD gene carriers. Lopez et al (2011) in another study reported a significant 
association between better clinical UHDRS scores and a higher level of education in 
individuals with manifest HD. In an earlier investigation by Trembath and colleagues (2010), 
greater sedentary behaviour was also found to be associated with an earlier motor onset in 
HD gene carriers.  
A wealth of evidence also indicates that environmental factors influence the age of onset, 
clinical presentation and progression in HD (Anca et al., 2004; Friedman et al., 2005; 
Georgiou et al., 1999; Wexler, 2004). In a landmark investigation conducted in Venezuela, 
Wexler et al (2004) found that after controlling for the CAG repeat expansion (accounts for 
40-70% of variability in the age of onset), environmental modifiers accounted for 60% of the 
remaining variability in the age of onset. Clinical case reports and general observations of 
monozygotic twins have reported similar findings. In particular, Friedman et al (2005) 
observed a seven year difference in the age of onset between monozygotic twins, despite 
identical genotypes (39 CAG repeats). Authors found evidence that smoking and exposure to 
pollutants contributed to discrepancies in the age of onset between these twins. Georgiou et al 
(1999) in another investigation reported marked phenotypic differences between 
monozygotic twins. In particular, one twin (A) displayed more pronounced motor 
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impairments, while the other twin (B) had more pronounced impairments in attention. 
Interestingly, this investigation further reported that twin B had a more rapid rate of 
deterioration that twin A. Similar to Friedman et al (2005), authors concluded that epigenetic 
pre and postnatal environmental factors may have influenced the different clinical profiles in 
the twins.  
These findings indicate that lifestyle factors influence the onset, progression and expression 
of HD. Lifestyle interventions may therefore have a positive impact on disease progression as 
well as clinical expression in people with HD.  
1.18 ENVIRONMENTAL ENRICHMENT AND MOUSE MODELS OF HD 
Numerous studies over the last decade have investigated the effectiveness of environmental 
enrichment as a treatment approach in HD R6/1, R6/2 and N171-82Q mouse models (for a 
comprehensive overview of the genetic and phenotypic characteristics of the mouse models 
see Appendix 1). The first such study was conducted by van Dellen and colleagues (2000) 
who demonstrated the effectiveness of environmental enrichment in delaying the onset of HD 
in male R6/1 mice. Statistically significant reductions in cerebral volume degeneration were 
noted, along with significant improvements in static horizontal rod deficits. Additionally, 
significant reductions in rear paw clasping rates were noted. Hockly et al (2002) also 
investigated three levels of environmental enrichment in R6/2 mice and similarly utilised 
rotarod assessments and post mortem brain volume to measure benefits. R6/2 mice at 4 
weeks of age were randomly placed in non-enriched, minimally-enriched or highly-enriched 
living conditions until 12 weeks of age. Quantitative testing at 4, 8 and 12 week intervals 
revealed delayed rotarod deficits (p<10
-5
) and statistically significant improvements in grip 
strength (p=0.03) in R6/2 mice in enriched environments relative to non-enriched mice. 
Enriched R6/2 mice also had delayed peristriatal cerebral volume loss, supporting the 
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previous findings by van Dellen and colleagues (Hockly et al., 2002; van Dellen et al., 2000). 
Schilling et al (2004) found the same using the N171-82Q mouse model of HD. Mice placed 
in environmentally enriched cages (with exercise wheels and hiding tubes) for three weeks 
exhibited a 73% improvement in the rotarod assessment compared to non-enriched mice in 
standard cages (p<0.0001). Further longitudinal studies (21 weeks) revealed longer life 
expectancy in mice in enriched environments relative to mice in standard caging (Lazic et al., 
2006).  
Following on from their earlier studies, van Dellen et al (2008) investigated the effectiveness 
of environmental stimulation relative to that of exercise alone in R6/1 HD transgenic mouse 
models. Motor performance measures and quantitative brain volume assessments taken at 5 
and 9 months showed that mice in standardised housing failed the static horizontal rod test 
while both the environmentally enriched and wheel running groups showed a delay in static 
horizontal rod deficits. Greatest improvements were exhibited by those mice in the 
environmentally enriched housing; the environmentally enriched group showed no deficits on 
the static horizontal rod test at 160 days, whereas the wheel running group exhibited an 80% 
deficit. In addition only the environmentally enriched housing group exhibited statistically 
significant improvements on the accelerating rotarod test (p<0.001). Lastly neither 
environmental enrichment nor wheel running housing conditions ameliorated shrinkage of the 
striatum and anterior cingulate cortex, or brain volume at nine months of age. These results 
indicate that environmental enrichment and wheel running effectively improve motor 
performance in the R6/1 mouse models, without changing the chronic brain atrophy that is 
seen in this murine model of HD (Van Dellen et al., 2008).  
Several other studies have now documented the neurological benefits of environmental 
enrichment. Spires et al (2004) rescued deficits in, Dopamine-and cAMP-regulated 
phosphoprotein, Mr 32 kDA (DDARP-32) and brain derived neurotrophic factor (BDNF) in 
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the striatum of R6 mice housed in environmentally enriched cages, which was important 
given that DDARP32 is primarily involved in the regulation of dopamine signalling, whilst 
BDNF may play a crucial role in some aspects of adult neurogenesis, synaptic plasticity and 
cell survival (Lee et al., 2002; Zuccato et al., 2001). In this last respect, Lazic and colleagues 
(2006) documented increased hippocampal neurogenesis and neuronal maturation in R6/1 
mouse models reared in an environmentally enriched cage. 
Whilst these results are positive, it is important to note that animal models of HD do not 
recapitulate the human HD condition. It is currently not known whether environmental 
enrichment strategies will be beneficial for people living with HD. To date only a handful of 
uncontrolled studies have evaluated the effects of environmental and/or lifestyle approaches 
in individuals with HD. The effects of environmental and/or lifestyle approaches have been 
beneficial in individuals with other neurodegenerative diseases such as multiple sclerosis 
(MS) and Parkinson’s disease  (PD) and provide a rationale for such interventions to be used 
in HD.  
1.19 LIFESTYLE INTERVENTIONS IN NEURODEGENERATIVE 
DISEASES 
Accumulating evidence indicates that multidisciplinary rehabilitation is beneficial for people 
living with other neurodegenerative disorders, such as MS and PD (Asano et al., 2014; Beer 
et al., 2012; Khan et al., 2007; Khan et al., 2011; Parashos, 2012; Post et al., 2011; Prizer and 
Browner, 2012; van der Marck and Bloem, 2014).  
Many studies have now shown that multidisciplinary rehabilitation is beneficial for people 
living with MS. In particular, short term multidisciplinary rehabilitation has been found to 
have positive effects on disability (Craig et al., 2003; Freeman et al., 1997; Judica et al., 
2011), physical impairment (Judica et al., 2011), fatigue (Judica et al., 2011; Sacco et al., 
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2011), gait (Sacco et al., 2011; Salhofer-Polanyi et al., 2013), transfer skills (Patti et al., 
2003), bladder impairment (Khan et al., 2010), sphincter control (Freeman et al., 1997), self-
care (Freeman et al., 1997; Patti et al., 2003), mood (Patti et al., 2002), social function (Patti 
et al., 2002) and quality of life (Patti et al., 2002) in people with MS. Longer duration 
multidisciplinary rehabilitation interventions have similarly reported improvements in 
disability (Khan et al., 2008), fatigue (Di Fabio et al., 1998) and functional independence 
(Kidd et al., 1995) in people living with MS. 
Multidisciplinary rehabilitation has also been reported to be beneficial for people suffering 
with PD. Short duration multidisciplinary rehabilitation interventions (ranging from 21 days 
to two months) have been reported to improve disability (Frazzitta et al., 2015), dyskinesia 
(Frazzitta et al., 2012a; Frazzitta et al., 2013), transfer skills (Ellis et al., 2008; Frazzitta et al., 
2015), mobility (Ellis et al., 2008; Frazzitta et al., 2015; Trend et al., 2002), balance 
(Frazzitta et al., 2014), voice articulation (Trend et al., 2002), speech (Trend et al., 2002), 
depression (Trend et al., 2002), mood (Guo et al., 2009), activities of daily living (Guo et al., 
2009), upper extremity function (Ellis et al., 2008) and quality of life (Guo et al., 2009; 
Tickle‐Degnen et al., 2010; Trend et al., 2002) in people living with PD. Recent evidence 
also shows that short duration multidisciplinary rehabilitation can improve clinical measures 
of disease progression (Unified Parkinson’s Disease Rating Scale Version II & III) as well as 
increase serum BDNF levels ((Frazzitta et al., 2012b; Frazzitta et al., 2013; Frazzitta et al., 
2015; Frazzitta et al., 2014). Longer duration multidisciplinary rehabilitation interventions 
have similarly reported benefits in people with PD, including improvements in motor 
function (Carne et al., 2005a; Carne et al., 2005b), depression (Marck et al., 2013), 
psychosocial functioning (Marck et al., 2013) and quality of life (Marck et al., 2013).  
Collectively, these findings indicate that multidisciplinary rehabilitation is useful for treating 
a diversity of problems in people with neurodegenerative disorders such as MS and PD.  
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1.20 MULTIDISCIPLINARY REHABILITATION AND HD  
Multidisciplinary rehabilitation is an interdisciplinary approach for treating clinical 
conditions. It typically comprises cognitive and motor exercises as well as social interaction 
in conjunction with pharmaceutical treatment. Specialised interdisciplinary teams often 
design, deliver and evaluate the therapeutic utility of multidisciplinary rehabilitation 
interventions for people with clinical conditions. The type, number and experience of 
specialists differ in each clinical setting considerably. Multidisciplinary rehabilitation is used 
to treat clinical features in other neurodegenerative disorders such as MS and PD that do not 
respond to pharmaceutical treatment alone (Parashos, 2012; Veenhuizen and Tibben, 2009).  
Expert opinion, preclinical evidence and clinical findings in other neurodegenerative 
disorders suggest that multidisciplinary rehabilitation may have a positive impact on 
symptoms and perhaps the disease processes involved in HD (Bates et al., 2014; Nance, 
2012; Spires et al., 2004; van Dellen et al., 2000; Veenhuizen and Tibben, 2009). Despite this 
positive sentiment, few studies have evaluated the therapeutic effectiveness of 
multidisciplinary rehabilitation for people living with HD. Preliminary evidence however 
suggests that multidisciplinary rehabilitation is safe, well tolerated and beneficial for people 
with HD (Piira et al., 2013; Veenhuizen et al., 2011; Zinzi et al., 2007). 
Zinzi and colleagues (2007) were the first group to evaluate the effectiveness of 
multidisciplinary rehabilitation in people with HD. In this study, multidisciplinary 
rehabilitation comprised six days of high intensity training, conducted for three weeks, three 
times a year, for two years. Significant improvements in balance, gait and functional capacity 
were found as a result of the intervention. 
In another study, Veenhuizen et al (2011) evaluated the effect of an outpatient 
multidisciplinary care program in twenty individuals with manifest HD. Individualised 
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multidisciplinary care models were prescribed to patients after consultation with a specialised 
multidisciplinary team (physician, psychologist, speech and language therapist, social 
worker, occupational therapist and case manager). Multidisciplinary care models were 
revised every six months to ensure that models were stimulating and achievable. Following 
eighteen months of outreaching multidisciplinary rehabilitation, patients, carers, and health 
care professionals were asked to complete a survey on the effectiveness of the program. 
Results of the survey showed that patients, carers and health care professionals were 
appreciative and perceived the program to be beneficial. Moreover, caregivers felt that the 
multidisciplinary rehabilitation program prolonged the time that patients lived at home.  
More recently, Piira et al (2013) investigated the effectiveness of an inpatient 
multidisciplinary rehabilitation intervention in thirty seven individuals with manifest HD. 
The multidisciplinary rehabilitation intervention comprised five times per week therapy 
(physiotherapy, occupational therapy, hydrotherapy and resistance exercise) for eight hours, 
for three weeks, three times during a year. Significant improvements in gait balance, physical 
quality of life, anxiety and depression were found in patients after the multidisciplinary 
rehabilitation intervention. 
These preliminary findings indicate that multidisciplinary rehabilitation is safe, well 
tolerated, and beneficial for motor and psychiatric features of HD. While informative, the 
previously mentioned trials lacked a control group limiting the validity of the conclusions 
derived. In addition, previous trials have not evaluated the impact of multidisciplinary 
rehabilitation on neuropathological features of the disease. It is therefore clear that additional 
evidence from randomised controlled investigations is required to confirm and expand on 
these promising findings. 
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1.21 THEORETICAL FRAMEWORK 
There is no cure or disease modifying strategy, and available pharmaceutical agents only 
provide partial relief of motor and psychiatric features of the disease. Prospective 
observational evidence indicates that lifestyle factors influence the onset and progression of 
clinical features as well as the rate of striatal volume loss in individuals with HD. Evidence 
from preclinical studies additionally shows that environmental enrichment preserves 
peristriatal structures, improves the clinical phenotype and survival of HD transgenic mouse 
models. Lastly, emerging evidence shows that rehabilitation programs can have major effects 
on clinical features, neuronal function and disease progression in those suffering with MS and 
PD.  
Despite these findings and expert recommendations, only three studies have investigated the 
effectiveness of multidisciplinary rehabilitation in people suffering with HD. These studies 
have shown that multidisciplinary rehabilitation can have favourable effects on motor 
function, mood, anxiety and physical quality of life. While encouraging, additional work is 
required to confirm and expand on these uncontrolled findings and determine its true effects 
on disease course. Studies investigating the factors underlying more debilitating aspects of 
HD are also required. 
Mobility and balance impairments contribute to a loss of ambulation and nursing home 
placement in HD. Despite these serious health implications, no study has investigated the 
factors that contribute to impairments in mobility and balance. Identifying factors that 
contribute to these impairments should inform the design of multidisciplinary rehabilitation 
interventions. The first aim of this thesis was therefore to investigate the factors that 
contribute to impairments in mobility and balance in people with manifest HD.  
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Accumulating evidence suggests that resistance training is beneficial for those living with 
neurodegenerative disorders. However, consensus regarding its utility still remains 
contentious among health care professionals. To better inform the present study and provide 
greater clarification for health care professionals, the therapeutic utility of resistance training 
on clinical aspects of neurodegenerative disorders was investigated through a literature 
review.  
The ultimate aim of this thesis was to confirm and expand on previous findings by 
comprehensively evaluating the effects of multidisciplinary rehabilitation on motor control, 
cognitive function, mood, body composition and quality of life in patients with manifest HD. 
This thesis also aimed to investigate, for the first time, the effects of multidisciplinary 
rehabilitation on neurodegeneration in cortical and sub-cortical structures and how this relates 
to cognitive function in individuals with manifest HD using magnetic resonance imaging.  
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1.22 HYPOTHESIS AND AIMS 
The overarching hypothesis of this thesis is that multidisciplinary rehabilitation improves 
clinical and neuropathological features of HD. 
Study 1 Aim:  
To identify factors that contribute to impairments in balance and mobility in HD.  
Study 2 Aim: 
To systematically evaluate the quality of published evidence on the effects of 
resistance exercise for individuals with neurodegenerative disorders. 
Study 3 Aim: 
To determine the effects of multidisciplinary rehabilitation on body composition, 
postural control, depression, quality of life and disease status in individuals with 
manifest HD. 
Study 4 Aim: 
To determine the effects of multidisciplinary rehabilitation on motor function and lean 
tissue mass in individuals with HD. 
Study 5 Aim: 
To determine the effects of multidisciplinary rehabilitation on structural brain changes 
and cognitive function in individuals with manifest HD. 
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CHAPTER 2 -  An Assessment of the Factors That Contribute to Balance and Mobility 
Impairments in Individuals with Huntington’s Disease 
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2.1 ABSTRACT 
Mobility and balance problems are common and often debilitating features of Huntington’s 
disease (HD). In this exploratory study we aimed to investigate the influence of disease 
severity, severity of motor deficits, lower limb muscle strength, cognition, executive function, 
lean muscle mass and reactivity on mobility and balance.  
Twenty-two individuals with HD were recruited from the North Metropolitan Area Mental 
Health Service, Perth, Australia. Pertinent demographic, genetic and disease progression 
information was recorded prior to testing. Balance was assessed using dynamic and static 
balance tasks. Mobility was assessed using self-paced and fast-paced mobility measures. 
Cognitive and executive measures were used to assess verbal learning and memory, 
information processing speed, attention, response inhibition and cognitive flexibility. Lower 
limb muscle strength was evaluated by maximal isokinetic and isometric voluntary 
contractions. Lean tissue mass was quantified using Dual-energy X-ray absorptiometry. 
Reactivity was measured using Moyart equipment.  
Univariate and multivariate linear regression statistical models were used to examine the 
influence of these measures on mobility and balance. Univariate analyses showed that disease 
severity as well as measures of information processing speed, attention, cognitive flexibility, 
response inhibition and lower limb strength, were strongly related with mobility and balance. 
Additionally multivariate analyses showed that disease severity, cognitive flexibility and 
knee flexion strength together were better able to explain mobility and balance performance 
than any single measure (50%-85%).  
In conclusion, our preliminary results suggest that as well as disease severity, cognitive and 
executive impairment and reduced lower limb strength contribute significantly to mobility 
and balance problems.  
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2.2 INTRODUCTION 
Problems with balance and mobility are commonly reported by individuals suffering with 
HD. Problems occur early in the disease course and worsen with disease progression (Rao et 
al., 2008). Impairments in balance and mobility often predict nursing home placement, 
increase the likelihood for falls and can severely impact on health related quality of life (Rao 
et al., 2005; Reilmann et al., 2012).  
There are no clinically proven treatment strategies for addressing balance and mobility 
problems in people with HD. Previous studies examining mobility and balance in people with 
HD have documented decreases in gait velocity and stride length, increases in stride-to-stride 
variability, double support time and step time, and increased postural sway (Delval et al., 
2007; Delval et al., 2006; Delval et al., 2008; Hausdorff et al., 1998; Hausdorff et al., 1997; 
Panzera et al., 2011; Tian et al., 1991). While providing a vivid description of mobility and 
balance issues, previous studies have failed to investigate clinical features that contribute to 
mobility and balance problems in HD.  
Studies in people with Parkinson’s disease (PD) have reported strong associations between 
muscle power and strength and performance on balance and mobility tasks (Nocera et al., 
2010; Paul et al., 2013b; Schilling et al., 2009). Task dependent relationships between 
cognition and mobility and balance have also been documented in PD (Paul et al., 2013b). 
Similar associations have been reported in people with multiple sclerosis (MS) (D'Orio et al., 
2012; Hoang et al., 2014; Kalron et al., 2011; Sosnoff et al., 2013b). In the elderly, age 
related losses of lean tissue have been reported to strongly predict mobility and balance 
problems (Krause et al., 2012). Individuals with HD, in addition to displaying movement 
symptoms, exhibit progressive cognitive and executive impairment (Stout et al., 2012; 
Tabrizi et al., 2009; Tabrizi et al., 2012; Tabrizi et al., 2011a; Tabrizi et al., 2013) as well as 
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skeletal muscle atrophy throughout the disease course (Robbinsa et al., 2006; Thompson et 
al., 2013), which may similarly adversely impact on balance and mobility. 
Emerging evidence suggests that in HD, reduced muscle strength, cognitive and executive 
problems as well as skeletal muscle atrophy are remediable to interdisciplinary rehabilitation 
approaches (Bonner-Jackson et al., 2013b; Khalil et al., 2013; Thompson et al., 2013). This 
exploratory study therefore aimed to investigate the influence of motor, cognitive, executive 
and body composition features of the disease on mobility and balance performance in people 
with HD as a better understanding of the contribution of these deficits to balance and 
mobility may lead to improved therapies in HD.  
2.3 MATERIALS AND METHODS 
2.3.1 Ethics approval  
This study was approved by the Human Research Ethics Committee at Edith Cowan 
University and the North Metropolitan Area Mental Health Service (NMAMHS) Human 
Research Ethics Committee. All participants provided written informed consent. 
2.3.2 Participants 
Sixty-two potential participants were identified using the Neuroscience Unit database of the 
NMAMHS. Participants were only included if they had received a positive genetic test, were 
formally diagnosed as symptomatic (Unified Huntington’s Disease Rating Scale Total Motor 
Score [UHDRS-TMS] ≥ 5), and had the ability to follow verbal or written instruction. 
Participants were not included if they had recent substance abuse, an unstable psychiatric 
state, confounding neurological condition or concomitant physical injury.  
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2.3.3 Study procedures 
Participants were evaluated over two weekends at Edith Cowan University using a variety of 
mobility and balance tasks as well as cognitive, executive, lower limb muscle strength, lean 
tissue mass and reactivity measures. All assessments were performed by accredited 
independent examiners.  
2.3.4 Outcome measures 
Dynamic and static balance was examined using the berg balance scale (BBS), sensory 
organisation test (SOT) and the repeated sit to stand test (RSST). Mobility over short and 
long distances was quantified using the timed walk test (TWT) and the six minute walk test 
(6MWT) (Quinn et al., 2013). These measures have previously been demonstrated to be 
reliable in individuals with HD (Khalil et al., 2010; Quinn et al., 2013). 
2.3.5 Predictor measures 
Disease severity and severity of motor abnormalities were quantified using the disease burden 
score and the UHDRS-TMS. Cognition and executive function was examined using a variety 
of clinically validated measures. The Hopkins Verbal Learning Test-Revised (HVLT-R) was 
used to measure verbal learning and memory (Brandt, 1991; Thompson et al., 2013). 
Information processing speed and attention were examined using the Symbol Digit 
Modalities Test (SDMT) (Smith, 1973; Thompson et al., 2013). Response inhibition and 
cognitive flexibility were examined using the Delis-Kaplan Executive Function System (D-
KEFS) Colour Word Interference Test (CWIT) and Trail Making Trials (TMT) (Thompson et 
al., 2013). Reactivity was measured using a visual response task. Dual-energy X-ray 
absorptiometry (DEXA; Hologic Discovery A) was used to quantify lean  tissue mass (g) 
(Goodman and Barker, 2011; Thompson et al., 2013). Lower limb muscle strength was 
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quantified using a maximal voluntary isometric and isokinetic knee flexion and extension 
contractions with automated dynamometry (Biodex, System 3, USA). Isokinetic knee 
extension and flexion strength was examined using 180°·s
-1
 (fast) and 30°·s
-1
 (slow) 
maximum voluntary contraction (MVC) test protocols. Isometric knee extension and flexion 
strength were also measured at 60° flexion. Individuals performed three maximal voluntary 
contractions for each strength protocol.  
2.4 STATISTICAL ANALYSIS  
Data is presented as mean, range and standard deviation (SD). Associations between balance 
and mobility tasks (outcome variables), disease severity, severity of motor abnormalities and 
measures of cognition, executive function, lower limb strength, lean tissue mass and 
reactivity (predictor variables) were determined using univariate linear regression analysis. 
Associations between multiple predictor variables and balance and mobility were then 
determined using multivariate linear regression. The results of the univariate linear regression 
analysis showed that measures of disease severity, attention, information processing speed, 
cognitive flexibility and response inhibition associated strongly with balance and mobility 
tasks. These predictor variables were entered into a multivariate linear regression model and 
assessed for association with each of the mobility and balance tasks. Backward selection 
estimation was then used to obtain the most significant multivariate model. Statistical 
significance was set at p 0.05. All statistical analyses were performed using STATA version 
9.1. 
2.5 RESULTS 
Of the sixty-two potential participants, twenty-two individuals agreed to voluntarily 
participate in the study (Table 2.1.). Of these, 16 were taking antidepressants, 12 anti-
psychotics and 5 anti-choreic medications. Demographic, disease severity, severity of motor 
42 
 
abnormalities, cognition, executive function, lower limb strength, lean tissue mass, reactivity, 
mobility and balance data are displayed in Tables 2.1 and 2.2.  
2.5.1 Balance 
Univariate analyses revealed significant associations between disease severity and 
performance on balance tasks (18%-50.0% for disease burden score). Moreover, measures of 
information processing speed, attention, cognitive flexibility, response inhibition and lower 
limb strength were significantly associated with performance on balance tasks (20.3-27% for 
correct oral, 18.2%-53.0% for word reading, 26.3%-49.5% for motor speed, 24.5%-42.7% for 
60˚ MVC knee flexion; Supplementary Tables 2.3, 2.4 and 2.5). Task dependent associations 
between measures of verbal learning and memory and performance on the RSST task were 
also found (total recall 21.3%). Lean tissue mass, reactivity and severity of motor 
abnormalities were found not to be related to balance task performance (Supplementary 
Tables 2.3, 2.4 and 2.5). 
Multivariate analyses showed that performance on the BBS was best explained by disease 
severity (disease burden score explained 57%; Supplementary Table 2.9). For the SOT, 
performance variability was best explained by disease severity and cognitive flexibility 
measures (disease burden score and motor speed together explained 50% of variability; 
Supplementary Table 2.9). Performance variability on the RSST was best explained by 
measures of cognitive flexibility and knee flexion muscle strength (motor speed and 60˚ 
MVC knee flexion strength together explained 72%; Supplementary Table 2.9). 
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Table 2.1 Participant characteristics 
Variables Mean (SD) (n=22) Range 
Age (Years) 50.85 ± 9.24 30.3-70 
Disease Duration 3.95 ± 4.26 0.3-17.3 
CAG (n) 44.22 ±  2.99 39-51 
Disease Burden Score 427.22 ± 118.05 269.5-596 
UHDRS-Total Motor 
Score 
26.45 ± 12.41 5-45 
CAG (n), cytosine-adenine-guanine repeat length, UHDRS, Unified Huntington’s Disease 
Rating Scale 
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Table 2.2 Study participant performance on outcome measures 
Study Assessments Mean (SD) Range 
Predictor Variables  
Cognition Assessments 
SDMT 
Correct Written 26.33 ± 10.57          10.00-48.00 
Incorrect Written 1.66 ± 1.95 0.00-6.00 
Correct Oral 29.71 ± 13.40           8.00-60.00 
Incorrect Oral 1.85 ± 2.34 0.00-7.00 
HVLT-R  
Total Recall 16.52  ±  6.20           4.00-30.00 
Delayed Recall  5.13 ± 2.35           1.00-9.00 
Retention 77.00  ±  22.59         33.00-129.00 
Recognition Discrimination Index 8.00  ±  3.08           2.00-15.00 
D-KEFS TMT 
Visual Scanning 35.42  ±  15.83         16.00-70.00 
Number Sequencing 59.57  ±  21.84          33.00-124.00 
Letter Sequencing 79.10  ±  55.56          31.00-234.00 
Number-Letter Sequencing 142.00 ± 54.24 61.00-239.00 
Motor Speed 65.44  ±  35.16 18.00-147.00 
D-KEFS CWIT  
Colour Naming 44.05  ±  15.72         22.00-78.00 
Word Reading 35.14  ± 13.81 20.00-73.00 
Inhibition 89.42  ± 33.52 40.00-186.00 
Lower Limb Strength Measures 
30°·s
-1
MVC Knee Extension 127.23  ±  54.36 40.80-217.10 
180°·s
-1
MVC Knee Extension 71.05 ± 29.92 20.90-128.45 
30°·s
-1
 MVC Knee Flexion 71.88  ±  32.44        15.60-138.95 
180°·s
-1
 MVC Knee Flexion 50.19  ±  19.33 14.30-96.00 
60° MVC Knee Extension 157.30  ±  49.06 71.10-238.95 
60° MVC Knee Flexion 65.46  ± 18.73        14.80-100.25 
Body Composition Assessment 
Lean Tissue Mass 52224.47 ± 10332.29     34362.20-68907.30 
Reactivity Assessments 
Visual Reaction Time (DOM) 0.69 ± 0.24 0.34-1.20 
Visual Reaction Time (NON) 0.67 ± 0.25         0.26-1.21 
Outcome Variables 
Balance Assessments  
SOT 54.04 ± 15.63 22.00-80.00 
BBS 46.59 ± 7.83 26.00-56.00 
RSST 28.62 ± 12.76          12.00-64.00 
Mobility Assessments  
TWT (Fast-paced) 6.17 ± 2.81 3.08-16.72 
TWT (Self-paced) 8.10  ± 2.63 5.90-17.18 
6MWT 466.19 ± 127.37 87.00-630.00 
DOM= dominant hand, NON= non-dominant hand 
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2.5.2 Mobility 
Univariate analyses showed significant associations between disease severity and 
performance of mobility tasks (disease burden score 43%-50%). Measures of attention, 
information processing speed, cognitive flexibility, response inhibition and lower limb 
strength measures were also associated with mobility task performance (correct oral 20%-
40.1%, word reading 34.1%-52.2%, motor speed 26.7%-52.8%, 60˚ MVC knee flexion 
strength 43%-60%; Supplementary Tables 2.6, 2.7 and 2.8). Task dependent associations 
between verbal learning and memory and mobility task performance were also evident (total 
recall, 19.5%; Supplementary Tables 2.6, 2.7 and 2.8). There was no evidence of associations 
between lean tissue mass, reactivity or severity of motor abnormalities and performance on 
mobility tasks (Supplementary Tables 2.6, 2.7 and 2.8). 
Multivariate analyses revealed that when measures were collectively considered, disease 
severity, cognitive flexibility and knee flexion strength measures explained a significantly 
greater proportion of performance variability on mobility tasks than any single measure 
(TWT-SP 85%, TWT-FP 72%, 6MWT 85%; Supplementary Table 2.9). 
2.6 DISCUSSION 
This study found that disease severity, lower limb muscle strength, cognition and executive 
function significantly influenced performance on balance and mobility tasks, while reactivity 
and lean tissue mass did not. Furthermore, this study showed that when all measures were 
collectively considered, the factors most critically related to performance on balance and 
mobility tasks were disease severity, cognitive flexibility and knee flexion strength, and 
together these measures better explained balance and mobility performance than any single 
measure. 
46 
 
An important finding of this study was that cognition and executive function significantly 
influenced performance on balance and mobility tasks. Similar findings have been found in 
people suffering from PD (Herman et al., 2014; Paul et al., 2013a; Paul et al., 2013b) and 
mild cognitive impairment (MCI) (Persad et al., 2008). Paul et al (2013a; 2013b) in two 
recent studies showed that executive function and cognition significantly influenced balance 
and falls in people with PD. Persad et al (Persad et al., 2008), in a similar study found that 
cognition and executive function were strongly related to balance and mobility in people with 
MCI. These findings highlight that deterioration of cognitive and executive function 
adversely impacts upon balance and mobility in people with neurodegenerative diseases. 
The relationship of lower limb strength with balance and mobility task performance was not 
unexpected. Interestingly though, we found that relationships were often dependent on the 
muscle group involved and the type of contraction performed, with the 60˚ MVC knee 
flexion measure demonstrating significant association with all balance and mobility tasks. 
Both 30°·s
-1
 MVC knee flexion and 180°·s
-1
 MVC knee flexion measures similarly 
demonstrated strong associations with performance on mobility tasks but not balance tasks. 
Broekmans et al (2013a) in a similar study found knee flexion strength to strongly predict 
walking capacity in people with MS. Knee flexor involvement during stabilization and 
mobility tasks in healthy individuals is well established (Chandler et al., 1998; Hughes et al., 
2001; Pavol et al., 2002), and likely explains our findings. Multidisciplinary interventions 
have been shown to improve lower limb strength and perception of balance in people with 
HD (Thompson et al., 2013), therefore mobility and balance problems may be amenable to 
such interventions.   
As expected, a strong relationship was observed between disease severity and performance 
on balance and mobility tasks, indicating a significant contribution of HD progression to 
movement disability. Of interest, is the finding that severity of motor abnormalities, as 
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measured by the UHDRS-TMS, was not significantly associated with performance on 
balance and mobility tasks. This finding has important clinical implications for the 
assessment of balance and mobility in HD. It illuminates the importance of identifying 
specific measures to supplement the UHDRS-TMS that can more sensitively quantify balance 
and mobility decrements.  
Lean tissue mass and reactivity demonstrated negligible associations with mobility and 
balance. This was an unexpected finding, considering that studies in PD have reported 
reactivity and lean muscle mass to be important clinical determinants of balance and mobility 
performance (Dibble et al., 2006; Paul et al., 2013a; Paul et al., 2013b). Discrepancies 
between findings are likely due to pathological and clinical differences between PD and HD 
(Jankovic, 2008; Sturrock and Leavitt, 2010), as well as methodological and sample size 
differences between the studies. 
Our findings result from a relatively small sample of individuals with manifest HD, most of 
whom were taking medication, as such our findings should be interpreted with a degree of 
caution. 
2.7 CONCLUSION  
Here we provide preliminary evidence that disease severity, lower limb weakness, cognitive 
impairment and executive dysfunction significantly influence mobility and balance in people 
with HD. Moreover, we show that key clinical features, when considered together, better 
explain performance on balance and mobility tasks than any single measure. Findings while 
preliminary, provide insight into the multiple clinical features that contribute to balance and 
mobility problems in HD, and provide a venue for targeted multidisciplinary rehabilitation 
strategies. 
48 
 
2.8 ACKNOWLEDGMENTS 
First and foremost the authors sincerely thank the study participants and their families for 
their gracious participation. Authors also sincerely thank Professor Roger Barker for critically 
reviewing this manuscript prior to submission. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
49 
 
2.9 SUPPLEMENTARY DATA 
Supplementary Table 2.3 Univariable associations between impairments (Predictor 
Variables) and performance on the BBS (Outcome Measure) 
Predictor Variable Adjusted R
2
 (%) P Value 
Unstandardised B (95% 
CI) 
BBS 
Demographic Variables 
Age 0.6 0.728 -0.066(-0.460:0.327) 
Disease Duration 0.6 0.713 -0.152(-1.00:0.701) 
CAG repeat 9.9 0.154 -0.824(-1.98:0.334) 
Disease Burden Score 34 0.004
* 
-0.038(-0.0639:-0.0137) 
UHDRS-TMS 2.7 0.467 -0.094(-0.036:0.172) 
Cognitive Measures 
SDMT 
Correct written 14.5 0.088 0.285(-0.047:0.618) 
Correct Oral 22.1 0.031
* 
0.278(0.027:0.528) 
HVLT-R 
Total Recall 9.2 0.181 0.38(-0.19:0.97) 
Delayed Recall 7.2 0.226 0.89(-0.60:2.38) 
Retention 0.3 0.795 -0.02(-0.181:0.141) 
Recognition Discrimination 
Index 
8.2 0.194 0.73(-0.404:1.864 
D-KEFS TMT 
Visual Scanning 4.2 0.371 -0.104(-0.34:0.133) 
Number Sequencing 17.3 0.061 -0.152(-0.313:0.007) 
Letter Sequencing  15.5 0.086 -0.057(-0.124:0.000) 
Number-Letter Sequencing 0.2 0.879 -0.007(-0.11:0.103) 
Motor Speed 26.3 0.030
* 
-0.121(-0.22:-0.13) 
D-KEFS CWIT 
Colour Naming 15.2 0.099 -0.204(-0.45:0.042) 
Word Reading 22.4 0.030
* 
-0.271(-0.51:-0.029) 
Inhibition 13.5 0.122 -0.09(-0.207:0.026) 
Lower Limb Strength Measures 
30°·s
-1
 MVC Knee Extension 4.5 0.343 0.03(-0.035:0.096) 
180°·s
-1
 MVC Knee 
Extension 
3 0.440 0.045(-0.07:0.16) 
30°·s
-1
 MVC Knee Flexion 10.5 0.141 0.07(-0.028:0.18) 
180°·s
-1
 MVC Knee Flexion 12.3 0.110 0.141(-0.035:0.318) 
60˚ MVC Knee Extension 0.1 0.849 0.00(-0.06:0.08) 
60˚ MVC Knee Flexion 13 0.018* 0.154(-0.042:0.351) 
Body Composition Measures 
Lean Tissue Mass 0.5 0.753 0.00 (-0.00:0.00) 
Reactivity Measures 
Visual Reaction Time (DOM) 2.4 0.492 0.00 (-0.00:0.00) 
Visual Reaction Time (NON) 4.2 0.357 -6.42(-20.63:7.78) 
DOM: dominant hand; NON: non-dominant hand; * Significant at the 0.05 level 
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Supplementary Table 2.4 Univariable associations between impairments (Predictor 
Variables) and performance on the SOT (Outcome Measure) 
Predictor Variable 
Adjusted R
2
 
(%) 
P Value 
Unstandardised B (95% 
CI) 
SOT (composite score) 
Demographic Variables 
Age 0.1 0.850 -0.0721(-0.859:0.715) 
Disease Duration 0.6 0.730 -0.286(-1.99:1.418) 
CAG repeat 12.9 0.101 -1.87(-4.15:0.400) 
Disease Burden Score 29.4 0.009
* 
-0.071(-0.123:-0.0198) 
UHDRS-TMS 7.5 0.218 -0.316(-0.83:0.202) 
Cognitive Measures 
SDMT 
Correct Written 15.4 0.079 0.56(-0.07:1.21) 
Correct Oral 27 0.015
* 
0.596(0.127:1.06) 
HVLT-R 
Total Recall 14.7 0.086 0.95(-0.147:2.047) 
Delayed Recall 10.9 0.133 2.19(-0.72:5.11) 
Retention 0.2 0.813 0.037(-0.28:0.359) 
Recognition Discrimination 
Index 
16.3 0.062 2.04(-0.11:4.2) 
D-KEFS TMT 
Visual Scanning 6.8 0.254 -0.263(-0.73:0.204) 
Number Sequencing 17.3 0.061 -0.15(-0.31:0.007) 
Letter Sequencing 15.5 0.086 -0.057(-0.124:0.009) 
Number-Letter Sequencing 0.2 0.879 -0.007(-0.11:0.103) 
Motor Speed 26.3 0.030
* 
-0.121(-0.22:-0.013) 
D-KEFS CWIT 
Colour Naming 3.7 0.434 -0.183(-0.66:029) 
Word Reading 18.2 0.050
* 
-0.47(-0.95:0.007) 
Inhibition 6.7 0.275 -0.11(-0.34:0.103) 
Lower Limb Strength Measures 
30°·s
-1
 MVC Knee Extension 4.2 0.360 0.058(-0.07:0.19) 
180°·s
-1
 MVC Knee Extension 3 0.434 0.091(-0.148:0.331) 
30°·s
-1
 MVC Knee Flexion 9.8 0.154 0.151(-0.061:0.364) 
180°·s
-1
 MVC Knee Flexion 10.4 0.143 0.26(-0.096:0.617) 
60˚ MVC Knee Extension 4.2 0.355 0.065(-0.079:0.211) 
60˚ MVC Knee Flexion 24.5 0.026* 0.427(0.055:0.798) 
Body Composition Measures 
Lean Tissue Mass 0.1 0.865 0.00(-0.00:0.00) 
Reactivity Measures 
Visual Reaction Time (DOM) 0.4 0.758 3.65(-20.75:28.05) 
Visual Reaction Time (NON) 4.8 0.325 11.16(-11.91:34.24) 
DOM: dominant hand; NON: non-dominant hand; * Significant at the 0.05 level 
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Supplementary Table 2.5 Univariable association between impairments (Predictor 
Variables) and performance on the RSST (Outcome measure) 
Predictor Variable Adjusted R
2
 (%) P Value 
Unstandardised B 
(95% CI) 
RSST 
Demographic Variables 
Age 4 0.373 0.275(-0.354:0.906) 
Disease Duration 0.0 0.897 0.0876(-1.307:1.482) 
CAG repeat 1.0 0.649 0.438(-1.541:2.418) 
Disease Burden Score 18 0.050
* 
0.045(0.000:0.0914) 
UHDRS-TMS 3.9 0.379 0.186(-0.245:0.618) 
Cognitive Measures 
SDMT 
Correct Written 22 0.032
* 
-0.58(-1.10:-0.056) 
Correct Oral 20.3 0.041
* 
-0.43(-0.85:-0.02) 
HVLT-R 
Total Recall 21.3 0.032
* 
-0.98(-1.88:-0.094) 
Delayed Recall 7.8 0.208 -1.511(-3.93:0.913) 
Retention 0.7 0.697 0.049(-0.212:0.3121) 
Recognition Discrimination 
Index 
17.5 0.053 -1.73(-3.48:0.021) 
D-KEFS TMT 
Visual Scanning 10.9 0.143 0.273(-0.101:0.647) 
Number Sequencing 10.4 0.154 0.192(-0.079:0.464) 
Letter Sequencing 22.51 0.035
* 
0.114(0.009:0.219) 
Number-Letter Sequencing 0.0 0.967 -0.003(-0.177:0.171) 
Motor Speed 49.5 0.001
* 
0.26(0.121:0.400) 
D-KEFS CWIT 
Colour Naming 25 0.029
* 
0.33(0.039:0.63) 
Word Reading 53 0.000
*
 0.68(0.377:0.99) 
Inhibition 7.3 0.264 0.085(-0.070:0.241) 
Lower Limb Strength Measures 
30°·s
-1
 MVC Knee Extension 4.1 0.363 -0-047(-0.155-0.059) 
180°·s
-1
 MVC Knee Extension 15 0.075 -0.165(-0.34:0.01) 
30°·s
-1
 MVC Knee Flexion 16.8 0.058 -0.161 (-0.32:0.006) 
180°·s
-1
 MVC Knee Flexion 15.7 0.068 -0.261(-0.544:0.020) 
60˚ MVC Knee Extension 2.7 0.466 -0.042(-0.162:0.077) 
60˚ MVC Knee Flexion 42.7 0.002* -0.465(-0.731:-0.198) 
Body Composition Measures 
Lean Tissue Mass 0.1 0.865 0.00(-0.00:0.00) 
Reactivity Measures 
Visual Reaction Time (DOM) 0.4 0.758 3.65(-20.75:28.05) 
Visual Reaction Time (NON) 4.8 0.325 11.16(-11.91:34.24) 
DOM: dominant hand; NON: non-dominant hand; * Significant at the 0.05 level 
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Supplementary Table 2.6 Univariable association between impairments (Predictor 
Variables) and performance on the 6MWT (Outcome measure) 
Predictor Variable Adjusted R
2
 (%) P Value 
Unstandardised B 
(95% CI) 
6MWT    
Demographic Variables 
Age 6.0 0.281 -3.315(-9.57:2.94) 
Disease Duration 2.9 0.461 -5.27(-19.95:9.40) 
CAG repeat 7 0.246 -11.01(-30.25:8.23) 
Disease Burden Score 41.2 0.002
* 
-0.675(-1.06:-0.288) 
UHDRS-TMS 18 0.056 -4.05(-8.2:0.108) 
Cognitive Measures 
SDMT 
Correct Written 37.9 0.003
* 
7.41(2.86:11.97) 
Correct Oral 40.1 0.002
* 
6.07(2.56:9.58) 
HVLT-R 
Total Recall 19.5 0.045
* 
9.07(0.229:17.922) 
Delayed Recall 15.21 0.081 21.00(-2.80:44.82) 
Retention 0.2 0.828 0.282(-2.39:2.95) 
Recognition Discrimination 
Index 
13.4 0.102 16.38(-3.59:36.36) 
D-KEFS TMT 
Visual Scanning 24 0.028
* 
-4.55(-8.56:-0.546) 
Number Sequencing 21.4 0.040
* 
-2.83(-5.52:-0.143) 
Letter Sequencing 31.6 0.012
* 
-1.32(-2.32:-0.32) 
Number-Letter Sequencing 0.0 0.950 -0.062(-2.23:2.11) 
Motor Speed 52.8 0.001
* 
-2.81(-4.28:-1.35) 
D-KEFS CWIT 
Colour Naming 45 0.002
* 
-5.309(-8.311:-2.306) 
Word Reading 52.2 0.000
*
 -6.66(-9.72:-3.60) 
Inhibition 26.4 0.024
* 
-1.90(-3.53:-0.27) 
Lower Limb Strength Measures 
30°·s
-1
 MVC Knee Extension 7.1 0.242 0.63(-0.462:1.722) 
180°·s
-1
 MVC Knee 
Extension 
14 0.094 1.59 (-0.295:3.479) 
30°·s
-1
 MVC Knee Flexion 25.2 0.020
* 
1.96 (0.341:3.59) 
180°·s
-1
 MVC Knee Flexion 21.9 0.033
* 
3.04(0.28:5.80) 
60˚ MVC Knee Extension 1.8 0.558 0.373(-0.936:1.683) 
60˚ MVC Knee Flexion 44.2 0.002* 4.74(2.01:7.47) 
Body Composition Measures 
Lean Tissue Mass 0.2 0.828 0.00(-0.00:0.00) 
Reactivity Measures 
Visual Reaction Time 
(DOM) 
10 0.162 
-167.21(-
407.8:73.38) 
Visual Reaction Time (NON) 16.7 0.066 -203.17:14.78) 
DOM: dominant hand; NON: non-dominant hand; * Significant at the 0.05 level 
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Supplementary Table 2.7 Univariable association between impairments (Predictor 
Variables) and performance on the TWT (Self Paced) (Outcome Measure) 
Predictor Variable 
Adjusted R
2
 
(%) 
P Value 
Unstandardised B 
(95% CI) 
TWT (Self Paced) 
Demographic Variables 
Age 2.6 0.482 0.048(-0.092:0.189) 
Disease Duration 5.1 0.325 0.155(-0.166:0.4763) 
CAG repeat 13.4 0.103 0.336(-0.074:0.747) 
Disease Burden Score 50 0.000
*
 0.0164(0.008:0.0243) 
UHDRS-TMS 13 0.115 0.075(-0.019:0.170) 
Cognitive Measures 
SDMT 
Correct Written 0.17 0.059 -0.11(-0.22:0.004) 
Correct Oral 20 0.042
* 
-0.094(-0.18:-0.003) 
HVLT-R 
Total Recall 10.2 0.158 -0.14(-0.35:0.061) 
Delayed Recall 12.5 0.116 -0.422(-0.95:0.11) 
Retention 0.0 0.911 -0.003(-0.062:0.056) 
Recognition Discrimination 
Index 
8.5 0.199 -0.28(-0.74:0.165) 
D-KEFS TMT 
Visual Scanning 12.8 0.121 0.073(-0.021:0.168) 
Number Sequencing 11.8 0.139 0.046(-0.016:0.109) 
Letter Sequencing 10.3 0.180 0.017(-0.008:0.043) 
Number-Letter Sequencing 0.7 0.806 0.005(-0.047:0.058) 
Motor Speed 26.7 0.034
* 
0.045(0.003:0.086) 
D-KEFS CWIT 
Colour Naming 8.5 0.199 -0.28(-0.74:0.165) 
Word Reading 34.1 0.009
* 
0.108(0.031:0.185) 
Inhibition 29.3 0.011
* 
0.110(0.028:0.192) 
Lower Limb Strength Measures 
30°·s
-1
 MVC Knee Extension 6.8 0.251 -0.013(-0.03:0.10) 
180°·s
-1
 MVC Knee Extension 11.2 0.139 -0.031(-0.073:0.011) 
30°·s
-1
 MVC Knee Flexion 6.8 0.251 -0.013(-0.037:0.010) 
180°·s
-1
 MVC Knee Flexion 14.6 0.087 -0.055(-0.119-0.008) 
60˚ MVC Knee Extension 5.6 0.300 -0.014(-0.042:0.013) 
60˚ MVC Knee Flexion 43 0.002* -0.104(-0.165:-0.043) 
Body Composition Measures 
Lean Tissue Mass 1.5 0.588 0.00(-0.00:0.00) 
Reactivity Measures 
Visual Reaction Time (DOM) 2.4 0.502 1.81(-3.73:7.36) 
Visual Reaction Time (NON) 7.8 0.217 3.09(-1.98:8.16) 
DOM: dominant hand; NON: non-dominant hand; * Significant at the 0.05 level 
54 
 
Supplementary Table 2.8 Univariable associations between impairments (Predictor 
Variables) and performance on the TWT (Fast Paced) (Outcome Measure) 
Predictor Variable 
Adjusted R
2
 
(%) 
P Value 
Unstandardised B 
(95% CI) 
TWT (Fast Paced) 
Demographic Variables 
Age 7 0.246 0.073(-0.055:0.202) 
Disease Duration 9.6 0.171 0.199(-0.094:0.492) 
CAG repeat 8.5 0.200 0.25(-0.144:0.646) 
Disease Burden Score 43 0.001
* 
0.0142(0.006:0.0221) 
UHDRS-TMS 13.6 0.100 0.073(-0.015:0.161) 
Cognitive Measures 
SDMT 
Correct Written 16.7 0.067 -0.10(-0.211:0.007) 
Correct Oral 18.33 0.053 -0.084(-0.169:0.001) 
HVLT-R 
Total Recall 16.2 0.071 -0.17(-0.35:0.015) 
Delayed Recall 20.1 0.037
* 
-0.51(-0.98:-0.034) 
Retention 1.2 0.63 -0.012(-0.067:0.042) 
Recognition Discrimination Index 11.8 0.128 -0.318(-0.735:0.099) 
D-KEFS TMT 
Visual Scanning 16.9 0.072 0.078(-0.00:0.164) 
Number Sequencing 11.11 0.151 0.042(-0.016:0.100) 
Letter Sequencing 16.0 0.089 0.02(-0.00:0.043) 
Number-Letter Sequencing 0.2 0.897 0.002(-0.042:0.047) 
Motor Speed 35.3 0.012
* 
0.047(0.012:0.083) 
D-KEFS CWIT 
Colour Naming 29 0.017
* 
0.08(0.017:0.160) 
Word Reading 43.4 0.001
* 
0.125(0.056:0.194) 
Inhibition 15.5 0.095 0.030(-0.005:0.066) 
Lower Limb Strength Measures 
30°·s
-1
 MVC Knee Extension 7.7 0.221 -0.013(-0.036:0.008) 
180°·s
-1
 MVC Knee Extension 9.8 0.165 -0.027(-0.067:0.012) 
30°·s
-1
 MVC Knee Flexion 19.3 0.046
* 
-0.035(-0.07:-0.00) 
180°·s
-1
 MVC Knee Flexion 11.6 0.132 -0.045(-0.106:0.015) 
60˚ MVC Knee Extension 4.8 0.338 -0.012(-0.039:0.014) 
60˚ MVC Knee Flexion 60 0.000* -0.112(-0.16:-0.06) 
Body Composition Measures 
Lean Tissue Mass 1.2 0.634 0.00(-0.00:0.00) 
Reactivity Measures 
Visual Reaction Time (DOM) 1.1 0.645 1.16(-4.05:6.39) 
Visual Reaction Time (NON) 4.5 0.352 2.20(-2.63:7.03) 
DOM: dominant hand; NON: non-dominant hand; * Significant at the 0.05 level 
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Supplementary Table 2.9 Associations between impairments (Predictor Variables) and task 
performance (Outcome Measure) from multiple Multivariable regression models 
Predictor Model 
Adjusted R
2 
(%) 
p-value 
Unstandardised B (95% 
CI) 
Performance on balance tasks 
BBS 
 
     Disease Burden Score 
 
57 
 
0.001
 
 
-0.051 [-0.076: -0.026] 
SOT 
 
     Disease Burden Score 
     Motor Speed 
50 
 
0.020
 
0.093 
 
-0.073 [-0.133:-0.0138] 
-0.177 [-0.388:0.034] 
RSST 
 
     60˚ MVC Knee Flexion 
     Motor Speed 
72 
 
0.011
 
0.002 
 
-0.314 [-0.544: -0.085] 
0.577 [0.238:0.896] 
Performance on mobility tasks 
TWT (Self Paced) 
 
      Disease Burden Score 
      60˚ MVC Knee Flexion 
      Motor Speed 
85 
 
0.002
 
0.003 
0.052 
 
0.010 [0.004: 0.016] 
-0.067 [-0.105: -0.029] 
0.020 [-0.000:0.0404] 
TWT (Fast Paced) 
 
     Disease Burden Score 
     60˚ MVC Knee Flexion 
     Motor Speed 
72 
 
 
0.001 
0.028 
0.041 
 
 
0.015 [0.007:0.024] 
-0.062 [-0.116:-0.007] 
 0.021 [-0.000:0.0403] 
6MWT 
 
     Disease Burden Score 
     60˚ MVC Knee Flexion  
     Motor Speed                       
85 
 
0.002 
0.039 
0.002 
 
-0.519 [-0.802:-0.237] 
1.975 [0.114: 3.83] 
-1.76 [-2.759:-0.768] 
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3.1 ABSTRACT 
Background: Strength training has, in recent years, been shown to be beneficial for people 
with Parkinson’s disease and multiple sclerosis. Consensus regarding its utility for these 
disorders nevertheless remains contentious among healthcare professionals. Greater clarity is 
required, especially in regards to the type and magnitude of effects as well as the response 
differences to strength training between individuals with Parkinson’s disease or multiple 
sclerosis.  
Objective: To examine the effects, magnitude of those effects and response differences to 
strength training between patients with Parkinson’s disease or multiple sclerosis. 
Data Sources: A comprehensive search of electronic databases including PEDro, PubMED, 
EMBASE, Cochrane Central Register of Controlled Trials, and CINAHL was conducted 
from inception to July 2014. 
Study Eligibility: English articles investigating the effect of strength training for individuals 
with neurodegenerative disorders were selected. Strength training trials that met the inclusion 
criteria were found for individuals with Parkinson’s disease or multiple sclerosis. 
Participants: Individuals with Parkinson’s disease or multiple sclerosis. 
Intervention: Strength training interventions included traditional (free weights/machine 
exercises) and non-traditional programs (eccentric cycling). 
Study Appraisal: Included articles were critically appraised using the PEDro scale. 
Results: Of the five hundred and seven articles retrieved, only twenty articles met the 
inclusion criteria. Of these, fourteen were randomised and six were non-randomised 
controlled articles in Parkinson’s disease or multiple sclerosis. Six randomised and two non-
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randomised controlled articles originated from three trials and were subsequently pooled for 
systematic analysis. Strength training was found to significantly improve muscle strength in 
people with Parkinson’s disease (15%-83.2%) and multiple sclerosis (4.5%-36%). Significant 
improvements in mobility (11.4%) and disease progression were also reported in people with 
Parkinson’s disease after strength training. Furthermore, significant improvements in fatigue 
(8.2%), functional capacity (21.5%), quality of life (8.3%), power (17.6%) and 
electromyography activity (24.4%) were found in individuals with multiple sclerosis after 
strength training.  
Limitations: Heterogeneity of interventions and study outcomes in Parkinson’s disease and 
multiple sclerosis trials. 
Conclusions: Strength training is useful for increasing muscle strength in Parkinson’s disease 
and to a lesser extent multiple sclerosis.  
Implications of key findings: Strength training is a useful adjunct treatment for Parkinson’s 
disease and multiple sclerosis. 
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3.2 INTRODUCTION 
Neurodegenerative disorders such as Parkinson’s disease and multiple sclerosis represent a 
major medical concern for health professionals and national healthcare bodies (Nance, 2012). 
Both disorders result from progressive neuronal dysfunction and neuronal cell death leading 
to progressive disability and eventual death (Lin and Beal, 2006). Classical signs and 
symptoms customary to both disorders include motor problems, cognitive impairment, 
behavioural disturbances and systemic abnormalities (Benedict and Zivadinov, 2011; 
Mitchell and Borasio, 2007; Olanow et al., 2009).  
There is no cure and few cost effective drug agents for treating people with Parkinson’s 
disease or multiple sclerosis (Evans et al., 2011; Lu et al., 2012). Recent advances in 
understanding the pathogenic mechanisms responsible for each disorder may aid in the 
identification and development of cost effective disease modifying agents in the future 
(Noyes et al., 2011). However, cost effective treatments, with disease modifying properties 
and symptomatic benefits are required in the short term. 
Accumulating evidence suggests that strength training is a useful therapy for addressing 
many of the clinical features that present in individuals with neurodegenerative disorders 
(Falvo et al., 2008; Hindle et al., 2013; Kjølhede et al., 2012). By definition, strength training 
refers to an intervention, in which participants train a muscle or group of muscles against an 
external resistance (Esco, 2013). While evidence suggests that lower limb strength training 
(i.e. leg press, knee extension and knee flexion) is beneficial for individuals with Parkinson’s 
disease and multiple sclerosis (Dalgas et al., 2010a; Dalgas et al., 2009; Dalgas et al., 2010b; 
Dalgas et al., 2013; Dodd et al., 2011; Schilling et al., 2010; Shulman et al., 2013), consensus 
regarding the effects, magnitude of those effects and disease dependent responses remain 
contentious. By contrast, the therapeutic utility of strength training is well recognised in the 
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elderly (Nelson et al., 2007), individuals with mild cognitive impairment and in those that 
have suffered a stroke. Health benefits associated with strength training in elderly individuals 
include improvements in strength (Fiatarone et al., 1990; Nelson et al., 1994), cardio-
respiratory capacity (Pereira et al., 2012), functional capacity (Mangione et al., 2010; Pereira 
et al., 2012), muscle activity (Cadore et al., 2013), body composition (Avila et al., 2010), 
mood (Pereira et al., 2013), cognition (Cassilhas et al., 2007; Liu-Ambrose et al., 2010), 
health related quality of life (Levinger et al., 2007) and enhanced hemodynamic activity on 
functional magnetic resonance imaging tasks (Nagamatsu et al., 2012). In individuals who 
have suffered a stroke, strength training has been found to improve muscular strength, upper 
and lower limb function and performance on functional tasks (Ada et al., 2006; Harris and 
Eng, 2010; Ouellette et al., 2004). Improvements in selective attention, conflict resolution, 
associative memory and regional patterns of functional brain activity have also been observed 
after strength training in seniors with mild cognitive impairment (Nagamatsu et al., 2012). 
In the last two years, three systematic reviews have evaluated the effects of strength training 
in either Parkinson’s disease or multiple sclerosis (Brienesse and Emerson, 2013; Kjølhede et 
al., 2012; Lima et al., 2013). Findings from these reviews suggest that strength training is 
useful for improving muscle strength and some measures of functional capacity in these 
disorders. Since the publication of these reviews, a number of randomised controlled trials 
have been published (Brienesse and Emerson, 2013; Kjølhede et al., 2012; Lima et al., 2013), 
somewhat limiting the informative capacity of previous reviews. Previous systematic reviews 
have also included trials with confounding supplementary interventions (i.e. creatine 
monohydrate and balance training) (Brienesse and Emerson, 2013; Lima et al., 2013) as well 
as trials without a disease control or comparison group (Brienesse and Emerson, 2013; 
Kjølhede et al., 2012). These methodological limitations may have led to an inaccurate 
appraisal of the effects of strength training as a therapy in individuals with Parkinson’s 
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disease or multiple sclerosis. It is of vital importance that systematic reviews accurately 
evaluate experimental therapies like strength training as such documents inform health 
professionals. 
In this systematic review we provide the most recent evidence to support a robust evaluation 
of the effect of strength training in people with Parkinson’s disease or multiple sclerosis. 
Unlike previous reviews, our study evaluates the effect of strength training alone, in people 
with Parkinson’s disease or multiple sclerosis. In addition, our study only selects trials that 
included individuals with multiple sclerosis or Parkinson’s disease in the control or 
comparison group. Moreover, our study evaluates through a meta-analysis, the magnitude of 
strength improvements in individuals with multiple sclerosis or Parkinson’s disease in 
response to strength training. Finally, unlike previous reviews, our study explores whether 
differences in response to strength training exist between individuals with multiple sclerosis 
or Parkinson’s disease. 
3.3 MATERIAL AND METHODS 
3.3.1 Search strategy  
A comprehensive search of electronic databases was conducted from inception to July 2014. 
Electronic searches were performed using PEDro, PubMED, EMBASE, Cochrane Central 
Register of Controlled Trials, and CINAHL databases. The search strategy utilised a 
population, intervention, comparison and outcome (PICO) approach (Moher et al., 2010). The 
population key words were “Parkinson’s disease”, “multiple sclerosis”, Alzheimer’s disease, 
amyotrophic lateral sclerosis, Huntington’s disease and spinocerebellar ataxia; the 
intervention key words were “strength training”, “progressive strength training”, “resistance 
training”, “weight training” and “strengthening programs”; and the outcome key words 
included “strength”, “disease severity”, “gait”, “balance”, “fatigue”, “functional capacity”, 
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“mood” and “quality of life”. This initial search only found trials on strength training in 
individuals with Parkinson’s disease or multiple sclerosis.  
As this was a literature review and did not involve the recruitment and assessment of patients, 
ethical approval was not necessary. 
3.3.2 Eligibility criteria 
Randomised controlled trials and non-randomised controlled trials that examined the effect of 
strength training in individuals suffering with multiple sclerosis or Parkinson’s disease were 
included in the review. Strength training was defined as an intervention in which participants 
exercised a muscle or group of muscles against an external resistance (Esco, 2013). Eligible 
studies included those examining the effect of strength training in individuals with multiple 
sclerosis and Parkinson’s disease. Exclusion criteria were as follows: (1) case studies; (2) 
observational studies; (3) studies with healthy controls or healthy comparison groups; and (5) 
studies employing supplementary intervention therapies in addition to or different from 
strength training.  
3.3.3 Data extraction 
Two independent authors (T.C and A.R) extracted data from the included studies. A 
specialised extraction form was designed and recorded the following methodological details 
for each study: 
 Publication details: authors and year of publication. 
 Details of the study: study design and number of participants, experimental and 
control interventions and reported outcomes (controls and experimental). 
 Participant characteristics: disease population, disease status and age. 
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 Specific intervention details: intervention groups, mode of strength training, targeted 
anatomical regions, setting in which the study was conducted, level of supervision, 
duration of the intervention (weeks), frequency of strength training, specific exercises 
employed, exercise intensity, number of sets and repetitions performed for each 
exercise, rest taken between sets and exercises and the progression method used for 
strength training interventions. 
 Moderator variables: participant retention and dropouts, participant adherence and 
adverse effects associated with strength training. 
Corresponding authors of studies were contacted as necessary for supplementary information 
not detailed in the publication. In cases where authors did not respond or did not provide 
supplementary methodological information pertaining to their publication, a not reported 
(NR) statement was assigned.  
3.3.4 Quality assessment  
All articles that satisfied the pre-defined inclusion criteria were independently rated for 
quality by two reviewers (T.C and A.R) using the Physiotherapy Evidence Database (PEDro) 
scale (Maher et al., 2003). The PEDro scale is an eleven points scale designed to examine the 
methodological quality of intervention studies. The scale evaluates the following 
methodological aspects: (1) specific eligibility criteria, (2) randomisation allocation, (3) 
concealed allocation, (4) baseline demographic similarities, (5) participant blinding, (6) 
therapist blinding, (7) outcome assessor blinding, (8) whether more than 85% of participants 
completed follow up for at least one primary outcome, (9) intention to treat analysis, (10) 
between group statistical comparisons and (11) point estimates and variability for at least one 
of the primary outcome measures. When rating each study, only criteria two-eleven are 
considered for the PEDro scale. Initial discrepancies between the independent authors were 
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resolved by consensus. In instances where discrepancies could not be resolved a final 
decision was made by another independent author (M.Z). 
3.3.5 Data analysis and synthesis  
For analysis, studies were categorised according to disease. The heterogeneity of populations 
and extensive variety of reported outcomes prevented a meta-analysis for all outcomes, with 
the exception of strength. While fifteen articles reported on strength as an outcome (Corcos et 
al., 2013; Dalgas et al., 2009; Dalgas et al., 2010b; Dalgas et al., 2013; Dibble et al., 2006; 
Dibble et al., 2009; Dodd et al., 2011; Fimland et al., 2010; Hass et al., 2012; Medina-Perez 
et al., 2014; Sabapathy et al., 2011; Schilling et al., 2010; Shulman et al., 2013), three articles 
by Dalgas et al (Dalgas et al.; 2010b; 2013) and two articles by Dibble et al (2006; 2009) 
appeared to originate from the same trial. Strength data from three articles by Dalgas et al 
(2009; 2010b; 2013) were pooled together into a single effect size for a better interpretation 
of the effects of strength training on strength as an outcome. Standardised effect sizes were 
calculated for the meta-analysis using pre and post strength mean values for each group 
(intervention and comparison) (Hedges and Olkin, 1985). Effect sizes were corrected for the 
magnitude of sample size of each study as suggested by Hedges and Olkin (1985). The risk of 
publication bias in trials was examined statistically using the egger regression test, with a 
significant publication bias considered to be p≤0.10. All statistical analyses were performed 
using STATA 9.1 (StataCorp LC, Texas, USA). 
3.4 RESULTS 
3.4.1 Articles included 
The database search strategy and results are presented in Figure 3.1. Five hundred and seven 
articles were identified by the initial search strategy. Four hundred and seventy one of the 
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identified articles were excluded based on their title. The abstracts of the remaining thirty-six 
articles were evaluated and six articles were excluded (Figure 3.1). Full texts of the remaining 
thirty articles were retrieved and reviewed, resulting in the exclusion of ten articles (Figure 
3.1). Of the twenty articles included in the systematic review, eight appeared to originate 
from three separate trials. Subsequently the extracted and reviewed data is representative of 
fifteen independent trials. 
 
 
 
 
 
 
 
 
 
 
 
 
 
507 Potential Articles Identified From Initial Database Searches 
 
36 Article Abstracts Retrieved For Evaluation 
471 Articles Excluded Based On Title 
 93 Duplicated Articles 
 352 Articles Not Relevant 
 14 Review Articles 
 5 Not Resistance Weight Bearing 
 6 Additional Complementary Therapy 
 
30 Full Text Articles Retrieved For Evaluation 
6 Articles Excluded 
 1 Not Comparable Outcomes 
 4 Not Resistance Weight Bearing 
 1 Home based & Not Weight Bearing 
 
20 Articles Systematically Evaluated 
10 Articles Excluded  
 8 Did Not Possess A Valid Comparison 
Group 
 2 Qualitative Studies 
8 Articles Excluded For Meta-analysis 
 5 Did Not Examine Strength 
 3 Articles originated from the same trial 
 
12 Articles Examining Strength Included In The Meta-Analysis 
Figure 3.1 Flowchart for selection of studies and included meta-analysis 
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3.4.2 Methodological quality 
The methodological quality of included trials varied considerably in both Parkinson’s disease 
and multiple sclerosis populations. PEDro scores ranged from four to eight points in both 
Parkinson’s disease (Bloomer et al., 2008; Corcos et al., 2013; Dibble et al., 2006; Dibble et 
al., 2009; Hass et al., 2012; Paul et al., 2014; Prodoehl et al., 2015; Sage et al., 2011; 
Schilling et al., 2010; Shulman et al., 2013) and multiple sclerosis trials (Broekmans et al., 
2011; Dalgas et al., 2010a; Dalgas et al., 2009; Dalgas et al., 2010b; Dalgas et al., 2013; 
DeBolt and McCubbin, 2004; Dodd et al., 2011; Fimland et al., 2010; Medina-Perez et al., 
2014; Sabapathy et al., 2011) (Table 3.1). 
3.4.3 Participants characteristics 
The number of trials included was eight in Parkinson’s disease (Bloomer et al., 2008; Corcos 
et al., 2013; Dibble et al., 2006; Dibble et al., 2009; Hass et al., 2012; Paul et al., 2014; 
Prodoehl et al., 2015; Sage et al., 2011; Schilling et al., 2010; Shulman et al., 2013) and 
seven in multiple sclerosis (Broekmans et al., 2011; Dalgas et al., 2010a; Dalgas et al., 2009; 
Dalgas et al., 2010b; Dalgas et al., 2013; DeBolt and McCubbin, 2004; Dodd et al., 2011; 
Fimland et al., 2010; Medina-Perez et al., 2014; Sabapathy et al., 2011). Disease population, 
study design, number of participants, stage of disease, mean age and standard deviation, trial 
intervention and trial outcomes are shown in Tables 3.2 and 3.3.  
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Table 3.1 Trial inclusions rated according to the PEDro scale 
Trials 
    PEDro criteria    
Total Score 
#1 #2 #3 #4 #5 #6 #7 #8 #9 #10 #11 
Parkinson’s disease 
RCT Paul et al (2014)
 
 Yes Yes Yes Yes Yes No Yes No Yes Yes Yes 8/10 
 
PRET-PD RCT Corcos et al
 
(2013) & Prodoehl et al 
(2015) 
Yes Yes Yes Yes No No Yes Yes No Yes Yes 7/10 
 Shulman et al (2013) Yes Yes No Yes Yes Yes No No No Yes Yes 6/10 
 Sage et al (2011) Yes Yes No Yes No No No Yes Yes Yes Yes 7/10 
 Bloomer et al (2008) Yes Yes No Yes No No No No No Yes Yes 4/10 
non-RCT Hass et al (2012) Yes Yes No Yes No No No Yes Yes Yes Yes 6/10 
 Schilling et al (2010) Yes Yes No Yes No No No No Yes No Yes 4/10 
 Dibble et al (2006; 2009) Yes No No Yes No No No Yes Yes Yes Yes 6/10 
Multiple Sclerosis 
RCT Medina-Perez et al (2014) Yes Yes No Yes No No No Yes Yes Yes Yes 6/10 
 
Dalgas et al (2010a; 2009; 
2010b; 2013) 
Yes Yes Yes Yes No No Yes No Yes Yes Yes 6/10 
 Dodd et al (2011) Yes Yes Yes Yes No No Yes Yes Yes Yes Yes 8/10 
 Broekmans et al (2011) Yes Yes Yes Yes No No No Yes No No Yes 6/10 
 Fimland et al (2010) Yes Yes No Yes No No No No No Yes Yes 4/10 
Non-RCT Sabapathy et al (2011) Yes Yes No Yes No No No Yes No Yes Yes 5/10 
 De Bolt et al (2004) Yes Yes No Yes No No No Yes No Yes Yes 6/10 
RCT randomised controlled trial, non-RCT non-randomised controlled trial 
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Table 3.2 Overview of trials of strength training interventions in individuals with Parkinson’s disease or multiple sclerosis 
Reference 
Experimental/ 
control (n) 
Stage of disease Mean age (SD) 
Experimental 
Intervention 
Control/Comparison 
Intervention 
Measures/ Results 
Parkinson’s disease 
RCT       
Paul et al (2014)  
Exp=20 
Con=20 
Hoehn & Yahr 
Exp=68.1 ± 5.6 
Con=64.5 ± 7.4 
Lower Body 
RE/Machine 
(non-continuous) 
Sham low intensity 
exercises trunk/lower 
body 
Power ↑ 
Strength ↑ 
Movement speed ↑ 
Falls  → 
Balance → 
Mobility → 
Functional capacity → 
PRET-PD RCT 
Corcos et al 
(2013) & 
Prodoehl et al 
(2015) 
Exp=24 
mFC=24 
Hoehn & Yahr  
I-V 
Exp= 59.0 ± 4.6 
mFC=58.6 ± 5.6 
Full Body RE/ Machine 
& Free Weights 
(non-continuous) 
Modified fitness counts 
UPDRS-III ↑ 
Strength ↑ 
Quality of life → 
Balance ↑* 
Mobility ↑* 
Functional capacity → 
Shulman et al 
(2013) 
Exp=28 
LIT=26 
HIT=26 
Hoehn & Yahr 
I-III 
Exp=65.3 ± 11.3 
LIT=65.8 ± 11.5 
HIT=66.1 ± 9.7 
Lower Body RE/ 
Machine 
(non-continuous) 
Low Intensity Treadmill 
High Intensity Treadmill 
Mobility ↑* 
Strength ↑ 
UPDRS-III (motor) ↑*  
Falls → 
Fatigue  → 
Quality of life → 
Mood → 
Sage et al 
(2011) 
Exp=18 
Con=18 
Aerobic=17 
Aquatic=12 
SAFEx=24 
NR 
Exp=68.7 ± 8.3 
Con=68.6 ± 8.1 
Aerobic=65.8 ± 9-9 
Aquatic=63.1 ± 9.2 
SAFE=68.0 ± 11 
Whole body work out 
(non-continuous) 
Daily living activities 
 
UPDRS-III ↑* 
 
Bloomer et al 
(2008) 
Exp=8 
Con=8 
Hoehn & Yahr 
I-II 
Exp= 61.0 ± 2.0 
Con= 57.0 ± 3.0 
Lower Body RE/ 
Machine 
(non-continuous) 
Standard care 
Oxidative & antioxidant 
markers ↑ 
Non-RCT       
Hass et al Exp=9 Hoehn & Yahr Exp= 67 ± 8.0 Lower Body & Core/ Standard care Mobility ↑ 
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(2012) Con=9 I-III Con= 64 ± 7.0 Machine & Theraband 
(non-continuous) 
Strength ↑ 
Schilling et al 
(2010) 
Exp=9 
Con=9 
Hoehn & Yahr 
I-II/III 
Exp= 61.3 ± 8.6 
Con= 57.0 ± 7.1 
Lower Body/ Machine 
(non-continuous) 
Standard care 
Strength ↑ 
Functional capacity → 
Mobility ↑* 
Balance → 
Dibble et al 
(2006; 2009) 
Exp=10 
Con=9 
Hoehn & Yahn  
I-III 
Exp=64.3 ± 9.6 
Con= 67.0 ± 10.2 
Eccentric resistance 
training ergometer 
(continuous) 
Standard care 
Strength ↑ 
Quadriceps muscle volume ↑* 
UPDRS-III (motor) → 
Quality of life ↑ 
Mobility ↑ 
Functional capacity (TUG) ↑ 
(stair descent)  
↑ * 
Multiple sclerosis 
RCT       
Medina-Perez et 
al (2014)  
Exp=30 
Con=12 
EDSS: 1.0-6.0 
Exp= 49.6 ± 11.0 
Con= 46.2 ± 7.5 
Lower Body/Machine 
(non-continuous) 
Standard Care 
Strength ↑ 
Power  ↑ 
Muscle Endurance → 
Dalgas et al 
(2010a; 2009; 
2010b; 2013) 
Exp=19 
Con=19 
EDSS: 3.0-5.5 
DC: RR 
Exp= 49.1 ± 8.4 
Con= 47.7 ± 10.4 
Lower Body/Machine 
(non-continuous) 
Standard care 
EMG activity ↑ 
Strength ↑ 
Thigh Volume ↑* 
Fatigue ↑* 
Mood ↑* 
Quality of life (physical) ↑* 
CSA II/IIa muscle fibres ↑* 
Functional capacity  ↑* 
Dodd et al 
(2011) 
Exp= 39 
Con= 37 
AID: 2,3 or 4 
DC: RR 
Exp= 47.7 ± 10.8 
Con= 50.4 ± 9.6 
Lower Body/Machine 
(non-continuous) 
Standard Care 
Strength ↑ 
Muscle Endurance ↑ 
Fatigue ↑ 
Quality of life (physical 
domain) ↑ 
Mobility → 
Broekmans et al 
(2011) 
Exp=11 
Exp+ES=11 
Con=14 
EDSS: 2.0-6.5 
Exp=4.5 ± 1.3 
Exp+ES=4.4 ± 0.9 
Con=4.1 ± 1.1 
Lower Body/Machine 
(non-continuous) 
Normal living habits 
Strength ↑ 
Mobility → 
Balance ↑ 
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Fimland et al 
(2010) 
Exp=7 
Con=7 
EDSS: 2.0-6.5 
DC: NR 
Exp= 53.0 ± 4.0 
Con= 54.0 ± 2.0 
Lower Body/Machine 
(non-continuous) 
Standard care 
Strength ↑ 
EMG activity↑ 
Motor output ↑ 
Non-RCT       
Sabapathy et al 
(2011) 
Exp=15 
END=6 
DSS: 1-3 
DC: RR, SP, PP 
Exp= 55.0 ± 7.0 
Upper & Lower Body & 
Core 
(non-continuous) 
Endurance Exercise 
Balance → 
Mobility → 
Strength → 
Mood → 
Quality of Life → 
Fatigue → 
MSIS physical→ 
MSIS psychological → 
DeBolt et al 
(2004) 
Exp= 19 
Con=17 
EDSS: 2.0-6.0 
Exp=51.6 ± 7.2 
Con=47.8 ± 10.5 
Weighted vest 
Home based resistance 
training 
(non-continuous) 
Standard care 
Leg extensor power ↑ 
Functional capacity → 
Balance → 
 
↑ indicates significant improvement, → indicates no significant change, ↓ indicates significant deterioration, ↑* time effect,  RCT = randomised 
controlled trial, non-RCT = non-randomised controlled trial, Exp = experimental group, Con = control group, RE = resistance exercise, ES = 
electro-stimulation, UPDRS-III = Unified Parkinson’s Disease Rating Scale Version-III, END = endurance training, SAFE = sensory attention 
focused-exercise, AID = ambulation index score, DC = disease course, RR = relapse remitting, EDSS = expanded disability status scale, DSS = 
disease steps scale, SP = secondary progressive, P = Primary progressive, EMG = electromyography, CSA= cross sectional area, MSIS = 
multiple sclerosis impact scale 
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Table 3.3 Summary details of the specific strength training interventions used in Parkinson’s disease or multiple sclerosis trials 
Trial Location Supervision Duration Frequency Exercises 
Multi vs 
Single Joint 
Intensity Sets Repetitions Rest Progression 
RCT (Parkinson’s disease) 
Paul et al 
(2014) 
University 
Lab 
Supervised 
(ratio NR) 
12 Weeks 
Twice 
Weekly 
Leg 
extension, 
knee flexion, 
hip flexion, 
hip 
abduction 
Single-joint 
1
st
 set 40% 
(1RM) 
2
nd 
set 50% 
(1RM) 
3
rd
 set 60% 
(1RM) 
3 Sets 8 Reps NR 5% 
PRET-PD 
RCT Corcos 
et al (2013)
 
& Prodoehl 
et al (2015) 
NR 
1:1 1
st
 6 
months 
TA 18 
months 
104 Weeks 
Twice 
Weekly 
Chest Press, 
Lat Pull 
Down, 
Reverse 
Flys, Leg 
Press, Hip 
Extension, 
Biceps Curl, 
Rotary Cuff, 
Shoulder 
Press, Tricep 
Extension, 
Back 
Extension, 
Knee 
Extension 
Multi-joint 
& single-
joint 
1
st
 8 
Weeks 
(30-40% 
1RM 
upper 
body/50-
60% 1RM 
lower body 
2
nd
 8 
Weeks 
(70-
80%1RM) 
1
st 
8 
Weeks (3 
sets) 
 
2
nd
 8 
Weeks (2 
sets) 
1
st
 8 Weeks 
(8 reps) 
 
2
nd
 8 Weeks 
(12 reps) 
NR 
5% or as 
allowed by 
equipment 
Shulman et 
al (2013) 
Medical 
Centre 
Supervised 
(ratio NR) 
12 Weeks 
Thrice 
Weekly 
Leg Press, 
Leg 
Extension, 
Leg Curl 
Multi-joint 
& single-
joint 
NR 2 Sets 10 Reps NR NR 
Sage et al 
(2011) 
Community 
based training 
facilities 
Supervised 
1:8 /1:10 
12 Weeks 
Thrice 
Weekly 
Whole body 
workout 
Multi-joint 
& single-
joint 
NR 3 Sets 10-15 Reps NR NR 
Bloomer et 
al (2008) 
NR 
Supervised 
(ratio NR) 
8 Weeks 
Twice 
Weekly 
Leg Press, 
Leg Curl, 
Calf press 
Multi-joint 
& single 
joint 
NR 3 Sets 5-8 Reps 
2-3 
minutes 
5-10% 
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Non-RCT (Parkinson’s disease) 
Hass et al 
(2012) 
NR 
Supervised 
(ratio NR) 
10 Weeks 
Twice 
Weekly 
Leg Press, 
Knee 
Extension & 
Flexion, 
Abdominal 
Curl, Back 
Extension, 
Seated Calf 
Raise 
Multi-joint 
& single 
joint 
70% 1RM 2 Sets 12-20 Reps 
5 
minutes 
10% 
Schilling et 
al (2010) 
NR 
Supervised 
(ratio NR) 
8 Weeks 
Twice 
Weekly 
Leg Press, 
Leg Curl, 
Calf Raises 
Multi-joint 
& single 
joint 
NR 3 Sets 
First 2 Sets 
8 Reps 
Third Set 5-
8 
NR 5-10% 
 
Dibble et al 
(2006; 
2009) 
 
NR 
 
Supervised 
(ratio NR) 
 
12 weeks 
 
Thrice 
Weekly 
 
Eccentric 
resistance 
training 
ergometer 
Multi-joint 
& single 
joint 
 
Rate of 
Perceived 
Exertion 7-
13 
 
1 set 
 
- 
 
- 
Week 1-2: 5 
mins 
Week 3: 5-
10 mins 
Week 4: 10-
15 mins 
Week 5-12: 
15-30 mins 
RCT (multiple sclerosis) 
Medina-
Perez et al 
(2014) 
Rehabilitation 
Centre 
Supervised 
(ratio NR) 
12 Weeks 
Twice 
Weekly 
Knee 
extension 
(bilateral, 
concentric/e
ccentric) 
Single-joint 
35-70% 
(MVIC) 
3 Sets 8-13 Reps 
3 
minutes 
NR 
Dalgas et al 
(2010a; 
2009; 
2010b; 
2013) 
NR 
Supervised 
1:2/1:4 
12 Weeks 
Twice 
Weekly 
Leg Press, 
Knee 
Extension & 
Flexion, Hip 
Flexion & 
Extension 
Multi-joint 
& single 
joint 
NR 
Weeks 1-
4 3 Sets; 
Weeks 5-
10 4 Sets; 
Weeks 
11-12 3 
Sets 
Weeks 1-2 
10 Reps; 
Weeks 3-6 
12 Reps; 
Weeks 7-8 
10 Reps; 
Weeks 9-12 
8 Reps 
2-3 
minutes 
(sets + 
exercise) 
NR 
Dodd et al 
(2011) 
Community 
Gym 
Supervised 
3:12 
10 Weeks 
Twice 
Weekly 
Leg Press, 
Knee 
Multi-joint 
& single 
NR 2 Sets 10-12 Reps 
2 
minutes 
NR 
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Extension & 
Flexion, Calf 
Raises, 
Reverse Leg 
Press 
joint 
Broekmans 
et al (2011)  
NR 
Supervised 
1:3 
20 Weeks 
50 training 
sessions 
(~60) min 
Leg Press 
Leg 
extension 
Leg Curl 
Multi-joint 
& single 
joint 
1-2 week: 
minimal 
reps 
3-6: 50-
60% 1RM 
7-8: 60% 
1RM 
9-10: 60% 
1RM 
11: 60% 
1RM 
12-14: 15 
RM 
15-17: 12 
RM 
18-20:10 
RM 
1-2: 1 
3-6: 1 
7-8: 2 
9-10: 2 
11: 2 
12-14: 2 
15-17: 2 
18-20: 2 
1-2: 10 
3-6: 10 
7-8: 10 
9-10: 12 
11: 12 
12-14: 15 
15-17: 12 
18-20: 10 
NR NR 
Fimland et 
al (2010) 
NR 
Supervised 
(ratio NR) 
3 Weeks 
Five Times 
Weekly 
Leg Press & 
Seated Calf 
Raise 
Multi-joint 
& single 
joint 
85-90% 
1RM 
4 Sets 4 Reps 
1-2 
minutes 
NR 
Non-RCT (multiple sclerosis) 
Sabapathy 
et al (2011) 
Health Facility 
Supervised 
(ratio NR) 
8 Weeks 
Twice 
Weekly 
Chest Press, 
Seated Row, 
Shoulder 
Abduction, 
Sit to Stand, 
Lunges, Hip 
Abduction, 
Step Ups & 
Tandom 
Stance 
Multi-joint 
& single 
joint 
NR 2-3 Sets 6-10 Reps 
0.5-1 
minute 
NR 
DeBolt et al 
(2004) 
Home Based NR 8 Weeks 
Thrice 
weekly 
Chair raises 
Forward 
Multi-joint 
& single 
NR 
Weeks 1 
& 3 2 
Weeks 1 & 
3 8-12 Reps; 
NR _ 
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lunges 
Step-ups 
Heel toe 
raise 
Leg curls 
joint Sets; 
Weeks 2 
& 4 3 
Sets; 
Weeks 5-
8 2 Sets 
Weeks 2 & 
4 8-12 Reps; 
Weeks 5-8 
8-10 Reps 
NR = Not
 
reported, RCT = randomised controlled trial, Non-RCT = non randomised controlled trial
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3.4.4 Intervention characteristics  
Of the eight trials conducted in individuals with Parkinson’s disease (Bloomer et al., 2008; 
Corcos et al., 2013; Dibble et al., 2006; Dibble et al., 2009; Hass et al., 2012; Paul et al., 
2014; Prodoehl et al., 2015; Sage et al., 2011; Schilling et al., 2010; Shulman et al., 2013) 
(five randomised controlled trials (Bloomer et al., 2008; Corcos et al., 2013; Paul et al., 2014; 
Prodoehl et al., 2015; Sage et al., 2011; Shulman et al., 2013) and three non-randomised 
controlled trials (Dibble et al., 2006; Dibble et al., 2009; Hass et al., 2012; Schilling et al., 
2010)), five used lower body strength training interventions (Bloomer et al., 2008; Dibble et 
al., 2006; Dibble et al., 2009; Paul et al., 2014; Schilling et al., 2010; Shulman et al., 2013), 
two used a full body strength training intervention (Corcos et al., 2013; Prodoehl et al., 2015; 
Sage et al., 2011) and one used a lower body and core strength training intervention (Hass et 
al., 2012) (Tables 3.2 and 3.3). Training protocols ranged from two to twenty-four months of 
twice to thrice weekly training (Bloomer et al., 2008; Corcos et al., 2013; Dibble et al., 2006; 
Dibble et al., 2009; Hass et al., 2012; Paul et al., 2014; Prodoehl et al., 2015; Sage et al., 
2011; Schilling et al., 2010; Shulman et al., 2013). Only two trials conducted in individuals 
with Parkinson’s disease reported on the level of supervision for strength training 
interventions (Corcos et al., 2013; Prodoehl et al., 2015; Sage et al., 2011).  
Of the seven trials conducted in multiple sclerosis (Broekmans et al., 2011; Dalgas et al., 
2010a; Dalgas et al., 2009; Dalgas et al., 2010b; Dalgas et al., 2013; DeBolt and McCubbin, 
2004; Dodd et al., 2011; Fimland et al., 2010; Medina-Perez et al., 2014; Sabapathy et al., 
2011) (five randomised controlled trials (Broekmans et al., 2011; Dalgas et al., 2010a; Dalgas 
et al., 2009; Dalgas et al., 2010b; Dalgas et al., 2013; Dodd et al., 2011; Fimland et al., 2010; 
Medina-Perez et al., 2014) and two non-randomised controlled trials (DeBolt and McCubbin, 
2004; Sabapathy et al., 2011)), five trials trained the lower body (Broekmans et al., 2011; 
Dalgas et al., 2010a; Dalgas et al., 2009; Dalgas et al., 2010b; Dalgas et al., 2013; Dodd et al., 
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2011; Fimland et al., 2010; Medina-Perez et al., 2014) and two trials trained the full body 
(DeBolt and McCubbin, 2004; Sabapathy et al., 2011) (Tables 3.2 and 3.3). Intervention 
protocols utilised in multiple sclerosis trials ranged from three weeks to six months of two to 
five times weekly training (Broekmans et al., 2011; Dalgas et al., 2010a; Dalgas et al., 2009; 
Dalgas et al., 2010b; Dalgas et al., 2013; DeBolt and McCubbin, 2004; Dodd et al., 2011; 
Fimland et al., 2010; Medina-Perez et al., 2014; Sabapathy et al., 2011). Of the seven trials 
conducted in individuals with multiple sclerosis, only three trials reported on the level of 
supervision for strength training interventions (Broekmans et al., 2011; Dalgas et al., 2010a; 
Dalgas et al., 2009; Dalgas et al., 2010b; Dalgas et al., 2013; Dodd et al., 2011).  
3.4.5 Risk of bias 
Statistical examination using the egger regression test revealed no publication bias (p=0.131).  
3.4.6 Intensity and progression of resistance exercise 
Two randomised (Corcos et al., 2013; Paul et al., 2014; Prodoehl et al., 2015) and two non-
randomised controlled trials (Dibble et al., 2006; Dibble et al., 2009; Hass et al., 2012) 
conducted in Parkinson’s disease reported on the intensity of strength training performed 
throughout the intervention, while three randomised controlled trials (Broekmans et al., 2011; 
Fimland et al., 2010; Medina-Perez et al., 2014) reported on the intensity of strength training 
in multiple sclerosis. The progression of strength training was reported by three randomised 
(Bloomer et al., 2008; Corcos et al., 2013; Paul et al., 2014; Prodoehl et al., 2015) and three 
non-randomised controlled trials (Dibble et al., 2006; Dibble et al., 2009; Hass et al., 2012; 
Schilling et al., 2010) in Parkinson’s disease. In contrast, there were no trials that reported on 
the progression of strength training in multiple sclerosis. 
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3.4.7 Participant retention, adherence, and adverse events  
Participant retention ranged from 75% to 100% in Parkinson’s disease trials (Bloomer et al., 
2008; Corcos et al., 2013; Dibble et al., 2006; Dibble et al., 2009; Hass et al., 2012; Paul et 
al., 2014; Prodoehl et al., 2015; Sage et al., 2011; Schilling et al., 2010; Shulman et al., 2013) 
and from 73.3% to 100% in multiple sclerosis trials (Broekmans et al., 2011; Dalgas et al., 
2010a; Dalgas et al., 2009; Dalgas et al., 2010b; Dalgas et al., 2013; DeBolt and McCubbin, 
2004; Dodd et al., 2011; Fimland et al., 2010; Medina-Perez et al., 2014; Sabapathy et al., 
2011) (Table 3.4). Four trials in multiple sclerosis ([Medina-Perez et al (2014) strength 
training group 95.4%; control group NR], [Dodd et al (2011) strength training group 92%; 
control group 62%], [Broekmans et al (2011) ~99% all groups] and [DeBolt et al (2004) 
strength training group 95%]) and one trial in Parkinson’s disease reported on participant 
adherence (Paul et al (2014) strength training group 84.1%; control group 94.1%) (Table 3.4). 
Five trials in Parkinson’s disease (Corcos et al., 2013; Hass et al., 2012; Paul et al., 2014; 
Prodoehl et al., 2015; Sage et al., 2011; Shulman et al., 2013) and six trials in multiple 
sclerosis (Broekmans et al., 2011; Dalgas et al., 2010a; Dalgas et al., 2009; Dalgas et al., 
2010b; Dalgas et al., 2013; Dodd et al., 2011; Fimland et al., 2010; Medina-Perez et al., 2014; 
Sabapathy et al., 2011) reported on adverse events (Corcos et al., 2013; Hass et al., 2012; 
Paul et al., 2014; Prodoehl et al., 2015; Sage et al., 2011; Shulman et al., 2013), with only 
minor or clinically unrelated medical issues reported (Table 3.4). 
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Table 3.4 Summary of retention, adherence and adverse events in Parkinson’s disease or multiple sclerosis strength training trials 
Trial 
Reference 
Participant Retention Dropouts Participant Adherence Adverse Events 
Parkinson’s disease     
RCT     
Paul et al (2014) 
RE: 18/20 (90%) 
CG: 18/20 (90%) 
RE: 2/20 (10%) 
CG: 2/20 (10%) 
RE: 84.1% 
CG: 94.1% 
RE: pelvic fracture (UTI), low 
back pain 
CG: exacerbated hernias (UTI) 
PRET-PD RCT Corcos et al 
 
 
& Prodoehl et al (2015) 
RE: 19/24 (79.2%) 
CG: 16/24 (66.6%) 
RE: 5/24 (20.8%) 
CG: 8/24 (33.3%) 
NR 
RE: 1 (wrist pain) 
CG: 1 (back surgery) 
Shulman et al (2013) 
RE: 22/28 (78.5%) 
CG: 22/26 (84.6%) 
CG: 23/26 (88.4%) 
RE: 6/28 (11.5%) 
CG: 4/26 (15.4%) 
CG: 3/26 (11.6%) 
NR No serious adverse events 
Sage et al (2011) 
RE 18/18 (100%) 
CG: 18/18 (100%) 
RE: 0/10 (0%) 
CG: 0/10 (0%) 
NR No adverse events 
Bloomer et al (2008) 
RE: 6/8 (75%) 
CG: 7/8 (87.5%) 
RE: 2/8 (25%) 
CG: 1/8 (12.5%) 
NR NR 
non-RCT     
Hass et al (2012) 
RE: 9/9 (100%) 
CG: 9/9 (100%) 
RE: 0/9 (0%) 
CG: 0/9 (0%) 
NR No adverse events 
Schilling et al (2010) 
RE: 8/9 (88.8%) 
CG: 7/9 (77.7%) 
RE: 1/9 (11.2%) 
CG: 2/9 (22.3%) 
NR NR 
Dibble et al (2006; 2009) 
RE: 10/10 (100%) 
CG: 9/10 (90%) 
RE: 0/10 (0%) 
CG: 1/10 (10%) 
NR NR 
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Multiple sclerosis     
RCT     
Medina-Perez et al (2014) 
RE: 30/30 (100%) 
CG: 12/12 (100%) 
RE: 0/30 (0%) 
CG: 0/12 (0%) 
RE: 95.4% 
CG: NR 
No adverse events 
Dalgas et al (2010a; 2009; 
2010b; 2013) 
RE: 15/19 (78.9%) 
CG: 16/19 (84.2%) 
RE: 4/9 (21.1%) 
CG: 3/19 (15.8%) 
NR RE: 1 (lower back pain) 
Dodd et al (2011) 
RE: 36/39 (92.3%) 
CG: 31/37 (83.7%) 
RE: 3/39 (7.7%) 
CG: 6/37 (16.3%) 
RE: 92% 
CG: 62% 
No adverse events 
Broekmans et al (2011) 
EXP: 11/11 (100%) 
EXP+ES: 10/11 (90%) 
CON: 12/14 (86%) 
EXP: 0/11 (0%) 
EXP+ES: 1/11 (9%) 
CON: 2/14 (14%) 
~99% all groups 
Severe relapse 
Perceived lack of time to continue 
Mild stroke (unrelated) 
Fimland et al (2010) 
RE: 7/7 (100%) 
CG: 7/7 (100%) 
RE: 0/7 (0%) 
CG: 0/7 (0%) 
NR No adverse events 
Non-RCT     
Sabapathy et al (2011) 
RE: 11/14 (73.3%) 
CG: 5/6 (83.3%) 
RE: 3/14 (26.6%) 
CG: 1/6 (16.7%) 
NR No adverse events 
DeBolt et al (2004) 
RE: 19/20 (95%) 
CG: 17/17 (100%) 
RE: 1/20 (5%) 
CG: 0/17 (0%) 
95% NR 
RE resistance exercise, CG comparison group, NR not reported  
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3.4.8 Outcomes measures 
Strength as an outcome measure in Parkinson’s disease 
Three randomised controlled trials evaluated the effect of strength training on strength in 
people with Parkinson’s disease (Corcos et al., 2013; Paul et al., 2014; Shulman et al., 2013). 
Strength was evaluated across trials using one repetition maximum (1RM) and maximum 
voluntary isometric contraction (MVIC) protocols with torque transducers, pneumatic 
resistance machines and dynamometers. Corcos et al (2013) found a significant improvement 
in elbow flexor muscle strength (1RM, 15%) in the strength training group, whilst off 
medication, after twenty-four months of upper and lower body resistance training. No 
significant differences in strength were found for the control group in this trial. Shulman et al 
(2013) in another trial found a significant improvement in leg press and leg extension 
strength (1RM, 16%) in individuals within the strength training group, but not in the high or 
low intensity treadmill training groups, after three months of thrice weekly resistance 
training. Paul et al (2014) also reported a significant improvement in lower limb strength 
(1RM, leg extension, 14.6%; knee flexion, 18.6%; hip flexion, 39.8%; hip abduction, 33.9%) 
and power (leg extension, 17.3%; knee flexion, 20.6%; hip flexion, 46.3%; hip abduction, 
43.1%)  in the strength training group in comparison to the sham comparison group after 12 
weeks of lower body resistance training. 
Three non-randomised controlled trials also evaluated the effect of strength training on 
strength and found significant improvements (Dibble et al., 2006; Dibble et al., 2009; Hass et 
al., 2012; Schilling et al., 2010). Hass et al (2012), after ten weeks of twice weekly lower 
body strength training, found a significant improvement in knee extension (1RM, 76%) and  
knee flexion (1RM, 57%) strength in the intervention group, but not in the control group. 
Schilling et al (2010) in another trial reported a significant improvement in leg press strength 
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(1RM, 22%) in the intervention group, whereas the control group showed no significant 
differences. Dibble et al (2006; 2009) similarly reported a significant improvement in 
quadriceps muscle strength (MVIC) in the more (average torque 23%; peak torque 18%) and 
less affected leg (average torque 16%; peak torque 83.2%) in the strength training 
intervention group only.  
Strength as an outcome in multiple sclerosis 
Five randomised controlled trials reported on strength as an outcome after strength training 
(Broekmans et al., 2011; Dalgas et al., 2009; Dalgas et al., 2010b; Dalgas et al., 2013; Dodd 
et al., 2011; Fimland et al., 2010; Medina-Perez et al., 2014), with all five trials reporting 
significant improvements in strength. Strength was evaluated across trials using MVIC, 
maximum voluntary dynamic contraction (MVDC) and 1RM strength protocols with 
pneumatic resistance machines, dynamometers and the Leg Extensor Power Rig. Medina-
Perez et al (2014) reported a significant improvement in knee extension strength (MVIC, 
7.7%) and power (40% MVIC, 15.6%) in the intervention group, but not in the control group 
after twelve weeks of strength training. Significant improvements in leg press strength (1RM, 
15%) in the intervention group, but not the control group were also reported by Dodd et al 
(2011) after strength training. Broekmans et al (2011) in line with Medina-Perez et al (2014), 
reported significant improvements in isometric strength in the knee flexors and extensors 
(MVIC, average knee extension 45° change: 10.8, average knee extension 90° change: 10, 
average knee flexor 45° change: 4, average knee flexion 90° change: 2.3) in the intervention 
group as a result of strength training. In another trial, Dalgas et al (2010a; 2009; 2010b; 2013) 
reported significant improvements in isokinetic, isometric and angular impulse knee extensor 
and flexor strength in the intervention group ([Dalgas et al (2013), MVIC at 70° knee flexion; 
knee extension: 13.2%, knee flexion: 13.8%], [Dalgas et al (2010b); MVDC, knee extension 
90º: 4.5%; knee extension 180º:10.2%; knee flexion 90º: 21.3%; knee flexion 180º: 18.6%], 
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[Dalgas et al (2009), MVIC, knee extension: 15.7%, knee flexion: 21.3%]), but not in the 
control group as a result of resistance training. Dalgas et al (2009) additionally reported a 
significant improvement in leg press strength. Fimland et al (2010) in another trial reported a 
significant improvement in plantar flexion strength (MVIC, 36%) in the strength training 
intervention group, but not in the control group. In a non-randomised controlled trial, DeBolt 
et al (2004) reported a significant improvement in leg extensor power (24%) in the 
intervention group, whereas the disease control group  showed no changes after strength 
training. 
In addition to muscle strength, significant study specific improvements in gait, clinical 
disease progression, functional capacity, quality of life, oxidative biomarkers, mood, fatigue, 
falls, skeletal muscle volume and electromyography activity were observed after strength 
training in individuals with multiple sclerosis or Parkinson’s disease (Bloomer et al., 2008; 
Broekmans et al., 2011; Corcos et al., 2013; Dalgas et al., 2010a; Dalgas et al., 2009; Dalgas 
et al., 2010b; Dalgas et al., 2013; DeBolt and McCubbin, 2004; Dibble et al., 2006; Dibble et 
al., 2009; Dodd et al., 2011; Fimland et al., 2010; Hass et al., 2012; Medina-Perez et al., 
2014; Paul et al., 2014; Prodoehl et al., 2015; Sabapathy et al., 2011; Sage et al., 2011; 
Schilling et al., 2010; Shulman et al., 2013).  
Parkinson’s disease measures 
Unified Parkinson Disease Rating Scale Version 3 
Three randomised (Corcos et al., 2013; Sage et al., 2011; Shulman et al., 2013) and one non-
randomised controlled trial (Dibble et al., 2009) conducted in Parkinson’s disease evaluated 
the effect of strength training on clinical disease progression using the Unified Parkinson’s 
Disease Rating Scale Version 3. Corcos et al (2013) reported a significant improvement on 
the Unified Parkinson’s Disease Rating Scale Version 3 in the intervention group (7.4 point 
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decrease), but not in the control group after twenty-four months of strength training. Shulman 
et al (2013) in another study similarly reported a significant improvement on the motor 
subscale of the Unified Parkinson’s Disease Rating Scale Version 3 in the strength training 
group. Furthermore, Sage et al (2011) found a significant improvement on the Unified 
Parkinson’s Disease Rating Scale Version 3 in the strength training group. Dibble et al (2009) 
by contrast found no improvement on the Unified Parkinson’s Disease Rating Scale Version 
3 in the intervention group after strength training.  
Functional Mobility 
Three randomised (Paul et al., 2014; Prodoehl et al., 2015; Shulman et al., 2013) and three 
non-randomised controlled trials (Dibble et al., 2006; Dibble et al., 2009; Hass et al., 2012; 
Schilling et al., 2010) evaluated the effect of strength training on mobility in individuals with 
Parkinson’s disease. Mobility was assessed across trials using the 10 Meter Timed Walk Test, 
6 Minute Walk Test, 50 Feet Walk Test and Timed Up and Go. Paul et al (2014) did not 
report significant changes in mobility after strength training. In contrast, Prodoehl et al 
(2015) and Shulman et al (2013) found significant improvements in mobility as a result of 
strength training. The three non-randomised controlled trials (Dibble et al., 2006; Dibble et 
al., 2009; Hass et al., 2012; Schilling et al., 2010) that reported on mobility as an outcome 
also documented improvements.  
Balance 
Two randomised (Paul et al., 2014; Prodoehl et al., 2015) and two non-randomised controlled 
trials (Sabapathy et al., 2011; Schilling et al., 2010) examined the effect of strength training 
on balance outcomes in Parkinson’s disease. Balance was evaluated across trials using a 
variety of outcomes including the Single Leg Stance, Choice Stepping Task, Berg Balance 
Scale, Functional Reach Test, 5 Time Sit To Stand Test and the Activities-specific Balance 
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Confidence scale. Paul et al (2014) did not find a significant improvement in balance as a 
result of strength training. Prodoehl et al (2015) by contrast reported a significant 
improvement in balance after strength training. Both non-randomised controlled trials 
(Sabapathy et al., 2011; Schilling et al., 2010) were unable to find a significant improvement 
in balance after strength training. 
Functional Capacity  
One randomised trial (Corcos et al., 2013) examined the effect of strength training on 
functional capacity. Corcos et al (2013) assessed functional capacity using the modified 
Physical Performance Test and reported no significant changes after strength training in the 
intervention or control group.   
Quality of Life 
Two randomised (Corcos et al., 2013; Shulman et al., 2013) and one non-randomised 
controlled trial (Dibble et al., 2009) evaluated the effect of strength training on quality of life. 
All three trials assessed quality of life using the 39-Item Parkinson’s Disease Questionnaire. 
Both randomised controlled trials (Corcos et al., 2013; Shulman et al., 2013) did not report a 
significant improvement in quality of life after strength training. Dibble et al (2009) by 
contrast reported a significant improvement in quality of life in the intervention group after 
strength training. 
Oxidative and Anti-oxidant Markers 
One randomised controlled trial (Bloomer et al., 2008) in Parkinson’s disease measured 
changes in blood oxidant and anti-oxidant marker levels and reported significant increases in 
anti-oxidant marker levels (superoxide dismutase [9.9%] and glutathione peroxidase [1.8%]) 
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and a significant reduction in oxidative stress marker levels (malondialdehyde [15%] and 
hydrogen peroxide [16%]). 
Mood 
One randomised controlled trial (Shulman et al., 2013) evaluated the effect of strength 
training on mood in Parkinson’s disease. Shulman et al (2013) found no significant changes 
in mood after strength training using the Beck Depression Inventory. 
Fatigue 
One randomised controlled trial (Shulman et al., 2013) evaluated the effect of strength 
training on fatigue in Parkinson’s disease. Shulman et al (2013) used the 16-item Parkinson 
Fatigue Scale and found no significant change in fatigue after strength training in the strength 
training intervention group or high and low intensity treadmill intervention groups. 
Falls 
Two randomised controlled trials (Paul et al., 2014; Shulman et al., 2013) evaluated the effect 
of strength training on falls in people with Parkinson’s disease. Falls were assessed using the 
New Freezing of Gait Questionnaire (Paul et al., 2014) and Falls Efficacy Scale (Shulman et 
al., 2013). No trial reported a significant effect on falls outcomes after strength training.  
Skeletal Muscle Volume   
One non-randomised controlled trial (Dibble et al., 2006) evaluated the effect of strength 
training on quadriceps muscle volume in Parkinson’s disease. Dibble et al (2006) found a 
significant increase in quadriceps muscle volume using magnetic resonance imaging after 
strength training in the intervention group only.  
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Multiple sclerosis 
Functional Mobility 
Two randomised (Broekmans et al., 2011; Dodd et al., 2011) and two non-randomised 
controlled trials (DeBolt and McCubbin, 2004; Sabapathy et al., 2011) evaluated the effect of 
strength training on functional mobility in multiple sclerosis. Functional mobility was 
assessed across trials using the 2 Minute Walk Test, 10 Meter Walk Test, Timed 25 Foot 
Walk and Timed Up and Go. No trial reported a significant improvement in mobility as a 
result of strength training.  
Balance 
One randomised (Broekmans et al., 2011) and two non-randomised (DeBolt and McCubbin, 
2004; Sabapathy et al., 2011) controlled trials evaluated the effect of strength training on 
balance in multiple sclerosis. Balance was evaluated across trials using the Functional Reach 
Test (Broekmans et al., 2011; Sabapathy et al., 2011), Four Square Step Test (Sabapathy et 
al., 2011) and Accusway
PLUS
 force platform (DeBolt and McCubbin, 2004). Broekmans et al 
(2011) reported a significant improvement in balance in the intervention group only as a 
result of strength training. However, Sabapathy et al (2011) and DeBolt et al (2004) did not 
find significant improvements in balance after strength training.  
Functional Capacity  
One randomised controlled trial (Dalgas et al., 2009) evaluated the effect of strength training 
on functional capacity outcomes in multiple sclerosis. Dalgas et al (2009) reported a 
significant improvement in functional capacity (computed as ¼ [Chair Stand Test post / Chair 
Stand Test pre] + [Stair Climb Test post / Stair Climb Test pre] + [10 Meter Walk Test post /10 
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Meter Walk Test pre] + [6 Minute Walk Test post / 6 Minute Walk Test pre] × 100) as a result of 
strength training. 
Quality of Life 
Two randomised (Dalgas et al., 2010a; Dodd et al., 2011) and one non-randomised controlled 
trial (Sabapathy et al., 2011) reported on quality of life outcomes after strength training in 
multiple sclerosis. Quality of life was assessed across trials using the Short Form-36 (Dalgas 
et al., 2010a; Sabapathy et al., 2011) and the World Health Organisation Quality of Life-
BREF (Dodd et al., 2011). Dodd et al (2011) and Dalgas et al (2010a) reported a significant 
improvement in quality of life in the intervention group  as a result of strength training. In 
contrast, Sabapathy et al (2011) found no significant improvement in quality of life after 
strength training.  
Electromyography Activity  
Two randomised controlled trials (Dalgas et al., 2013; Fimland et al., 2010) assessed the 
effect of strength training on electromyography activity during maximum voluntary isometric 
contractions. Dalgas et al (2013) recorded surface electromyography signals from the Vastus 
Lateralis, Rectus Femoris and Semitendinosus during maximal voluntary isometric 
contractions of the knee flexors and extensors (assessed at 70° knee flexion), using bipolar 
electrodes. The upper electrode of each pair was placed at the midpoint between the Spina 
Iliaca anterior superior and patellar basis. After twelve weeks of strength training, Dalgas et 
al (2013) found significant improvements in maximal isometric (μV) knee extension and 
knee flexion activity (Semitendinosus: 27.6%; Vastus Lateralis: 27%; Rectus Femoris: 28%) 
in the intervention group, but not the control group. Fimland et al (2010) recorded surface 
electromyography activity during maximum voluntary isometric contractions of the plantar 
flexors (ankle positioned at 90°), using bipolar surface electrodes placed according to Surface 
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Electromyography for the Non-Invasive Assessment of Muscles (SENIAM) 
recommendations. Fimland et al (2010) reported significant improvements (15%) in surface 
electromyography activity of the plantar flexors after three weeks of strength training in the 
intervention group in comparison to the control group. 
Skeletal Muscle Volume and Architecture 
Only one randomised controlled trial (Dalgas et al., 2010b) measured changes to thigh 
volume, muscle fibre numbers, type and size. Muscle biopsies of the Vastus Lateralis (middle 
portion) were taken to assess changes in muscle fibre number, type and size. Dalgas et al 
(2010b) reported a significant increase in the cross sectional area of type II and IIa vastus 
lateralis muscle fibres after strength training in the intervention group only. 
 Fatigue  
Two randomised (Dalgas et al., 2010a; Dodd et al., 2011) and one non-randomised controlled 
trial (Sabapathy et al., 2011) evaluated the effect of strength training on fatigue in multiple 
sclerosis. Fatigue was assessed across trials using a variety of outcomes including the 
Modified Fatigue Scale and Fatigue Severity Scale, Multidimensional Fatigue Inventory. 
Dodd et al (2011) reported a significant improvement in the level of fatigue experienced 
(24%) after ten weeks of twice weekly strength training. Similar findings were reported by 
Dalgas et al (2010a), who reported a 10% improvement in the level of fatigue experienced 
after strength training. Sabapathy et al (2011) also reported a significant improvement in the 
level of fatigue experienced as a result of strength training. 
Mood 
One randomised (Dalgas et al., 2010a) and one non-randomised controlled trial (Sabapathy et 
al., 2011) examined the effect of strength training on mood outcomes in multiple sclerosis. 
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Dalgas et al (2010a) reported significant improvements (-2.4 points) in mood using the Major 
Depression Inventory as a result of strength training. In contrast, Sabapathy et al (2011) 
found no significant changes in mood using the Beck Depression Inventory after strength 
training.  
Muscle Endurance 
Two randomised controlled trials (Dodd et al., 2011; Medina-Perez et al., 2014) evaluated the 
effect of strength training on muscle endurance in multiple sclerosis. Medina-Perez et al 
(2014) measured muscle endurance as the maximum number of repetitions that a participant 
could perform during a single set of knee extension using a load of 40% of the maximum 
voluntary isometric contraction, while Dodd et al (2011) measured endurance by counting the 
number of repetitions that a participant could complete on the seated leg press and reverse leg 
press using a load of 50% of 1 RM. Medina-Perez et al (2014) did not find a significant 
change in muscle endurance in the intervention or control group after strength training. In 
contrast, Dodd et al (2011) reported a significant improvement in muscle endurance in the 
intervention group relative to the control group after strength training.  
3.5 DISCUSSION 
This review found that strength training is useful for improving muscle strength in 
Parkinson’s disease and to a lesser extent multiple sclerosis. Evidence also showed that 
strength training is helpful for improving clinical measures of disease progression and 
mobility in Parkinson’s disease. However, the evidence is unclear regarding the efficacy of 
strength training on falls, quality of life, fatigue, functional capacity and balance in 
Parkinson’s disease. In multiple sclerosis, strength training was also found to improve 
fatigue, quality of life, muscle power, electromyography activity and functional capacity. 
However, its effect on balance and mood remains equivocal. 
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An increase in strength was the most consistently reported benefit of strength training in 
people with Parkinson’s disease and multiple sclerosis. A meta-analysis of the extracted 
strength data revealed that strength training had a larger effect on strength in people with 
Parkinson’s disease (d=0.87) than multiple sclerosis (d=0.33) (Figure 3.2). Different 
pathological mechanisms underpinning impairments in strength in each disease are likely to 
account for this discrepancy. For instance, impairments in strength in multiple sclerosis are 
thought to be mediated by central (de Haan et al., 2000; Ng et al., 2004) (spinal and 
supraspinal mechanisms) and muscular deficits (Carroll et al., 2005; Garner and Widrick, 
2003; Kent-Braun et al., 1997), while in Parkinson’s disease impairments in strength are 
thought to result from central deficits only (Bridgewater and Sharpe, 1998; Corcos et al., 
1996; Yanagawa et al., 1989). This finding suggests that strength training may only produce 
meaningful benefits in strength in people with Parkinson’s disease.  
Strength training trials in Parkinson’s disease also reported improvements in mobility. The 
improvements were reported on short and longer duration mobility assessments, suggesting 
that strength training has a favourable effect on multiple aspects of mobility. This finding is 
consistent with the supposition that muscle strength strongly predicts mobility in people with 
Parkinson’s disease (Allen et al., 2010; Paul et al., 2013b). Surprisingly, no improvements in 
mobility were reported in individuals with multiple sclerosis after strength training. This 
finding was unexpected, as the strength training interventions in Parkinson’s disease and 
multiple sclerosis trials, for the most part, used similar training frequencies (two-three times 
per week), resistance exercises (leg press, knee extension, knee flexion and calf raises) and 
sets per exercise (two-three). This may indicate that strength training is not capable of 
improving mobility in individuals with multiple sclerosis. The inability to improve mobility 
may be explained by the smaller improvements in strength observed in individuals with 
multiple sclerosis. Indeed, recent findings show that muscle strength significantly predicts 
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performance on mobility tasks in individuals with multiple sclerosis (Broekmans et al., 
2013b). Alternatively, it is possible that the strength training interventions used in the 
multiple sclerosis trials were unable to provide a stimulus sufficient to improve mobility in 
multiple sclerosis, and perhaps more intense or specific training interventions may be 
required.   
In addition, strength training was found to have a positive effect on disease progression in 
people with Parkinson’s disease (Unified Parkinson’s Disease Rating Scale-Version 3). 
Interestingly, improvements in disease progression were observed in a cohort with mild to 
advanced disability that were not on medication, suggesting that strength training alone, may 
be capable of positively impacting on disease progression in individuals at all stages of 
Parkinson’s disease. The positive effect of strength training on disease progression may have 
been mediated by favourable central changes. For instance, recent evidence shows that 
repetitive force generation increases neuronal activation in the basal ganglia, thalamus, 
parietal cortex, cerebellum and motor cortex (Dai et al., 2001; Dettmers et al., 1995; Ehrsson 
et al., 2000; Florin et al., 2013). Furthermore, emerging evidence has shown that exercise 
interventions can increase regional brain volume and structural connectivity in patients with 
Parkinson’s disease and other neurodegenerative disorders (Bonzano et al., 2014; Burciu et 
al., 2013; Prosperini et al., 2014b; Sehm et al., 2014). Further studies are required to confirm 
the latter remarks.  
In multiple sclerosis trials, improvements in strength were accompanied by significant 
improvements in fatigue, quality of life, muscle power, maximal electromyography activity 
and functional capacity. The reported improvements in fatigue are of clinical interest given 
that 33-75% of individuals with multiple sclerosis suffer from fatigue (Berger et al., 2013; 
Comi et al., 2001; Freal et al., 1984). Nevertheless this finding was not surprising, given that 
exercise has previously been reported to improve fatigue in multiple sclerosis (Andreasen et 
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al., 2011). The improvements in fatigue may in part explain the benefits observed in quality 
of life, especially considering that fatigue is an important predictor of quality of life in people 
with multiple sclerosis (Amato et al., 2001; Kargarfard et al., 2012). The increases in muscle 
power and maximal electromyography activity are consistent with the observed 
improvements in strength. The reported improvements in lower limb strength, fatigue and 
muscle power likely contributed to the improvement in functional capacity documented by 
Dalgas et al (2009). Indeed, recent findings have shown that strength (Broekmans et al., 
2013a), fatigue (Motl et al., 2013) and muscle power (Paul et al., 2013b) significantly 
influences functional capacity in individuals with multiple sclerosis and other 
neurodegenerative disorders. 
It is important to note that most trials included in this systematic review recruited individuals 
with mild to moderate disability. The higher level of disability in individuals at advanced 
stages of Parkinson’s disease or multiple sclerosis may have led researchers to only include 
individuals at early to middle stages of both diseases. The same level of benefits after 
strength training may not be possible in individuals at more advanced stages of Parkinson’s 
disease or multiple sclerosis. Future trials assessing the effect of strength training in 
individuals with Parkinson’s disease and multiple sclerosis with a severe level of disability 
are therefore warranted.  
In general, the trials displayed adequate methodological quality, with PEDro scores ranging 
from four to eight in both diseases. The major methodological shortcomings found using the 
PEDro scale included a failure to report concealed allocation (criteria 3), participant blinding 
(criteria 5), therapist blinding (criteria 6), and outcome assessor blinding (criteria 7). It is 
important to acknowledge that it is often not possible to blind participants or therapists to 
exercise or group allocation (Foley et al., 2006). Trial scores generated using the PEDro scale 
may therefore underestimate the quality of evidence.  
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In addition to evaluating trials using the PEDro scale, we also performed a critical appraisal 
of specific intervention characteristics important to strength training trials. This appraisal 
found that specific intervention characteristics were typically well detailed, with the 
exception of the level of supervision and strength training intensity. The lack of data reported 
on the level of supervision and the intensity of strength training performed is of concern in 
particular, as a high level of supervision as well as an appropriate intensity of strength 
training is required to maximise therapeutic benefits and avoid potential injury (Dalgas et al., 
2007). The poor level of reporting on strength training progression in multiple sclerosis trials 
is also concerning, given that modulating the progression of strength training is important to 
avoid injury and training plateaus (Medicine, 2013). The inadequate reporting of participant 
adherence in both disease populations was also worrisome, as it does not enable internal and 
external examination of what dose of strength training is required to maximise therapeutic 
benefits and avoid injury in such populations.  
Based on our findings and American College of Sports Medicine guidelines, we recommend 
that individuals with multiple sclerosis or Parkinson’s disease perform progressive sub-
maximal strength training(whole body single and multi-joint resistance exercises) on at least 
two non-consecutive days per week for an hour under direct supervision (e.g. physiotherapist, 
exercise physiologist, strength and conditioning specialist) to improve muscle strength and 
other disease specific clinical features (Parkinson’s disease: mobility and disease progression; 
multiple sclerosis: fatigue, quality of life, muscle power, maximal electromyography activity 
and functional capacity). 
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Limitations 
Lack of consistent reporting and heterogeneity of study outcomes between trials made it 
difficult to draw firm conclusions beyond improvements in muscle strength with respect to 
the benefits of strength training for individuals with multiple sclerosis or Parkinson’s disease. 
3.6 CONCLUSION 
Trials investigating the effect of strength training in individuals with Parkinson’s disease or 
multiple sclerosis are in their infancy. Nevertheless, benefits in strength were found after 
strength training in individuals with Parkinson’s disease and, to a lesser extent, in multiple 
sclerosis. Some evidence was also found to suggest that strength training has a positive effect 
on clinical disease progression and mobility in individuals with Parkinson’s disease. 
Similarly, some evidence showed that strength training is beneficial for muscle power, 
maximum electromyography activity, fatigue, functional capacity and quality of life in 
individuals with multiple sclerosis. Additional trials employing high quality methodological 
designs are required to confirm and expand on these findings. Such trials may provide 
evidence based rationale for using strength training as a therapy for other neurodegenerative 
disorders such as Alzheimer’s disease and Huntington’s disease. 
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Figure 3.2 Meta-analysis of trials that measured muscle strength 
 
 
 
 
 
 
 
96 
 
3.7 CONFLICT OF INTEREST 
The authors of the manuscript declare no actual or potential conflicts of interest. 
3.8 ACKNOWLEDGEMENTS  
The authors of this manuscript would like to thank Professor Roger Barker for his comments 
on the manuscript. 
3.9 AUTHOR CONTRIBUTIONS 
Mr Travis Cruickshank and Mr Alvaro Reyes contributed equally to the concept of the study, 
development of the search strategy analysis, analysis of the results, and writing of the 
manuscript. Both authors had full access to the data and take responsibility for the integrity of 
the data and the accuracy of the data analysis. Professor Mel Ziman contributed to the 
interpretation of the results, critical revision of the article for important intellectual content, 
editing of the manuscript and final approval of the version to be published.  
 
 
 
 
 
 
 
 
 
 
97 
 
CHAPTER 4 – The Effects of Multidisciplinary Rehabilitation in Patients with Early-
To-Middle-Stage Huntington’s Disease: A Pilot Study 
 
Published: European Journal of Neurology, 2013, Volume 20, Issue 9, Pages 1325-1334 
Jennifer A. Thompson, PhD
a#
, Travis M. Cruickshank, BSc
a#
, Luis E. Penailillo, MSc
b
, 
Joseph W. Lee, MRCPsych
c
, Robert U.  Newton, PhD
b
, Roger A. Barker, PhD, MRCP
a,d
 &  
Melanie R. Ziman, PhD
a,e   
#
These authors contributed equally to this work. 
a
School of Medical Sciences, Edith Cowan University, Perth, Australia. 
b
School of Exercise & Health Sciences, Edith Cowan University, Perth, Australia.  
c
Neurosciences Unit, North Metropolitan Area Mental Health Service, WA State Department 
of Health, Perth, Australia. 
d
Cambridge Centre for Brain Repair, Cambridge, UK.  
e
School of Pathology and Laboratory Medicine, University of Western Australia, Perth, 
Australia. 
Running Title: Multidisciplinary Rehabilitation in HD 
Keywords: Neurodegenerative, Exercise Therapy, Occupational Therapy, Resistance 
Training, Chorea.  
 
 
 
98 
 
4.1 ABSTRACT  
Background 
Despite advances in the understanding of Huntington’s disease (HD), treatment remains 
symptomatic. Multidisciplinary rehabilitation, however, appears to impact disease 
progression. Here we show the feasibility, safety and efficacy of a nine-month 
multidisciplinary rehabilitation program in a small cohort of early-to-middle-stage HD 
patients.  
Methods 
Twenty HD patients were assigned to two groups, equally matched for cognitive and motor 
scores. One group received the intervention, whilst the other served as control. The Unified-
Huntington’s-Disease-Rating-Scale-Total-Motor-Score was the primary outcome measure.  
Neurocognitive/psychological tests, body composition, postural stability, strength and quality 
of life assessments were secondary outcome measures. 
Results 
The intervention reduced motor and postural stability deterioration, with minor improvements 
in depression, cognition and quality of life.   Significant gains were observed for fat-free 
mass and strength.  
Conclusion 
This pilot study suggests that a prolonged multidisciplinary rehabilitation program in early-
to-middle-stage HD is feasible, well-tolerated and associated with therapeutic benefit. Further 
explorative, larger studies are warranted.   
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4.2 INTRODUCTION 
Huntington’s disease (HD) is a neurodegenerative disorder characterised by progressive 
motor, behavioural and cognitive impairments.  No cure or disease-modifying therapies exist 
(Nance, 2012), and treatment remains symptomatic. There is an urgent need, therefore, to 
identify therapies capable of impacting on the disease. 
Multidisciplinary rehabilitation has improved gait, balance, depression, quality of life (QOL) 
and cognition in people with Alzheimer’s and Parkinson’s disease (Ellis et al., 2008; Trend et 
al., 2002; Wade et al., 2003), yet few studies have examined multidisciplinary rehabilitation 
in HD. The most extensive study to-date examined the effect of an intense, intermittent two-
year program in 40 early-to-middle-stage HD patients (Zinzi et al., 2007). The program was 
feasible, well-tolerated and associated with positive motor benefits. Similarly, another study 
in HD demonstrated that 18 months of multidisciplinary care was feasible and perceived as 
beneficial (Veenhuizen et al., 2011).  
We therefore designed and implemented a nine-month multidisciplinary rehabilitation 
program, and assessed the effect on motor function, cognition, depression, body composition, 
postural stability and QOL in a small cohort of early-to-middle-stage HD patients to evaluate 
its feasibility, safety and efficacy.   
4.3 METHODS 
4.3.1 Design 
Twenty early-to-middle-stage HD patients were assigned to two equal groups based on 
cognitive and motor scores, with the intervention group randomly assigned. Research was 
conducted in accordance with the Declaration of Helsinki, with informed consent provided. 
Ethics approval was granted by the Human Research Ethics Committee of Edith Cowan 
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University and the North Metropolitan Area Mental Health Service (NMAMHS). This project 
was registered with the Australian New Zealand Clinical Trial Registry 
(ACTRN12610000218099). 
4.3.2 Participants 
Participants in Perth, Australia were recruited utilising NMAMHS databases. Inclusion 
criteria included a positive genetic test, clinical disease diagnosis (Unified-Huntington’s-
Disease-Rating-Scale-Total-Motor-Score [UHDRS-TMS] ≥5), ability to follow verbal 
instruction and perform sub-maximal exercise. Exclusion criteria included recent substance 
abuse, an unstable psychiatric or medical condition, or confounding neurological conditions. 
Medication was adjusted by physicians where necessary.  Some individuals in the 
intervention (I) and control (C) groups commenced new medication; anti-psychotics (I 2; C 
2), anti-depressants (I 0; C 1), anxiolytics (I 1; C 2) and anti-dyskinetics (I 0; C 1). 
4.3.3 Outcome Measures 
The primary outcome measure was the UHDRS-TMS, performed by J.L. Secondary outcome 
measures, assessed over one day per timepoint, are detailed below.  All assessors except 
occupational therapists (OTs) were blinded. 
Body composition was quantified using Dual Energy X-Ray Absorptiometry (Hologic 
Discovery A). Postural stability/balance assessments utilised the Sensory Organisation Test 
(Neurocom SMART Balance Master) and the Activities-Specific Balance Confidence (ABC) 
Scale. Strength was assessed throughout rehabilitation. Neurocognitive/psychological tests 
included Symbol Digit Modalities Test (SDMT), Hopkins Verbal Learning Test-Revised 
(HVLT-R), D-KEFS Colour Word Interference Test and Trail Making Trials, Beck 
Depression Inventory-II (BDI-II). The Goal Attainment Scale (GAS) examined achievement 
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of patient-derived goals. QOL perceptions were evaluated using the SF-36v2 Health 
Questionnaire and Huntington's-Disease-Quality-of-Life-Battery-for-Carers (HDQOL-C).   
4.3.4 Intervention  
Following baseline data analysis, exercise physiologists and physiotherapists designed 
clinical and home-based exercise programs, and OTs formulated personalised patient-focused 
programs targeting deficits detected by psychologists.  
The clinical exercise program comprised supervised group sessions (nine-months, once-
weekly; 5 minute warm-up, 10 minutes aerobic exercise, 40 minutes resistance exercise, 5 
minute cool-down) in an exercise clinic. A tailored, self-monitored home-based exercise 
program (six-months, three-times weekly) was employed after careful instruction. OT 
programs were provided for one hour per fortnight, for six-months. 
4.4 STATISTICAL ANALYSIS 
Student’s independent or paired t-tests assessed continuous variables.  Mann Whitney U and 
Fischer’s Exact tests assessed ordinal variables. Results are reported as mean ± standard error 
of the mean (SEM), with p<0.05 considered significant. Effect size calculations (Cohen’s d),  
performed using G*Power Software Version 3.0.10 (Faul et al., 2007), were interpreted as 
small (d=0.20), medium (d=0.50) or large (d=0.80).  
4.5 RESULTS 
Fifty-six HD patients were approached, and twenty-five volunteered to participate. Three 
withdrew prior to randomisation (frailty, falls, delusions) and two prior to completion (no 
wish to continue; I 1: C 1), with one participant transferred to the control group due to an 
adverse medication reaction. No statistical between-group differences existed for baseline 
demographics, depression, motor or cognitive assessments (Table 4.1). Participants 
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demonstrated high adherence to clinical exercise and OT sessions (85%), and moderate 
adherence to the home-based exercise program (56%).  No adverse events were reported. 
Rehabilitation produced a medium-large effect on UHDRS-TMS scores (Figure 4.1a), 
impacting on chorea (medium-large effect) and tandem walking (p=0.015) components.  
Significant between-group differences were observed for fat mass, fat-free mass, lower/upper 
body strength, written errors (SDMT) and for the walking-up-and-down-stairs component of 
the ABC-UK, with a large effect for the walking-around-the-house component (Table 4.1; 
Figure 4.1b-d). Small-to-medium effects were noted for D-KEFS, HVLT-R, BDI-II, QOL 
and postural stability (Table 4.1; Figure 4.1). GAS revealed partial or complete achievement 
of goals in 7 of 9 intervention participants. 
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Table 4.1 Participant Characteristics (n; I=9; C=11). 
 
ABC-UK, Activities-specific Balance Confidence Scale; BDI-II, Beck depression Inventory-
II; CAG, cytosine-adenine-guanine; CWIT, Colour Word Interference Test; D-KEFS, Delis-
Kaplan Executive Function System; HVLT-R, Hopkin’s Verbal Learning Test-Revised; RDI, 
Recognition Discrimination Index; SDMT, Symbol Digit Modalities Test; TMT, Trail 
Making Trials. 
 
Variable Intervention Control p 
Demographics 
Age (Years) 53.8 ±2.9 52.2 ±2.6 >0.05 
CAG (n) 43.1 ±1.1 43.7 ±0.7 >0.05 
CAG Index 399.0 ±53.7 416.1 ±23.3 >0.05 
Body composition Baseline Final Baseline Final p 
Fat-Free Mass (kg) 52.1 ±3.9 53.4 ±4.2 55.4 ±3.2 54.6 ±2.9 0.047 
Fat Mass (kg) 21.6 ±2.5 22.5 ±2.6 21.9 ±2.6 20.4 ±2.6 0.014 
Total Mass (kg) 73.7 ±4.6 75.8 ±5.0 77.3 ±3.8 75.0 ±3.3 0.017 
Body Mass Index (kg/m
2
) 26.2 ±1.3 26.9 ±1.4 27.1 ±1.3 26.7 ±1.3 0.070 
Bone Mineral Density 
(g/cm
3
) 
1.1 ±0.0 1.1 ±0.0 1.1 ±0.0 1.1 ±0.0 >0.05 
SDMT      
Written 
Correct 
Incorrect 
 
30.0 ±4.9 
2.6 ±0.8 
 
27.4 ±3.9 
1.2 ±0.3 
 
25.4 ±3.3 
0.6 ±0.3 
 
23.3 ±2.8 
1.4 ±0.6 
 
>0.05 
0.042 
Oral 
Correct 
Incorrect 
 
35.8 ±5.4 
3.0 ±0.9 
 
30.8 ±5.3 
2.1 ±0.8 
 
25.9 ±3.2 
5.6 ±5.0 
 
28.0 ±3.4 
1.0 ±0.4 
 
>0.05 
>0.05 
HVLT-R      
Total Recall 19.2 ±1.8 16.3 ±2.6 14.3 ±1.7 14.7 ±1.6 >0.05 
Delayed Recall 5.9 ±0.7 5.8 ±1.3 5.4 ±0.7 4.5 ±0.7 >0.05 
Retention 80.3 ±7.7 75.9 ±10.8 85.3 ±5.9 68.7 ±10.1 >0.05 
RDI 8.3 ±0.9 7.3 ±1.3 7.3 ±0.9 7.9 ±1.0 >0.05 
D-KEFS      
TMT      
Visual Scanning 34.3 ±5.3 43.2 ±6.7 31.4 ±3.5 36.8 ±4.2 >0.05 
Number Sequencing 55.6 ±6.2 63.8 ±9.6 59.9 ±5.8 57.5 ±7.7 >0.05 
Letter Sequencing 67.9 ±14.0 71.0 ±14.3 78.2 ±17.0 65.2 ±11.3 >0.05 
Number/Letter Switching 150.4 ±21.7 144.3 ±27.8 192.0 ±27.1 122.2 ±17.9 >0.05 
Motor Speed 54.1 ±9.4 61.4 ±11.2 69.5 ±11. 8 60.8 ±7.7 >0.05 
CWIT      
Colour Naming 46.6 ±6.7 50.63 ±8.2 42.8 ±4.4 47.8 ±5.8 >0.05 
Word Reading 33.8 ±3.8 33.25 ±4.1 30.2 ±3.1 29.9 ±3.7 >0.05 
Inhibition 90.9 ±16.9 90.9 ±17.0 87.3 ±7.0 86.2 ±8.1 >0.05 
BDI-II 10.8 ±3.2 5.6 ±1.6 12.9 ±2.6 10.0 ±2.5 >0.05 
ABC-UK      
Walking around the house 
Walking up or down stairs 
81.1 ±8.7 
63.3 ±12.9 
87.1 ±6.0 
72.7 ±12.6 
81.4 ±5.9 
71.8 ±8.2 
75.6 ±9.6 
63.3 ±13.4 
0.077 
0.024 
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a b 
c d 
e f 
%; P     197.9; 0.005    175.5; 0.052    225.9; 0.094 %; P     209.2; 0.004    188.6; 0.004    235.1; 0.094 
Figure 4.1 (a-f) Changes to clinical outcomes after multidisciplinary rehabilitation 
a) Unified-Huntington’s-Disease-Rating-Scale-Total-Motor-Score at baseline and final 
assessment (n; I=9; C=11); b-d) Strength outcomes for upper and lower body (n; I=9; C=11); 
values are shown for the intervention group as a whole, and for female and male sub-groups 
to indicate gender response.  Percentage of overall change (%) and statistical significance (p) 
from commencement of maximal training (point 3) to final assessment are also indicated; e) 
Changes in postural stability at final assessment relative to baseline (n; I=9; C=11); f) 
Changes in SF-36v2 health scores at final assessment relative to baseline (n; I=9; C=11).  
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4.6 DISCUSSION 
This pilot study demonstrates the feasibility and safety of a nine-month multidisciplinary 
rehabilitation program in twenty HD patients. Relative to control subjects, intervention 
recipients exhibited reduced motor and postural stability deterioration, and significant 
increases in fat-free mass and strength.  Strength improvements have not been reported to-
date, perhaps because previous programs spanned only eight weeks (Khalil, 2012). The 
minimal impact on cognitive outcomes observed here may be obscured by lack of sensitivity 
of testing procedures, normally requiring large sample sizes (Stout et al., 2012).  Changes in 
QOL perceptions reflected functional outcomes. 
Although positive, the pilot study has significant limitations, including lack of long-term 
follow-up (precluding examination of a carry-over effect on cessation), limited sample size, 
and low frequency of supervised rehabilitation, optimally requiring two-three sessions per 
week.  Assessment tools may also lack sensitivity to detect subtle changes.  
In conclusion, we demonstrate that early-to-middle-stage HD patients can successfully 
participate in prolonged multidisciplinary rehabilitation as an adjunct to medication and 
further explorative, larger studies are warranted. Encouragingly, despite the small sample size 
and low exercise frequency, small improvements were detected.  Future studies would benefit 
from more frequent rehabilitation, including a high-intensity aerobic component (Baker et al., 
2010) to maximise cognitive improvements.   
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5.1 ABSTRACT 
Background: Progressive neurological dysfunction with secondary muscle wasting and 
weakness is a physically disabling trait of Huntington’s disease (HD) that contributes to 
impairments in functional capacity. Preliminary evidence suggests that multidisciplinary 
rehabilitation is useful for treating impairments in functional capacity and therapeutically 
addressing body composition abnormalities in individuals with manifest HD. Resistance 
exercise also appears helpful for increasing muscular strength and lean tissue mass in other 
neurodegenerative disorders. The purpose of this study was to evaluate the utility of a 
multidisciplinary rehabilitation intervention encompassing resistance exercise on muscle 
wasting and weakness and related functional impairments in individuals with HD. 
Methods: Twenty-two participants with manifest HD were recruited and randomly assigned 
to an intervention or control group. Participants in the intervention group were provided with 
a nine month multidisciplinary rehabilitation intervention, while those in the control group 
maintained their usual care. Participants were assessed using muscle wasting (loss of lean 
tissue mass), lower extremity muscle strength, balance and mobility measures before and 
after the trial. Paired t-tests were used to examine changes within each group for muscle 
wasting, lower extremity muscle strength, balance and mobility measures. Unpaired t-tests 
were used to examine changes in relative values between groups for muscle wasting, lower 
extremity muscle strength, balance and mobility measures. 
Results: Significant increases in muscle strength in the knee extensors and flexors were 
found in the intervention group. The intervention group also displayed significantly greater 
lean tissue mass than the control group after multidisciplinary rehabilitation. Furthermore, a 
significant deterioration in mobility was observed in the control group, whereas the 
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intervention group showed no such changes. There were no significant changes in balance in 
either group.  
Conclusions: Multidisciplinary rehabilitation is useful for improving muscular strength in the 
lower extremities as well as preserving lean tissue mass and mobility in manifest HD.  
Trial Registration: This study was registered with the Australian New Zealand Clinical Trial 
Registry (ACTRN12610000218099) 
Keywords: balance, mobility, muscle strength, muscle mass, Huntington’s disease 
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5.2 BACKGROUND 
Huntington’s disease (HD) is a chronic neurodegenerative disorder of the nervous system. 
Over the course of the disease individuals suffer from progressive neurological deficits 
leading to secondary muscle wasting (Kosinski et al., 2007; Turner et al., 2007) and weakness 
(Busse et al., 2008; Kosinski et al., 2007). The development of these clinical features 
contributes to functional impairments (Cruickshank et al., 2014), a reduced quality of life (Ho 
et al., 2009) and nursing home placement (Rao et al., 2005). 
Muscular wasting has been described previously in patients and rodent models of HD (Aziz 
and Roos, 2013; Ribchester et al., 2004; Sanberg et al., 1981). The mechanisms underpinning 
it are not yet clear, however lifestyle passivity, mitochondrial dysfunction (Rivera-Sánchez et 
al., 2014), transcriptional dysregulation (Luthi-Carter et al., 2002a; Strand et al., 2005) and 
myocyte defects (van der Burg et al., 2009) are thought to be the primary aetiological factors. 
Muscular wasting and associated weakness, particularly in the lower extremities (Busse et al., 
2008; Kosinski et al., 2007), contributes to impairments in functional capacity (Cruickshank 
et al., 2014). 
Recent evidence from our group shows that muscular weakness in the lower extremities 
contributes to impairments in balance and mobility in individuals with manifest HD 
(Cruickshank et al., 2014). Similar findings have been reported in individuals with other 
neurodegenerative disorders (Broekmans et al., 2013a; Paul et al., 2013b). In particular, Paul 
et al (Paul et al., 2013a; Paul et al., 2013b) showed that muscle weakness in the lower 
extremities contributes to impaired balance and mobility as well as falls in individuals with 
Parkinson’s disease (PD). Furthermore, Broekmans et al (Broekmans et al., 2013a) showed 
that lower extremity muscle strength is a significant predictor of walking capacity in 
individuals with multiple sclerosis.  
111 
 
Therapeutic strategies that positively impact on muscle weakness/mass and the underlying 
aetiological mechanisms may favourably impact on functional capacity in individuals with 
HD. Accumulating evidence suggests that multidisciplinary rehabilitation is a useful 
therapeutic approach for treating functional impairments that present in HD. For example, 
Zinzi et al (2007) reported improvements in balance and mobility in a small sample of 
individuals with HD after twelve months of intensive, intermittent, multidisciplinary 
rehabilitation. More recently, Piira et al (2013) found improvements in mobility, balance, 
mood and quality of life after twelve months of intensive tri-monthly multidisciplinary 
rehabilitation. Finally recent work by our group has shown that weekly multidisciplinary 
rehabilitation over nine months favourably impacts on weight loss and adipose tissue loss in 
individuals with manifest HD (Thompson et al., 2013). When assessed separately, resistance 
exercise has been shown to increase lean tissue mass and muscular strength in individuals 
with multiple sclerosis and PD (Dalgas et al., 2009; Dalgas et al., 2010b; Dibble et al., 2006; 
Shulman et al., 2013). Multidisciplinary rehabilitation interventions encompassing resistance 
exercise may therefore be useful for treating muscular wasting and weakness as well as 
related functional impairments in individuals with HD.  
The objective of this study was to evaluate the utility of a nine month multidisciplinary 
rehabilitation intervention, encompassing resistance exercise, on lean tissue mass, muscle 
strength, balance and mobility in individuals with manifest HD.  
5.3 METHODS  
5.3.1 Study design  
The present study was a nine month randomised controlled pilot trial. A simple 
randomisation procedure was used to assign participants to an intervention or a control group, 
using computer generated random numbers. Participants in the intervention group were 
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provided with a nine month multidisciplinary rehabilitation intervention, while participants in 
the control group were asked to maintain their usual care throughout the trial. After the trial, 
participants in the control group were provided with the same nine month multidisciplinary 
rehabilitation intervention for ethical purposes. Both groups were tested at baseline (pre-trial) 
and after nine months (post-trial) using lean tissue mass, lower extremity muscle strength, 
mobility and balance measures. 
5.3.2 Study approval, registration, and patient consent 
Ethical approval was granted by the Human Research Ethics Committees at Edith Cowan 
University and North Metropolitan Area Mental Health Service (NMAMHS). Written 
informed consent was provided by all study participants. This study was registered with the 
Australian New Zealand Clinical Trial Registry (ACTRN12610000218099). 
5.3.3 Participants 
Potential participants were identified using the Neuroscience Unit database of the North 
Metropolitan Area Mental Health Service (NMAMHS). Inclusion criteria included a family 
history of HD, a positive genetic test for the HD mutation (CAG >39), manifest disease 
(Unified Huntington’s Disease Rating Scale-Total Motor Score [UHDRS-TMS] ≥5), the 
capacity to follow written or verbal instruction, the ability to perform sub-maximal aerobic 
and resistance exercise and aged 18 years or older. Participants were excluded if they had 
recent drug or alcohol abuse, possessed a confounding neurological condition or concomitant 
physical condition which was a contraindication for exercise.  
5.3.4 Multidisciplinary rehabilitation intervention  
The trial intervention was designed following baseline assessment by physical therapists, 
exercise physiologists and occupational therapists. The intervention was designed to target 
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muscular wasting and weakness in the lower extremities as well as balance and mobility. The 
intervention comprised a clinical exercise program, home based exercise program and 
fortnightly occupational therapy. The clinical exercise program consisted of once weekly 
aerobic and resistance exercise for an hour in a clinical exercise centre. The home-based 
exercise program (to be performed thrice weekly) consisted of muscle strengthening and fine 
motor exercises. The home-based exercise program was only provided to participants after 
careful instruction and familiarisation. Occupational therapy consisted of cognitive and 
functional exercises designed to enhance cognitive and functional independence (see 
Supplementary Tables 5.4, 5.5 and 5.6). 
5.3.5 Study procedures 
Participants were examined by formally trained assessors. The same assessors were used at 
baseline and at the nine month assessment time point to ensure the reliability of collected 
data. All assessors were blinded to group allocation.  
5.3.6 Outcome measures 
Lean tissue mass  
Total lean tissue mass was quantified to evaluate muscle wasting using dual-energy X-ray 
Absorptiometry (Hologic, Inc, Waltham, MA)(Goodman and Barker, 2011; Thompson et al., 
2013). 
Lower extremity muscle strength 
Maximum voluntary contraction of knee flexors and extensors was examined using isokinetic 
and isometric strength test protocols with automated dynamometry (Biodex Medical Systems, 
Shirley, NY, USA). Automated dynamometry has been previously shown to be a reliable 
measure of muscle strength changes in people with neurodegenerative disorders (Dalgas et 
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al., 2009). Prior to testing, participants were comfortably seated and safely secured using two 
padded chest straps and one padded waist strap. Additional straps were placed just above the 
knee and ankle to secure the tested limb and restrict extraneous movement. Once securely 
seated, participants were positioned with their lateral condyle aligned with the dynamometers 
axis of rotation. Participants were then instructed to perform three sub-maximal isokinetic 
extension and flexion contractions at 30%, 50% and 70% of their perceived maximum 
voluntary contraction (MVC). Isokinetic and isometric muscle strength testing was performed 
shortly after the individuals performed the sub-maximal contractions. Isokinetic muscle 
strength protocols examined knee extensor (KE) and knee flexor (KF) and muscle strength at 
180°·s
-1
 (fast) and 30°·s
-1 
(slow) velocities. Isometric knee extensor and flexor muscle 
strength was also examined at 60° of knee flexion. Each individual performed three 
contractions per test, with one minute separating each testing protocol. The average of the 
two highest values recorded was used for statistical analysis. 
Mobility 
Changes to fast and self-paced walking were examined using the 10 m Timed Walk Test 
(Quinn et al., 2013). Fast-paced walking was also examined using the 4 m Timed Walk Test. 
Time was recorded for both tests using a standard stopwatch. Walking endurance was 
assessed using the 6 Minute Walk Test (Quinn et al., 2013). The total distance travelled for 
the 6 Minute Walk Test was recorded using a trundle wheel. These measures were 
specifically chosen as they have previously been documented to be reliable measures of 
mobility performance in people with manifest HD (Khalil et al., 2010; Quinn et al., 2013). 
Balance 
Changes to dynamic and static balance were assessed using the Berg Balance Scale (BBS) 
and the 10 repetition Chair Stand Test (CST) (Khalil et al., 2010; Quinn et al., 2013). Time 
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taken to complete the CST was recorded using a standard stopwatch. Participants performed 
two trials for each assessment. These measures were specifically chosen as they have 
previously been documented to be reliable measures of mobility performance in people with 
manifest HD (Khalil et al., 2010; Quinn et al., 2013). 
5.4 STATISTICAL ANALYSIS  
Changes within each group for lean tissue mass, lower extremity muscle strength, mobility 
and balance outcomes were examined using a paired t-test. An unpaired t-test was used to 
assess relative changes in lean tissue mass, muscle strength, mobility and balance between 
groups. Relative changes were calculated as the mean difference between pre-trial and post-
trial values. Data are presented as mean and standard deviations. Statistical examination of 
the data was performed with STATA version 9.1 (Stata Corp, 4905 Lakeway Dr, Texas 
77845 USA). 
5.5 RESULTS 
Between January 2010 and May 2010 sixty six individuals with manifest HD were identified 
and invited to participate in this research trial. Twenty five (38%) satisfied the inclusion 
criteria and consented to participate. Three participants (12%) withdrew prior to 
randomisation (due to frailty, excessive falls and delusions) and three (13.6%) before the 
conclusion of the trial (did not want to continue) (see Figure 5.1).  
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Enrolment Assessed for eligibility (n=66) 
Excluded (n=44) 
 Did not meet inclusion criteria (n=4) 
 Declined to participate (n=32) 
 Other reasons (n=8) 
 
Allocated to intervention group 
(n=11) 
 Received allocated intervention 
(n=9) 
Allocated to control group (n=11) 
 Participated as a control 
(n=10) 
Lost to follow-up (n=2) 
 Severe mental health issues 
(n=1) 
 Discontinued intervention (did 
not enjoy the intervention (n=1) 
 
Lost to follow-up (n=1) 
 Presented with a confounding 
neurological condition (n=1)  
 
Analysed (n=9) 
 
Analysed (n=10) 
  
Randomised (n=22) 
Allocation  
Follow-Up  
Analysis  
Figure 5.1 Participant recruitment and study flow 
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Participants in the intervention group displayed high adherence to the supervised clinical 
program (85%), moderate adherence to the home based program (56%), and high adherence 
to occupational therapy sessions (84.2%).  
Table 5.1 displays demographic data and information on disease severity, disease duration, 
and the severity of motor abnormalities (UHDRS-TMS) in the intervention and control 
groups. Table 5.2 displays changes in medication and supplements throughout the study. 
Figure 5.2 and Table 5.3 show measures of lean tissue mass, muscular strength in the lower 
extremities and balance and mobility before and after the trial and relative changes in these 
values. There were no significant differences between groups at baseline for demographics, 
disease severity, disease duration, severity of motor abnormalities or for any of the recorded 
outcome measures. 
Table 5.1 Participant demographics at baseline (Mean ± SD) 
 
Variable Intervention group Control group p value 
No. (M/F) 9 (4/9) 10 (6/4)  
Age (years) 53.77 ± 8.56 50.80 ± 7.81 NS 
CAG (n) 43.11 ± 3.25 44.1 ± 1.96 NS 
Disease Burden 
Score 
399.40 ± 161.33 428.20 ± 71.57 NS 
UHDRS-TMS 24.88 ± 13.56 25.20 ± 12.29 NS 
CAG (n), cytosine-adenine-guanine expansion; UHDRS-TMS, Unified Huntington’s Disease 
Rating Scale-Total Motor Score; NS, not significant  
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Table 5.2 Participant medication and supplements throughout the study 
 
Participants Trial Active Follow-up 
Intervention Group  NA 
Participant 1 Fish Oil NA 
Participant 2 - NA 
Participant 3 
Aripiprazole, Amantadine, 
Citalopram, Olanzapine 
NA 
Participant 4 
Folate, Activated B3, 
Multivitamins, CoQ10 
NA 
Participant 5 
Haloperidol, Paroxetine, 
Atorvastatin 
NA 
Participant 6 
Olanzapine, Escitalopram, 
Fish Oil, Vitamin D, Zimtat 
NA 
Participant 7 Aripiprazole, Escitalopram NA 
Participant 8 Tetrabenazine, Fluoxetine NA 
Participant 9 
Atorvastatin, Aspirin, 
Prazosin 
NA 
Control Group   
Participant 10 
Telmisartan, Clonazepam, 
Olanzapine, Amantadine, 
Omega 3 
Telmisartan, Vesicare, 
Amantadine, Clonazepam,  
Olanzapine, Mirtazapine 
Participant 11 
Venlafaxine, Mirtazapine, 
Dimebon, Olanzapine 
Venlafaxine, Mirtazapine, 
Olanzapine 
Participant 12 
Pariet, Mirtazapine, 
Olanzapine, Escitalopram, 
Benzhexol, Varenidine 
Tartrate 
Aripiprazole, Olanzapine, 
Mirtazapine, Pariet, 
Escitalopram, Nitrazepam 
Participant 13 
Escitalopram, Olanzapine, 
Megafolate, CoQ10 
Escitalopram, Olanzapine, 
Megafolate, CoQ10 
Participant 14 
Thyroxine, Escitalopram, 
Olanzapine, Multivitamins 
Thyroxine, Escitalopram, 
Olanzapine, Multivitamins, 
Simvastin 
Participant 15 Mirtazapine, Thyroxine 
Mirtazapine, Escitalopram, 
Aripiprazole, Lorazepam, 
Iron tables 
Participant 16 
Olanzapine, Citalopram, 
Mirtazone 
Olanzapine, Citalopram, 
Mirtazone 
Participant 17 
Escitalopram, Olanzapine, 
Propranolol 
Aripiprazole, Neurontin 
Participant 18 Setraline Setraline 
Participant 19 Cadesartan Cilexitil - 
NA, not applicable 
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Figure 5.2 Changes in lower extremity muscle strength in individuals with manifest HD 
 
The effects of nine months of multidisciplinary rehabilitation on changes in maximum 
voluntary contraction (MVC) muscle strength in the knee extensors (KE) and knee flexors 
(KF) of individuals with manifest HD. * Indicates significant differences in muscle strength 
between baseline and post-intervention. 
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Table 5.3 Changes (mean SD) in lean tissue mass, balance and mobility after nine months of multidisciplinary rehabilitation in the intervention 
and control group 
 
 Intervention Group (n=9) Control Group (n=11) 
 Pre-trial Post-trial p value Pre-trial Post-trial p value 
Lean tissue mass 
49763.16  ± 
11223.87 
51034.46  ± 
12210.80 
0.066 
53885.72  ± 
10387.53 
52248.34  ± 
10387.53 
0.060 
BBS 46.88 ± 9.15 48.11 ± 8.76 0.326 44.9 ± 7.35 44.8 ± 6.35 0.484 
CST 28.07 ± 13.16 27.33 ± 11.85 0.427 32.40 ± 12.55 32.00 ± 18.95 0.435 
10 m TWT (SP) 8.37 ± 3.68 8.35 ± 4.06 0.472 8.02 ± 1.92 8.61 ± 1.72 0.111 
10 m TWT (FP) 6.49 ± 4.38 7.10 ± 3.61 0.187 6.14 ± 1.36 7.09 ± 2.43 0.050* 
4 m TWT 3.46 ± 2.53 2.97 ± 1.39 0.134 2.79 ± 0.86 3.35 ± 1.18 0.001* 
6MWT 474.37 ± 169.59 449.37 ± 145.68 0.079 443.50 ± 101.62 391.50 ± 132.05 0.024* 
BBS, Berg Balance Scale; CST, Chair Stand Test; TWT (SP), Timed Walk Test (self-paced), TWT (FP), Timed Walk Test (fast-paced), 4 m 
TWT, Four Meter Timed Walk Test, 6MWT, Six Minute Walk Test  
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5.5.1 Effects of multidisciplinary rehabilitation  
Changes to lean tissue mass 
Table 5.3 displays relative changes in lean tissue mass during the trial. There were no 
significant changes to lean tissue mass within each group after the nine month trial, however 
an examination of the relative changes in lean tissue mass between groups revealed that the 
intervention group had significantly greater lean tissue mass after the intervention than the 
control group (intervention group: 1271.30g ± 2275.05g; control group: -1637.38g ± 
3024.08g; p=0.015). 
Changes in maximal lower extremity muscle strength 
Figure 5.2 displays changes in maximal lower extremity muscle strength. Knee extensor 
muscle strength increased significantly at slow (43.4% p=0.000) and fast velocities (22.3% 
p=0.040) in the intervention group, whereas it remained relatively unchanged in the control 
group (slow velocity, -3.5% p>0.05; fast velocity, 3.02% p>0.05). Individuals in the 
intervention group also displayed increases in knee flexor muscle strength at slow (22.7%; 
p=0.056) and fast velocities (26.19%; p=0.027). By contrast, knee flexor muscle strength 
decreased or remained unchanged at slow (-13.5%; p>0.05) and fast velocities (0.04%; 
p>0.05) in the control group. Increases in isometric muscle strength in the knee extensors 
(25.3%; p=0.000) and flexors (21.09%; p=0.025) were also found in the intervention group, 
while the control group displayed a slight decrease in isometric knee extensor (-0.07%; 
p>0.05) and flexor (-3.36%; p>0.05) muscle strength. An examination of changes in 
isokinetic and isometric knee extensor and flexor muscle strength between groups showed 
that the intervention group had significantly greater muscle strength than the control group 
after nine months of multidisciplinary rehabilitation [KE 180˚ (intervention group: 17.20 Nm 
± 19.82 Nm) vs (control group: 1.95 Nm ± 11.23 Nm) p=0.025; KF 180˚ (intervention group: 
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12.00 Nm ± 16.10 Nm) vs (control group: 0.20 Nm ± 8.46 Nm) p=0.029; KE 30˚ 
(intervention group: 44.21 Nm ± 18.33 Nm) vs (control group: -4.66 Nm ± 21.17 Nm) 
p=0.000; KF 30˚ (intervention group: 20.65 Nm ± 21.35 Nm) vs (control group: -3.52 Nm ± 
7.57 Nm) p=0.001; KE 60˚ (intervention group: 37.66 Nm ± 19.05 Nm) vs (control group: -
1.17 Nm ± 22.79 Nm) p=0.000; KF 60˚ (intervention group: 17.92 Nm ± 18.32 Nm) vs 
(control group: -2.05 Nm ± 13.79 Nm) p=0.007].  
Changes to mobility 
Changes in mobility for both groups are displayed in Table 5.3. There were no significant 
changes in the 10 m Timed Walk Test, 4 m Timed Walk Test or 6 Minute Walk Test mobility 
measures in the intervention group during the trial period. In contrast, the control group 
displayed a significant deterioration on the 6 Minute Walk Test (13.2%), the fast-paced 
component of the 10 m Timed Walk Test (13.3%) and the 4 m Timed Walk Test (16.7%) 
after nine months. An analysis of the relative changes between groups revealed that the 
intervention group performed significantly better than the control group on the 4 Meter 
Timed Walk Test after nine months [(intervention group -0.49s ± 1.96s) vs (control group 
0.56s ± 1.02s) p=0.011]. 
Changes to balance 
Changes to balance for both groups are shown in Table 5.3. There were no significant 
changes in balance within or between groups throughout the study.   
5.6 DISCUSSION 
This study showed that multidisciplinary rehabilitation is useful for increasing muscular 
strength in the lower extremities. In addition this study showed that multidisciplinary 
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rehabilitation favourably impacts on lean tissue mass and mobility in individuals with 
manifest HD.  
Previous studies have shown that muscular strength in the lower extremities is significantly 
reduced in individuals with manifest HD (Busse et al., 2008). Here we show that muscular 
strength is remediable to multidisciplinary rehabilitation. Specifically, we found that muscle 
strength in the knee flexors and extensors was significantly increased after multidisciplinary 
rehabilitation. The observed increases in lower extremity muscle strength are encouraging, 
especially considering that muscle weakness in the lower limbs contributes to balance and 
mobility problems in HD (Cruickshank et al., 2014). Increases in muscle strength may be 
attributed to the resistance exercise component of the intervention in this study. Studies of 
resistance exercise in other neurodegenerative disorders have consistently reported increases 
in muscle strength (Corcos et al., 2013; Dalgas et al., 2009; Dalgas et al., 2010b; Shulman et 
al., 2013). Taken together these results collectively suggest that interventions encompassing 
resistance exercise should be considered for improving muscle strength in individuals with 
HD and other neurodegenerative disorders. 
Muscle wasting is a well-documented feature of HD that is not amenable to drug therapy 
(Aziz and Roos, 2013; van der Burg et al., 2009). In this study, multidisciplinary 
rehabilitation was found to favourably impact on lean tissue mass. Despite no baseline 
differences, the intervention group illustrated significantly greater lean tissue mass after the 
intervention when compared to the control group. This finding extends our previous work, 
where significant increases in body weight and fat mass were found following 
multidisciplinary rehabilitation (Thompson et al., 2013). The favourable effect of 
multidisciplinary rehabilitation on lean tissue is most likely attributable to the resistance 
exercise component of the intervention. Indeed there is some literature showing that 
resistance exercise increases muscle mass in the elderly (McCartney et al., 1995; Yarasheski 
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et al., 1999; Yarasheski et al., 1993) and in those with multiple sclerosis and Parkinson’s 
disease (Dalgas et al., 2010b; Dibble et al., 2006). These results suggest that resistance 
exercise may be a useful therapeutic strategy for addressing muscle wasting in individuals 
with HD as well as for other neurodegenerative disorders.  
Similar to earlier investigations, we found that multidisciplinary rehabilitation had a 
favourable effect on mobility in individuals with manifest HD (2013; Zinzi et al., 2007). In 
particular, we found that mobility was preserved in individuals in the intervention group, 
whereas it deteriorated in individuals in the control group. This finding confirms earlier 
exploratory findings by Piira et al (2013) and Zinzi et al (2007), who reported improvements 
in mobility after a twelve and twenty-four month intensive intermittent multidisciplinary 
rehabilitation intervention. Collectively, these findings suggest that multidisciplinary 
rehabilitation is a useful strategy for improving mobility in individuals with manifest HD.  
In contrast to previous work (2013; Zinzi et al., 2007), we did not find any evidence to 
support the use of multidisciplinary rehabilitation for balance problems in individuals with 
manifest HD. Specifically, we found that balance was unchanged in the intervention group 
and the control group at the conclusion of the study. The short duration of the current 
intervention compared with previous studies may have accounted for our inability to find 
significant changes in balance in the current sample of individuals with HD. Moreover, the 
lack of formalised balance training in our intervention, unlike previous studies (2013; Zinzi et 
al., 2007), may have accounted for our inability to also see any such improvements. 
Formalised balance training may be necessary to improve balance in people with HD.  
The present study is not without limitations. Our findings were collected from a relatively 
small sample of individuals with manifest HD. In addition, individuals remained on 
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medication throughout the study, which may have influenced some of the favourable effects 
associated with this multidisciplinary rehabilitation intervention.  
5.7 CONCLUSIONS 
This study provides preliminary evidence that multidisciplinary rehabilitation is an effective 
treatment strategy for increasing muscular strength in the lower extremities and favourably 
impacts on muscular mass and mobility in individuals with manifest HD. We recommend 
larger controlled trials to confirm the therapeutic utility of multidisciplinary rehabilitation as 
an adjunct treatment approach for reduced muscle strength, muscle wasting and mobility 
problems in individuals with HD. 
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5.9 SUPPLEMENTARY DATA 
Supplementary Table 5.4 Clinical exercise program 
Abbreviations: Reps= Repetitions 
Exercise 
Mode 
Exercises 
Utilised 
Multi/Single 
Joint 
Exercises 
Duration  Intensity Progression 
Active Warm 
Up 
 
Walking 
(Treadmill) 
Cycling 
(Ergometer) 
Step ups 
Not 
Applicable 
 
3-5 
minutes 
40-60% 
 
Increase warm 
up intensity 
Decrease 
recovery period 
Aerobic 
Exercise 
Walking 
(Treadmill) 
Cycling 
(Ergometer) 
 
Not 
Applicable 
8-10 
minutes 
60-80% 
Increase intensity 
% (cadence/ 
resistance) 
Resistance 
Exercise 
Leg Press Multi-joint 
40 
minutes 
60-80% 
2-4 Sets 
8-12 Reps 
Increase training 
volume (kg) 
 
Knee 
Extension 
Single-joint  
60-80% 
2-4 Sets 
8-12 Reps 
Increase training 
volume (kg) 
 Knee Flexion Single-joint  
60-80% 
2-4 Sets 
8-12 Reps 
Increase training 
volume (kg) 
 
Leg 
Abduction/ 
Adduction 
Single-Joint  
60-80% 
2-4 Sets 
8-12 Reps 
Increase training 
volume (kg) 
 
Lat Pull 
Down 
Multi-joint  
60-80% 
2-4 Sets 
8-12 Reps 
Increase training 
volume (kg) 
 
Supported 
Row 
Multi-joint  
60-80% 
2-4 Sets 
8-12 Reps 
Increase training 
volume (kg) 
 Chest Press Multi-joint  
60-80% 
2-4 Sets 
8-12 Reps 
Increase training 
volume (kg) 
 
Abdominal 
Crunches 
Single-Joint  
60-80% 
2-4 Sets 
8-12 Reps 
Increase training 
volume 
(additional 
weight) 
Cool Down 
Walking 
(Treadmill) 
Cycling 
(Ergometer) 
Not 
Applicable 
3-5 
minutes 
40-60% Not Applicable 
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Supplementary Table 5.5 Home-based exercise program 
ROM, range of motion 
 
 
 
 
 
 
 
Exercise 
Mode 
Exercises Utilised 
Multi/Single 
Joint 
Exercise 
Duration Progression 
Fine Motor 
 
Laser tracing 
Button tying 
Speed/Accuracy 
trade-off 
Not 
Applicable 
15 minutes 
Increase the 
difficulty of 
objects traced 
Increase the 
number and vary 
the size of the 
buttons tied 
Decrease shape 
size in the 
speed/accuracy 
trade-off tasks 
Resistance 
Exercise 
Knee 
Extension/Flexion 
Single Joint 45 minutes  
Increase 
resistance 
(Sanctbands) 
 Wall Push Multi-joint  
Progress to push-
ups on knees and 
then to full ROM 
push-ups 
 
Leg Abduction/ 
Adduction 
Single-joint  
Increase 
resistance 
(Sanctbands) 
 Row Multi-joint  
Increase 
resistance 
(Sanctbands) 
 
Abdominal 
Crunches 
Single-joint  
Increase time in 
eccentric and 
concentric 
contraction phases 
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Supplementary Table 5.6 Occupational therapy program 
 
 
 
 
 
 
Exercise Modality Tasks Utilised Progression 
Daily Activities 
 
Cooking 
 
Laundry 
 
Gardening 
 
 
Eating 
Increase difficulty of cooking 
 
Perform laundry without cues 
 
Increased gardening to an 
independent state 
 
Improve the use and 
manipulation of eating 
utensils 
Planning/Organisation 
Utilisation of a diary 
(written or 
electronic) 
 
Planning social 
activities 
Increase the number and 
difficulty of tasks throughout 
the day 
Memory 
 
 
Facial Recognition 
 
 
 
 
Increase the number of faces 
to be recognised 
 
 
Problem Solving 
Sudoku 
 
 
Board Puzzles 
 
 
Boggle 
 
Mastermind 
Increase the difficulty of the 
Sudoku game 
 
Increased the difficulty and 
size of puzzle 
 
Include time constraints 
 
Include time constraints 
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6.1 ABSTRACT 
Background 
There is a wealth of evidence detailing grey matter degeneration and loss of cognitive 
function over time in individuals with Huntington’s disease (HD). Efforts to attenuate 
disease-related brain and cognitive changes have been unsuccessful to date. Multidisciplinary 
rehabilitation, comprising motor and cognitive intervention, has been shown to positively 
impact on functional capacity, depression, quality of life and some aspects of cognition in 
individuals with HD. This exploratory study aimed to evaluate, for the first time, whether 
multidisciplinary rehabilitation can slow further deterioration of disease-related brain changes 
and related cognitive deficits in individuals with manifest HD. 
Methods 
Fifteen participants with manifest HD undertook a multidisciplinary rehabilitation 
intervention spanning nine months. The intervention consisted of once-weekly supervised 
clinical exercise, thrice weekly self-directed home based exercise and fortnightly 
occupational therapy. Participants were assessed using MR imaging and validated cognitive 
measures at baseline and after nine months.  
Results 
Participants displayed significantly increased grey matter volume in the right caudate and 
bilaterally in the dorsolateral prefrontal cortex after nine months of multidisciplinary 
rehabilitation. Volumetric increases in grey matter were accompanied by significant 
improvements in verbal learning and memory (Hopkins Verbal Learning-Test). A significant 
association was found between grey matter volume increases in the dorsolateral prefrontal 
cortex and performance on verbal learning and memory.  
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Conclusions 
This study provides preliminary evidence that multidisciplinary rehabilitation positively 
impacts on grey matter changes and cognitive functions relating to verbal learning and 
memory in individuals with manifest HD. Larger controlled trials are required to confirm 
these preliminary findings. 
Key Words 
Cognition, executive function, Huntington’s disease, neuropathology, rehabilitation 
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6.2 INTRODUCTION 
Huntington’s disease (HD) is a degenerative disorder of the nervous system caused by an 
unstable cytosine-adenine-guanine (CAG) expansion in exon 1 of the HTT gene (MacDonald 
et al., 1993). Despite progress, there is still no cure and available drug agents only provide 
partial relief of motor and psychiatric symptoms. There is, therefore, an urgent need to trial 
treatments that can impact on disease-related brain changes and clinical aspects of HD. 
Over the last decade, parcellation and voxel based morphometry (VBM) imaging studies 
have shown evidence of grey matter (GM) degeneration in cortical and subcortical brain 
structures in HD (Dominguez et al., 2013; Georgiou-Karistianis et al., 2013a; Hobbs et al., 
2011). Degeneration of GM is particularly pronounced in the striatum, commencing up to 20 
years prior to clinical onset (Georgiou-Karistianis et al., 2013a; Tabrizi et al., 2013). Over the 
course of the disease, GM loss becomes more widespread, with atrophy also observed in 
frontal and occipital cortices (Dominguez et al., 2013; Tabrizi et al., 2013).  
Deficits in cognitive function also arise in HD, even prior to diagnosis, presumably as a result 
of the neurodegenerative processes (Stout et al., 2012). In early HD, there are documented 
deficits in attention (Georgiou-Karistianis et al., 2012), psychomotor speed (Stout et al., 
2012), working memory (Stout et al., 2012), planning and inhibition (Ho et al., 2003). In the 
absence of effective treatments, these deficits worsen over time, negatively impacting on 
functional independence and quality of life (Eddy and Rickards, 2013).  
The loss of GM has been shown to correlate with a decline in cognitive performance in HD. 
Scahill et al (2013) have shown that loss of GM in cortical and subcortical structures 
significantly correlates with poorer performance on emotional recognition, working memory 
and odour identification tasks. Harrington et al (2014) have further shown that degeneration 
of fronto-striatal and fronto-parietal structures correlates with poorer performance on 
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attention, processing speed, verbal learning and memory and emotional recognition tasks. 
Recent evidence suggests that lifestyle factors significantly influence disease-related brain 
and cognitive changes in HD. Bonner-Jackson et al (2013a) have shown that greater cognitive 
reserve (computed as the composite of innate intelligence and educational level) is associated 
with a slower rate of volume loss in the caudate nucleus and putamen and greater 
preservation of cognitive function in pre-manifest HD. Moreover, higher education status is 
significantly associated with a better cognitive outcome on the Unified Huntington’s Disease 
Rating Scale (UHDRS) in manifest HD (López‐Sendón et al., 2011). Finally, lifestyle 
passivity has been shown to significantly influence the onset of symptoms in HD (Trembath 
et al., 2010). Treatment strategies that enrich lifestyle may impact on disease-related brain 
changes and a loss of cognitive function in HD and warrant further investigation. 
Previous studies have shown that environmental enrichment can preserve peristriatal 
structures and cognitive function in HD rodent models (van Dellen et al., 2000; Wood et al., 
2010). Moreover, lifestyle interventions, such as multidisciplinary rehabilitation, have been 
shown to improve aspects of cognition, functional capacity, depression and quality of life 
(Piira et al., 2013; Thompson et al., 2013; Veenhuizen et al., 2011; Zinzi et al., 2007). When 
assessed separately, cognitive and motor interventions have also been reported to increase 
hippocampal, GM and white matter volume in the elderly and those with neurodegenerative 
disorders (Bonzano et al., 2014; Burciu et al., 2013; Erickson et al., 2011; Kühn et al., 2014).  
The outlined findings informed our decision to evaluate the utility of multidisciplinary 
rehabilitation on disease-related brain changes and cognitive function in manifest HD. 
Specifically, we evaluated the effects of multidisciplinary rehabilitation on attenuating GM 
loss and associated declines in cognitive function. We hypothesised that multidisciplinary 
rehabilitation would increase GM volume in dorsolateral prefrontal cortex (DLPFC), striatum 
and hippocampus structures known to be functionally relevant to cognitive function. In 
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addition, we expected GM volume increases to be associated with better cognitive outcomes.  
6.3 MATERIALS AND METHODS 
6.3.1 Study design 
The present investigation was a nine month exploratory study on the effects of 
multidisciplinary rehabilitation on brain structure and cognition in individuals with manifest 
HD. The duration of the intervention was chosen for two reasons: 1) structural changes can 
be detected in individuals with manifest HD after six months (Henley et al., 2006), and 2) 
evidence has shown that rehabilitation interventions can have favourable effects on brain 
structure after two weeks (Burciu et al., 2013). 
6.3.2 Study approval, registration, and patient consent 
Ethical approval was granted by the Edith Cowan University and North Metropolitan Area 
Mental Health Service (NMAMHS) Human Research Ethics Committees. Written informed 
consent was provided by all participants.  
6.3.3 Participants 
Fifteen participants with manifest HD were recruited using the North Metropolitan Area 
Mental Health Service Neuroscience Unit Database. Inclusion criteria included a family 
history of HD, a positive genetic test for the HD mutation (CAG >39), manifest disease 
(Unified Huntington’s Disease Rating Scale-Total Motor Score [UHDRS-TMS] >5), the 
capacity to follow written or verbal instruction, the ability to perform sub-maximal aerobic 
and resistive exercise and aged 18 years or older. Participants were excluded if they suffered 
from recent drug or alcohol abuse, had a confounding neurological condition or concomitant 
physical, cardiovascular or respiratory condition which contraindicated exercise. Medication 
adjustments were recorded routinely throughout the trial (see Table 6.1). 
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Table 6.1 Participant demographics  
 
No Sex 
CAG 
length 
Age 
Disease 
Duration 
(Years) 
DBS 
UHDRS-
TMS 
Medication (baseline) Medication (during) 
1 Male 46 57 7.6 596 45 
Aripiprazole, Mirtazapine, 
Escitalopram 
Aripiprazole 
Escitalopram 
2 Male 42 71 9.5 461.5 59 
Clonazepam, Olanzapine 
Amantadine, Mirtazapine 
Clonazepam, Olanzapine 
Amantadine, Mirtazapine 
3 Female 46 51 2.3 535.5 18 
Venlafaxine, Mirtazapine, 
Olanzapine 
Setraline, Creatine, CoQ10, 
Venlafaxine, Mirtazapine, 
Olanzapine 
4 Male 45 47 1.8 446.5 52 
Aripiprazole, Olanzapine, 
Mirtazapine, Escitalopram, 
Nitrazepam 
Aripiprazole, Olanzapine, 
Mirtazapine, Escitalopram, 
Nitrazepam, Benzhexol 
5 Female 46 45 4.2 472.5 36 
Olanzapine, Escitalopram, 
CoQ10 
Olanzapine, Escitalopram, CoQ10 
6 Female 44 54 0.9 459 19 - Olanzapine, Escitalopram 
7 Female 41 50 0.6 275 25 
Mirtazapine, Escitalopram, 
Aripiprazole, Lorazepam 
Mirtazapine, Escitalopram, 
Aripiprazole, Lorazepam, 
Tetrabenazine, Propranolol 
8 Male 44 48 1.4 408 58 
Aripiprazole, Gabapentin, 
Escitalopram, Olanzapine 
Amantadine, Clonazepam, 
Amantadine, Gabapentin, 
Pramipexole 
9 Female 44 50 10.5 433.5 44 Tetrabenazine 
Fluoxetine, Tetrabenazine, 
Actonel 
10 Female 39 49 3.3 175 39 - - 
11 Male 41 61 0.9 335.5 13 - - 
12 Female 43 56 1.4 427.5 32 Haloperidol, Paroxetine Haloperidol, Paroxetine 
13 Male 41 53 17.3 297 5 CoQ10 CoQ10 
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14 Male 44 48 1 408 12 Escitalopram Aripiprazole, Escitalopram 
15 Male 40 68 6.7 310.5 17 Prazosin 
Aripiprazole, Atenolol, 
Atorvastatin, Clonazepam, 
Clopidogrel, Quetiapine,  
Summary 8M/7F 
43.6 ± 
2.2 
52.5 ± 
6.6 
4.6 ± 4.8 
402.7 ± 
107.7 
31.6 ± 
17.5 
NA NA 
DBS, Disease Burden Score (age × [CAG-35.5]), UHDRS-TMS, Unified Huntington’s Disease Rating Scale-Total Motor Score 
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6.3.4 Multidisciplinary rehabilitation intervention 
The intervention was designed after baseline assessment of the participants by an experienced 
interdisciplinary team consisting of physical therapists, exercise physiologists, occupational 
therapists and strength and conditioning specialists. The intervention consisted of a clinical 
exercise program, a home-based exercise program and fortnightly occupational therapy. The 
clinical exercise program consisted of supervised weekly aerobic and resistance exercises for 
an hour. The home-based exercise program involved thrice weekly self-directed muscle 
strengthening and fine motor exercises for an hour. Occupational therapy consisted of a 
variety of paper and pencil, verbal planning, memory and problem solving exercises designed 
to enhance cognition and executive function  (see Supplementary Tables 6.3, 6.4 and 6.5). 
Adherence to clinical exercise and occupational therapy sessions were recorded by clinical 
exercise specialists and occupational therapists using a training diary. Adherence to the home 
based exercise sessions were recorded by patients using a provided training diary.  
6.3.5 Outcome measures 
Magnetic Resonance Imaging 
Structural MR (magnetic resonance) images from 15 participants were acquired at baseline 
and 9-month follow-up using a 3T Philips Achieva Scanner and a Philips 8 - channel head 
coil (Philips Healthcare. Best, The Netherlands). Structural scans consisted of a T1 3D Turbo 
Field Echo (TFE) scan (400x400, 130 slices, 1 × 1 × 1mm voxels, TR = 5.8 ms, TE = 2.7 
ms).  
Voxel-based morphometry (VBM) was performed on structural MR images to determine 
increases and decreases in GM volume between baseline and 9 months. As implemented in 
FSL-VBM Version 1.1, the VBM (Douaud et al., 2007), protocol included removal of non-
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brain tissue from each participant’s images, tissue segmentation into GM, spatial 
normalization (non-linearly to MNI 152) at 2 x 2 x 2 mm
3
 resolution and (non-linear) 
registration to a right-left symmetric, study-specific GM template (average of all individual 
grey matter images). These images were modulated and then smoothed with a Gaussian 
kernel of ~4.6mm full width half maximum (FWHM). 
Cognitive and Executive Function Measures 
Cognitive performance was evaluated at baseline and at nine months using a variety of 
cognitive measures previously shown to be sensitive in HD (Stout et al., 2012; Tabrizi et al., 
2013). The Colour Word Interference Test (CWIT) and Trail Making Test components of the 
Delis-Kaplan Executive Function System (D-KEFS) (Delis et al., 2001; Delis et al., 2004) 
were used to examine response inhibition and cognitive flexibility. The Symbol Digit 
Modalities Test (SDMT) (Smith, 1982) was used to examine information processing speed 
and attention. Verbal learning and memory were examined used the Hopkins Verbal Learning 
Test-Revised (HVLT-R) (Brandt, 1991). All cognitive assessments were performed by 
cognitive raters blinded to the treatment condition.  
6.4 STATISTICS  
Demographic data are given as means and standard deviations. We used linear regression to 
estimate the increase or decrease in GM volume between baseline and 9 months. The 
regression model included separate explanatory variables for each participant (for each 
subject's mean effect) and age. Analysis was focused on regions of interest (ROIs) defined a 
priori based on previous studies in HD shown to be functionally relevant in terms of 
cognitive capacity (as reflected in episodic memory performance). ROIs included the 
striatum, hippocampus, and dorsolateral prefrontal cortex (DLPFC). Inferential statistics were 
carried out using a non-parametric permutation method (as implemented by FSL’s randomise 
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tool). Only clusters with >10 contiguous voxels at a significance level of p<0.05 were 
considered to be indicative of significant longitudinal change. As we adopted an exploratory 
analysis strategy with ROIs clearly defined a priori, no correction for multiple comparisons 
was applied. GM volume change was also evaluated beyond the ROIs. In this case, maps 
were thresholded at p<0.01 (uncorrected) and voxels were considered significant within 
clusters of >10 contiguous voxels. The normality of cognitive data was assessed using the 
Schapiro-Wilk test. Changes in cognitive performance were assessed using mean values at 
baseline and at nine months with paired t-tests. Statistical significance was set at (p≤0.05). 
All statistical analyses were performed using STATA 9.1 (Stata Corp, 4905 Lakeway Dr, 
Texas 77845 USA). We then investigated the functional relevance of change in GM volume 
in the ROIs, as reflected by associations between significant volume changes and significant 
change in performance measures from the HVLT-R (follow-up score minus baseline score): 
total recall, delayed recall, retention and the recognition discrimination index (RDI). The 
HVLT-R was chosen as dysfunction in recall and recognition memory is an important clinical 
feature of HD (Montoya et al., 2006). In order to quantify GM volume change, we created a 
single difference image for each participant by subtracting the follow-up from the baseline 
smoothed, modulated image generated by the VBM protocol. The relationship between 
volume change in ROIs and change in cognitive function was then assessed voxel-wise by 
means of FSL’s randomise tool. Age was included as a covariate in all analyses.  
6.5 RESULTS 
6.5.1 Demographics 
Table 6.1 displays demographic data and information on disease duration, disease burden and 
severity of motor abnormalities. Participants displayed high adherence to the supervised 
clinical program (84.2%), moderate adherence to the home-based program (58.6%) and high 
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adherence to occupational therapy sessions (79.2%).  
6.5.2 Structural brain changes 
Figure 6.1 shows significant volumetric increases in GM in the DLPFC bilaterally and in the 
tail of the right caudate nucleus after multidisciplinary rehabilitation. All remaining ROIs, 
including the right hippocampus, left putamen and accumbens showed GM volume loss. 
Beyond these ROIs, changes in GM volume were also observed. The superior thalami, left 
inferior temporal pole, right subcallosal cortex and parasagittal primary motor areas exhibited 
increases in GM volume. By contrast, the left anterior insula, right posterior 
cingulate/precuneus, left lateral occipital cortex, subcallosal cortex and focal areas in the 
temporal cortex bilaterally showed GM volume loss (Figure 6.2), consistent with previous 
neuroimaging studies in individuals with HD (Dominguez et al., 2013; Georgiou-Karistianis 
et al., 2013a; Tabrizi et al., 2012; Tabrizi et al., 2011a; Tabrizi et al., 2013). 
6.5.3 Cognitive and executive function changes 
Significant improvement was observed on the delayed recall (number of words recalled after 
delay) component of the HVLT-R after nine months of multidisciplinary rehabilitation (see 
Table 6.2). No significant changes were found for CWIT, TMT and SDMT outcomes after 
nine months of multidisciplinary rehabilitation (see Table 6.2).  
6.5.4 Correlation analyses 
Increased GM volume in the DLPFC (bilaterally) was found to be significantly associated 
with preserved performance on the RDI of the HVLT-R (see Figure 6.1). 
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Figure 6.1 Significant GM volume changes after multidisciplinary rehabilitation in individuals with manifest HD 
 
a) Significantly increased GM volume in the DLPFC and right caudate nucleus tail after nine months of multidisciplinary rehabilitation in 
individuals with HD (red-yellow), and a significant correlation between increased GM volume in DLPFC and preserved performance on the RDI 
task (green). Results are displayed on the study specific template normalized to MNI space (p<0.05, uncorrected). b) Scatterplot illustrating the 
correlation between increased DLPFC volume at the peak voxel and preserved performance on the RDI task 
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Figure 6.2 Whole brain GM volume changes in individuals with manifest HD 
 
Results of the VBM analysis beyond the ROIs after nine months of multidisciplinary rehabilitation. GM volume loss in blue; GM volume 
increases in red-yellow. Results are displayed on the study specific template normalized to MNI space (p<0.01, uncorrected) 
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Table 6.2 Changes in cognitive function after nine months of multidisciplinary rehabilitation 
in individuals with manifest HD. 
 
Outcome Measures Baseline (n=15) Post-trial (n=15) p value 
CWIT    
Colour naming 48.35 ± 18.86 52.35 ± 22.57 p=0.0999 
Word reading 34.00  ± 10.97 35.35 ± 9.77 p=0.3249 
Inhibition 91.00 ± 39.25 93.57 ± 41.39 p=0.4525 
TMT    
Visual scanning 38.76 ± 15.76 43.52 ± 15.98 p=0.1149 
Number sequencing 55.73 ± 19.87 61.80 ± 23.49 p=0.0507 
Letter sequencing 61.92 ± 34.05 66.21 ± 30.77 p=0.1262 
Motor speed 58.75 ± 27.39 62.31 ± 25.90 p=0.2433 
HVLT-R    
Free recall 17.66 ± 5.56 16.73 ± 6.21 p=0.2019 
Delayed recall 4.92 ± 2.36 6.28 ± 3.14 p=0.0130* 
Retention 76.16 ± 29.21 81.22 ± 27.32 p=0.1866 
Recognition 8.06 ± 3.08 8.93 ± 2.34 p=0.0793 
SDMT    
Correct written 27.00 ± 10.25 26.78 ± 9.96 p=0.4525 
Correct oral 31.00 ± 14.17 28.46 ± 15.59 p=0.1374 
CWIT, Colour Word Interference Test; TMT, Trail Making Trials; HVLT-R, Hopkins Verbal 
Learning Test-Revised; SDMT, Symbol Digits Modalities Test. Significance was set at 
*p<0.05 
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6.6 DISCUSSION 
This exploratory investigation has shown that multidisciplinary rehabilitation is capable of 
increasing GM volume and enhancing some aspects of cognitive function in HD. 
Specifically, we found evidence of increased GM volume in the right caudate and bilaterally 
in the DLPFC, as well as an improvement in verbal learning and memory after nine months 
of multidisciplinary rehabilitation. We also found a significant association between increased 
GM volume in the DLPFC and preserved performance in verbal learning and memory. 
Similar to previous investigations in HD, we observed GM volume loss in most cortical and 
subcortical brain regions (Dominguez et al., 2013; Georgiou-Karistianis et al., 2013a; Hobbs 
et al., 2011; Kassubek et al., 2005; Kipps et al., 2005; Mühlau et al., 2007; Mühlau et al., 
2009; Peinemann et al., 2005; Tabrizi et al., 2012; Tabrizi et al., 2011b; Tabrizi et al., 2013). 
In this study however, after multidisciplinary rehabilitation, we also observed increased GM 
volume in the DLPFC and in the right caudate nucleus in individuals with manifest HD. 
While this is the first study to report such a finding, recent work has shown that cognitive 
reserve (computed as the composite of intelligence and educational status) influences the rate 
of volume loss in caudate and putamen structures in individuals with pre-manifest HD 
(Bonner-Jackson et al., 2013b). Moreover, environmental enrichment has been shown to 
preserve peristriatal cerebral volume in the R6/1 HD mouse model (van Dellen et al., 2000). 
Motor and cognitive interventions have additionally been shown to increase hippocampal 
volume, white matter and grey matter volume as well as cortical thickness in the left middle 
frontal gyrus, inferior frontal gyrus, superior temporal gyrus in the elderly and those with 
other neurodegenerative disorders (Bonzano et al., 2014; Boyke et al., 2008; Burciu et al., 
2013; Engvig et al., 2010; Engvig et al., 2012; Erickson et al., 2010; Erickson et al., 2011; 
Lövdén et al., 2012; Prosperini et al., 2014b; Sehm et al., 2014). These findings provide 
evidence to suggest that lifestyle factors play an important role in modulating the pathology 
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and clinical profile of HD. 
The structural brain changes observed in the present study and others may reflect an increase 
in neurogenesis and/or favourable changes to neuronal morphology (Lazic et al., 2006; 
Nithianantharajah et al., 2009; Nithianantharajah and Hannan, 2013). This supposition stems 
from compelling evidence showing that environmental enrichment can increase markers of 
neurogenesis within the hippocampus (Lazic et al., 2006) as well as increase the diameter of 
dendritic spines in the R6/1 HD mouse model (Nithianantharajah et al., 2009). Molecular and 
cellular mechanisms that may have encouraged the surmised neurogenesis and/or alterations 
in neuronal morphology in response to multidisciplinary rehabilitation include an increased 
expression of neurotrophins like brain derived neurotrophic factor (BDNF), enhanced 
cerebral angiogenesis, and a decrease in elevated circulating glucocorticoids (i.e. cortisol) 
(Rothman and Mattson, 2013). BDNF enhances neurite outgrowth, synaptogenesis and cell 
survival, encouraging neurogenesis and experience-dependent synaptic plasticity (Rothman 
and Mattson, 2013). Recent preclinical data suggests that BDNF-dependent neurogenesis is 
tightly coupled with cerebral angiogenesis (Chen et al., 2013), and that both are dynamically 
modulated by changes in circulating glucocorticoid levels (Gray et al., 2013a; Shikatani et al., 
2012; Weinstein et al., 2010). In particular, elevated glucocorticoid levels dampen cerebral 
angiogenesis and BDNF expression in healthy rodent’s facilitating a decrease in neurogenesis 
(Gray et al., 2013a; Rothman and Mattson, 2013; Shikatani et al., 2012). It is possible that 
multidisciplinary rehabilitation facilitates an adaptive stress response that decreases 
circulating glucocorticoids, thereby enhancing cerebral angiogenesis and BDNF expression, 
encouraging neurogenesis and structural brain changes in HD patients. 
There are currently no therapies that arrest or attenuate the progressive loss of cognitive 
function seen in individuals with HD. Here we found evidence of an improvement in verbal 
learning and memory after nine months of multidisciplinary rehabilitation. These findings 
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extend on our previous work, where task-specific improvements in processing speed 
measures were found after a nine month controlled investigation of multidisciplinary 
rehabilitation in individuals with manifest HD (Thompson et al., 2013). Moreover, these 
findings support experimental studies documenting improvements in cognitive performance 
in rodent models of HD after environmental enrichment (Wood et al., 2010; Wood et al., 
2011). While evidence is limited in HD, an increasing number of studies are showing that 
motor and cognitive interventions positively impact on cognitive function in the elderly 
(Bherer et al., 2013; Erickson et al., 2011; Liu-Ambrose et al., 2010) and those suffering with 
MCI (Hampstead et al., 2011; Hampstead et al., 2012; Smith et al., 2013), MS (Flavia et al., 
2010; Mattioli et al., 2010; Shatil et al., 2010; Solari et al., 2004) and PD (Calleo et al., 2011; 
París et al., 2011; Sammer et al., 2006). It is likely that the improvements in verbal learning 
and memory observed in this study resulted from the positive impact of multidisciplinary 
rehabilitation on caudate and DLPFC structures.  
It is well known that degeneration of GM contributes to the development of cognitive deficits 
and progressive loss of cognitive function (Harrington et al., 2014; Scahill et al., 2013). In 
this study, we found a significant association between increases in GM volume in the DLPFC 
and preserved performance in verbal learning and memory. This finding is not unexpected 
given that memory retrieval and recognition is driven primarily by DLPFC connectivity in 
healthy individuals and in those with HD (Georgiou-Karistianis et al., 2013b). 
A number of limitations must be taken into account when considering our findings. First, 
there was no control group, which limits our ability to derive definitive conclusions on the 
efficacy of multidisciplinary rehabilitation on disease pathology and clinical features in HD. 
Second, the small sample of HD participants in this study makes generalizability difficult. 
Lastly, participants remained on medication throughout the study, which may have 
influenced the therapeutic response to multidisciplinary rehabilitation.  
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Despite these limitations, our findings provide the very first evidence that multidisciplinary 
rehabilitation is effective in increasing regional GM volume in cortical and subcortical brain 
regions in HD. Results also show that multidisciplinary rehabilitation is capable of improving 
some aspects of cognition over a nine month period. Moreover, we found that increased GM 
volume in the DLPFC was associated with preservation of verbal learning and memory. 
These findings collectively indicate that neuroplasticity may still be present in HD and 
amenable to multidisciplinary rehabilitation. Future randomised controlled trials with larger 
sample sizes, longer duration interventions, more comprehensive imaging and cognitive 
outcomes and appropriate detraining periods are nevertheless required to confirm and expand 
on our preliminary findings. 
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6.8 SUPPLEMENTARY DATA 
Supplementary Table 6.3 Exercises used in the clinical exercise program throughout the 
study 
Reps, Repetitions, kg, kilograms 
Exercise 
Mode 
Exercises 
Utilised 
Multi/Single 
Joint 
Exercises 
Duration  Intensity Progression 
Active Warm 
Up 
 
Walking 
(Treadmill) 
Cycling 
(Ergometer) 
Step ups 
Not 
Applicable 
 
3-5 
minutes 
40-60% 
 
Increase warm 
up intensity 
Decrease 
recovery period 
Aerobic 
Exercise 
Walking 
(Treadmill) 
Cycling 
(Ergometer) 
 
Not 
Applicable 
8-10 
minutes 
60-80% 
Increase intensity 
% (cadence/ 
resistance) 
Resistance 
Exercise 
Leg Press Multi-joint 
40 
minutes 
60-80% 
2-4 Sets 
8-12 Reps 
Increase training 
volume (kg) 
 
Knee 
Extension 
Single-joint  
60-80% 
2-4 Sets 
8-12 Reps 
Increase training 
volume (kg) 
 Knee Flexion Single-joint  
60-80% 
2-4 Sets 
8-12 Reps 
Increase training 
volume (kg) 
 
Leg 
Abduction/ 
Adduction 
Single-Joint  
60-80% 
2-4 Sets 
8-12 Reps 
Increase training 
volume (kg) 
 
Lat Pull 
Down 
Multi-joint  
60-80% 
2-4 Sets 
8-12 Reps 
Increase training 
volume (kg) 
 
Supported 
Row 
Multi-joint  
60-80% 
2-4 Sets 
8-12 Reps 
Increase training 
volume (kg) 
 Chest Press Multi-joint  
60-80% 
2-4 Sets 
8-12 Reps 
Increase training 
volume (kg) 
 
Abdominal 
Crunches 
Single-Joint  
60-80% 
2-4 Sets 
8-12 Reps 
Increase training 
volume 
(additional 
weight) 
Cool Down 
Walking 
(Treadmill) 
Cycling 
(Ergometer) 
Not 
Applicable 
3-5 
minutes 
40-60% Not Applicable 
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Supplementary Table 6.4 Exercises used in the home-based exercise program throughout 
the study 
ROM, range of motion 
 
 
 
 
 
Exercise 
Mode 
Exercises Utilised 
Multi/Single 
Joint 
Exercise 
Duration Progression 
Fine Motor 
 
Laser tracing 
Button tying 
Speed/Accuracy 
trade-off 
Not 
Applicable 
15 minutes 
Increase the 
difficulty of 
objects traced 
Increase the 
number and vary 
the size of the 
buttons tied 
Decrease shape 
size in the 
speed/accuracy 
trade-off tasks 
Resistance 
Exercise 
Knee 
Extension/Flexion 
Single Joint 45 minutes  
Increase 
resistance 
(Sanctbands) 
 Wall Push Multi-joint  
Progress to push-
ups on knees and 
then to full ROM 
push-ups 
 
Leg Abduction/ 
Adduction 
Single-joint  
Increase 
resistance 
(Sanctbands) 
 Row Multi-joint  
Increase 
resistance 
(Sanctbands) 
 
Abdominal 
Crunches 
Single-joint  
Increase time in 
eccentric and 
concentric 
contraction phases 
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Supplementary Table 6.5 Exercises used in occupational therapy sessions throughout the 
study 
 
 
 
 
 
 
Exercise Modality Tasks Utilised Progression 
Daily Activities 
 
Cooking 
 
Laundry 
 
Gardening 
 
 
Eating 
Increase difficulty of cooking 
 
Perform laundry without cues 
 
Increased gardening to an 
independent state 
 
Improve the use and 
manipulation of eating 
utensils 
Planning/Organisation 
Utilisation of a diary 
(written or 
electronic) 
 
Planning social 
activities 
Increase the number and 
difficulty of tasks throughout 
the day 
Memory 
 
 
Facial Recognition 
 
 
 
 
Increase the number of faces 
to be recognised 
 
 
Problem Solving 
Sudoku 
 
 
Board Puzzles 
 
 
Boggle 
 
Mastermind 
Increase the difficulty of the 
Sudoku game 
 
Increased the difficulty and 
size of puzzle 
 
Include time constraints 
 
Include time constraints 
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CHAPTER 7 – GENERAL DISCUSSION & FUTURE DIRECTIONS 
Despite intense scientific efforts, there is still no cure or disease modifying strategy for HD, 
and available pharmaceutical agents only provide partial relief of psychiatric and involuntary 
motor features (Dominguez and Munoz-Sanjuan, 2014; Mason and Barker, 2009; Pidgeon 
and Rickards, 2013). Lifestyle factors are known to influence the structure of the brain as 
well as the onset and progression of clinical features in people living with HD (Bonner-
Jackson et al., 2013b; Georgiou et al., 1999; Lopez-Sendon et al., 2011; Trembath et al., 
2010; Wexler, 2004). Lifestyle enrichment strategies, particularly multidisciplinary 
rehabilitation may therefore have desirable effects on clinical and neuropathological aspects 
of HD. Currently, there is only a handful of  exploratory studies  that have evaluated the 
effects of multidisciplinary rehabilitation on clinical aspects of HD (Piira et al., 2013; 
Veenhuizen et al., 2011; Zinzi et al., 2007). Considering the potential benefits of 
multidisciplinary rehabilitation for patients, as well as the lack of inherent side effects and the 
necessity for a better multidisciplinary care model for HD, it is obvious that further 
investigations are warranted. 
The work presented in this thesis is therefore timely. The central aim of this thesis was to 
determine the clinical utility of multidisciplinary rehabilitation on clinical and 
neuropathological aspects of HD (Chapters 4, 5 and 6). In order to design a comprehensive 
multidisciplinary rehabilitation intervention, and because balance and mobility are two of the 
most debilitating aspects of HD, the factors contributing to impairments in mobility and 
balance were investigated first of all (Chapter 2) (Cruickshank et al., 2014). Published 
rehabilitation strategies, with favourable effects on mobility and balance in other 
neurodegenerative disorders, were also investigated through a literature search (Chapter 3). 
As a result of our investigations in study 1, lower extremity muscle weakness and the decline 
in specific cognitive abilities (processing speed, attention, cognitive flexibility, response 
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inhibition) were found to predict balance and mobility impairments in people with manifest 
HD (Cruickshank et al., 2014). Our findings were in line with previous reports in PD and MS 
(Broekmans et al., 2013b; D'Orio et al., 2012; Paul et al., 2013b; Sosnoff et al., 2013a). For 
example, Paul et al (2013b) reported that lower extremity muscle power significantly predicts 
balance and mobility performance in PD and more recent evidence has shown that cognitive 
deficits also contribute to mobility impairments in PD (Gurevich et al., 2014). Moreover, 
recent studies indicate that lower extremity strength is a significant predictor of mobility in 
patients with MS (Broekmans et al., 2013a). Deficits in processing speed and innate 
intelligence have also been documented to predict mobility outcomes in patients with MS 
(D'Orio et al., 2012). These findings collectively infer that some commonality exists between 
the outlined neurodegenerative disorders with respect to the clinical factors underpinning 
balance and mobility impairments. It is therefore likely that rehabilitation interventions with 
favourable effects on balance and mobility in neurodegenerative disorders like PD and MS 
will be beneficial for HD patients. 
An emerging body of evidence indicates that resistance exercise is beneficial for people with 
neurodegenerative disorders (Corcos et al., 2013; Dalgas et al., 2013; Medina-Perez et al., 
2014; Shulman et al., 2013). Consensus regarding the efficacy of resistance exercise for 
neurodegenerative populations nevertheless requires further elucidation. As part of this thesis, 
a systematic investigation of the effects of resistance exercise as a therapy for people with 
neurodegenerative disorders was performed. An intensive systematic literature search for 
studies of resistance exercise in neurodegenerative disorders only identified studies in PD and 
MS. A critical appraisal of the identified studies revealed that resistance exercise has 
favourable disease dependent effects on muscle strength, mobility, balance, clinical disease 
progression, fatigue, functional capacity, quality of life, disease biology, electromyography 
activity, mood, skeletal muscle mass and architecture (Bloomer et al., 2008; Broekmans et 
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al., 2011; Corcos et al., 2013; Dalgas et al., 2010a; Dalgas et al., 2009; Dalgas et al., 2010b; 
Dalgas et al., 2013; DeBolt and McCubbin, 2004; Dibble et al., 2006; Dibble et al., 2009; 
Dodd et al., 2011; Fimland et al., 2010; Hass et al., 2012; Medina-Perez et al., 2014; Paul et 
al., 2014; Sage et al., 2011; Schilling et al., 2010; Shulman et al., 2011). As expected, the 
most robust effects were found for muscle strength outcomes. Interestingly, a meta-analysis 
of changes in muscle strength revealed greater effects for people with PD. Different 
pathological mechanisms underpinning each neurodegenerative disorder likely account for 
the outlined discrepancy in the magnitude of muscle strength changes. Importantly, 
improvements in mobility were reported in a number of the included PD studies. Individuals 
suffering with HD display similar strength and mobility deficits. In line with our results in 
HD from study 1 and the results of our systematic review (study 2), it can be surmised that 
resistance exercise would have favourable effects on muscle strength and in turn mobility in 
people with HD.  
The outlined findings from study 1 and 2 informed our decision to incorporate resistance 
exercise into our multidisciplinary rehabilitation intervention along with other rehabilitation 
components including aerobic exercise, physical therapy and cognitive rehabilitation. The 
latter rehabilitation components were selected given their favourable effects on brain 
structure and function, functional capacity and cognitive abilities in the elderly and 
individuals with neurodegenerative disorders (Colcombe et al., 2006; Erickson et al., 2010; 
Erickson, 2013; Erickson and Kramer, 2009; Erickson et al., 2012; Erickson et al., 2011; 
Filippi et al., 2012; Khalil et al., 2013; Nombela et al., 2011).  
As previously outlined, the central aim of this thesis was to evaluate the clinical utility of 
multidisciplinary rehabilitation on clinical and neuropathological aspects of HD. To the best 
of our knowledge, this was the first controlled trial of multidisciplinary rehabilitation in 
people with HD. Data from this trial showed that multidisciplinary rehabilitation is safe, well 
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tolerated and well received by patients with HD. From a clinical standpoint, the data showed 
that multidisciplinary rehabilitation can improve muscle strength, self-perceived balance and 
body composition outcomes (Thompson et al., 2013). A preservation of mobility was also 
observed.  
The significant improvements observed in muscle strength were somewhat expected given 
the large resistance exercise component of the multidisciplinary rehabilitation intervention. 
This finding is nevertheless of clinical importance, especially considering the wealth of data 
showing that muscle strength predicts functional capacity and falls in neurodegenerative 
disorders, including HD (Aziz and Roos, 2013; Cruickshank et al., 2014; Padilla et al., 2006; 
Paul et al., 2013a; Paul et al., 2013b). The improved muscle strength in the intervention 
participants contrasted strongly with a static level of muscle strength in the no intervention 
controls. Importantly, contrary to previous evidence declines in muscle strength were not 
observed in the control group (Busse et al., 2008). This indicates that declines in muscle 
strength may not be a universal feature of HD, but rather may reflect deconditioning that has 
taken place over many years as individuals become progressively immobilised.  
An improvement in balance confidence accompanied increases in muscle strength in the 
intervention participants (Thompson et al., 2013). We did not however find favourable effects 
on other balance measures (Berg Balance Scale and dynamic computerised posturography). 
The Berg Balance Scale and dynamic computerised posturography have been shown to be 
reliable and valid measures of static and dynamic balance in patients with HD (Kloos et al., 
2014; Quinn et al., 2013). These results indicate that patient perceived improvements in 
balance do not reflect actual balance improvements. This may in part be due to a lack of 
insight which has been previously documented in patients with HD. Our findings, at least in 
part, contrast with previous work. For example, Piira et al (2013) reported significant 
improvements in balance in patients with HD after intensive intermittent multidisciplinary 
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rehabilitation using the Berg Balance Scale. Methodological differences likely account for the 
outlined discrepancy in findings. In particular, Piira et al (2013) used a larger cohort of 
patients with HD and incorporated formalised balance training exercises into their 
intervention. 
In contrast to previous work (Piira et al., 2013; Zinzi et al., 2007), we did not observe 
improvement on mobility outcomes. Instead, we found that patients randomised to the 
intervention group maintained their level of performance on mobility tasks, while those in the 
control showed deterioration on several mobility outcomes. This suggests that mobility may 
be preserved by multidisciplinary rehabilitation. In an earlier study, Zinzi et al (2007) found a 
significant improvement in mobility in a small sample of HD patients after an intensive 
intermittent multidisciplinary rehabilitation intervention. More recently, Piira et al (2013) 
reported a significant improvement on mobility outcomes in a larger sample of HD patients, 
using a similar intervention protocol. The outlined differences in findings may be attributed 
to differences in the intervention intensity. Piira et al (2013) and Zinzi et al (2007) used an 
intensive intermittent multidisciplinary rehabilitation intervention, whereas the current study 
used a longer duration moderate intensity multidisciplinary rehabilitation approach. Emerging 
evidence suggests that intensive rehabilitation interventions may produce more robust motor 
benefits in those with neurodegenerative disorders (Frazzitta et al., 2012a; Frazzitta et al., 
2012b; Frazzitta et al., 2013).   
Significant increases in body weight, lean tissue and fat mass were also important findings of 
our study (Thompson et al., 2013). Weight loss, skeletal muscle atrophy (Farrer and Meaney, 
1985; Farrer et al., 1985; Trejo et al., 2004; van der Burg et al., 2009) and adipose tissue 
alterations (van der Burg et al., 2009) are well reported features of HD. Weight loss is  
closely associated with a faster rate of disease progression (Aziz and Roos, 2013; Myers et 
al., 1991; van der Burg et al., 2009). The favourable changes to weight observed in this study 
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may therefore have a positive effect on disease progression, however this remains 
speculative, and subject to future investigation. Alterations in metabolic, endocrine signalling 
and immune pathways as well as a reduction in ghrelin-producing neurons in the stomach 
have all been implicated as pathological mediators of changes in body composition (van der 
Burg et al., 2008). Recent evidence indicates that elevated levels of stress may also mediate 
abnormal changes in body composition (Du et al., 2014). Multidisciplinary rehabilitation may 
positively impact on these mediators of weight loss, thereby improving or forestalling 
pathological changes in body composition. In line with this, exercise has been shown to 
upregulate ghrelin (Markofski et al., 2014), suppress leptin release (Ko and Choi, 2013; 
Lichtenstein et al., 2014; Rämson et al., 2012), exert anti-inflammatory effects (Gleeson et 
al., 2011) and reduce psychological stress (Greenwood and Fleshner, 2011; Puterman et al., 
2010) in healthy adults. 
Exploratory data additionally showed, for the first time, that multidisciplinary rehabilitation 
can increase GM volume in structures known to degenerate in people with HD. While 
structural increases in brain volume have not been reported previously in HD patients, 
preclinical studies have shown that environmental enrichment can preserve peristriatal 
structures in transgenic HD mice (van Dellen et al., 2000). Motor and cognitive interventions 
have additionally been shown to increase hippocampal volume as well as preserve white 
matter and grey matter volume in elderly people (Boyke et al., 2008; Engvig et al., 2010; 
Engvig et al., 2012; Erickson et al., 2010; Erickson et al., 2011). Exploratory findings from 
this study also showed that multidisciplinary rehabilitation can increase GM volume in a 
region dependent manner in patients with HD. Significant increases in GM volume were 
observed in the caudate nucleus and DLPFC of patients after multidisciplinary rehabilitation 
and were associated with verbal learning and memory. These findings are of clinical 
relevance for several reasons. First, the increases in GM volume were observed in structures 
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known to degenerate in people with HD (Dominguez et al., 2013; Georgiou-Karistianis et al., 
2013a; Hobbs et al., 2011; Kipps et al., 2005; Tabrizi et al., 2013). Second, a significant 
improvement in verbal learning and memory has not been reported previously in patients 
with HD after any therapy (Mason and Barker, 2009; Piira et al., 2013; Venuto et al., 2012). 
Lastly, the significant association between increases in GM volume in the DLPFC and verbal 
learning and memory performance indicates that structural brain changes can occur in 
association with multidisciplinary rehabilitation with a clinically meaningful impact. 
While multidisciplinary rehabilitation was found to improve some motor, body composition, 
cognitive and neuropathological outcomes, we found no improvement in mood, quality of life 
and bone mineral density. A number of cognitive outcomes also remained unchanged as did a 
number of brain structures that displayed GM volume losses. While unfavourable, this latter 
finding is in line with previous observational evidence reporting GM volume losses in 
cortical and subcortical structures (Georgiou-Karistianis et al., 2013a; Georgiou-Karistianis et 
al., 2013c; Tabrizi et al., 2012; Tabrizi et al., 2011a; Tabrizi et al., 2013). Our inability to find 
significant changes in mood was not surprising considering that BDI data showed no 
evidence of a depressive syndrome in study participants at baseline (Thompson et al., 2013).  
A lack of changes on the SF-36 was somewhat unexpected. Previous studies have reported 
mixed findings with respect to the effects of rehabilitation on quality of life outcomes in 
manifest HD. Piira et al (2013) reported a significant improvement on the physical 
component, but not mental component of the SF-36 in a large cohort of HD patients after a 
one year intensive intermittent multidisciplinary rehabilitation intervention. In another study, 
Khalil et al (2013) reported no significant changes on the SF-36 in HD patients following a 
short physical therapy intervention. The small sample size used in this study coupled with the 
generic nature of the SF-36, likely accounts for our inability to find significant changes in 
quality of life. Studies with larger samples using an HD specific quality of life assessment are 
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required to appropriately assess the efficacy of multidisciplinary rehabilitation on quality of 
life in individuals with manifest HD.  
The inability to find significant changes in bone mineral density in this study was also 
unexpected. However, it is important to note that no changes in bone mineral density were 
observed in the control group at the completion of the study. This suggests that bone mineral 
density is perhaps not an ideal biomarker, particularly given the duration of the current study. 
Previous work has shown that individuals with pre-manifest HD display lower bone mineral 
content relative to healthy age matched controls (Goodman and Barker, 2011). Moreover, 
preclinical studies have documented a lower bone mineral density in the R6/2 mouse model 
(Björkqvist et al., 2006). However, there is no data on longitudinal changes in bone mineral 
density in people with HD. It is possible that changes in bone mineral density manifest over 
many years as result of sedentary behaviour and taking medication (Bonelli et al., 2002) (or 
may in some way just relate to gene status). With this in mind, it may be possible to find 
favourable changes in bone mineral density using longer duration interventions. In support of 
this, recent evidence showed that high intensity resistance exercise interventions over twelve 
months increases bone mineral density in older adults (Kemmler et al., 2010) .  
With the exception of verbal learning and memory, there was no evidence of performance 
improvements on other cognitive domains. However, it is important to note that significant 
deterioration on cognitive outcomes was not observed in the control group. These findings 
were not unexpected, especially considering the slow temporal profile of cognitive 
deterioration in people with HD, and the small sample of HD patients used in the current 
study. A recent study by Stout et al (2012), reported that only the SDMT, Circling Tracing 
Indirect and Stroop Word Reading assessments show robust evidence of cognitive 
deterioration over 12 months in early HD. However, for these assessments sample size 
estimates for a 50% effective treatment, 90% power and two tailed p<0.05 group 
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comparisons were estimated to be 150 (SDMT), 289 (Circling Tracing Indirect) and 337 
(Stroop Word Reading). Evidence also indicates that these assessments are strongly 
influenced by motor control (handedness, speech and ocular control) and psychiatric 
symptom severity (Eddy and Rickards, 2014), limiting the validity of these measures for 
assessing cognitive capacity in HD. Future rehabilitation studies aimed at improving 
cognitive function require more careful methodological considerations, particularly with 
respect to the sample size, selection of cognitive assessments (minimise time dependent 
tasks) and duration of intervention utilised.  
Beyond the caudate nucleus and DLPFC, GM volume loss was observed in the left anterior 
insula, right posterior cingulate/precuneus, left lateral occipital cortex, subcallosal cortex and 
focal areas in the temporal cortex. This is in line with findings from many prospective 
observational trials (Georgiou-Karistianis et al., 2013a; Georgiou-Karistianis et al., 2013c; 
Tabrizi et al., 2012; Tabrizi et al., 2011a; Tabrizi et al., 2013). These findings affirm the 
usefulness of structural imaging as a biomarker for prospective treatment trials. In addition, 
these results illuminate the possibility that multidisciplinary rehabilitation may exert region-
dependent effects on the brain. Favourable region-dependent effects on hippocampal volume 
have been documented previously after a one year aerobic exercise intervention in older 
adults (Erickson et al., 2011). Combining rehabilitation strategies with different positive 
region-dependent effects may therefore provide more robust benefits for brain structures 
overall.   
The work presented in this thesis is not without limitations. First, the sample size was small, 
therefore the findings from this study cannot be generalised to the wider HD community. 
Second, the work presented in this thesis only included individuals with mild to moderate 
HD. Individuals with advanced HD were not included in the present work owing to their 
inability to perform necessary outcome measures and many of the programmed 
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multidisciplinary rehabilitation exercises. As such, our findings are not reflective of nor can 
they generalised to the entire spectrum of manifest HD. Third, studies lacked a long term 
follow up period, which precludes the possibility of examining the duration of benefits from 
multidisciplinary rehabilitation. Fourth, study five did not include a control group limiting the 
significance of the reported findings. However, given that there is a wealth of evidence 
showing degeneration in the caudate nucleus and DLPFC, and no proven therapies with 
neurorestorative effects, our findings are of clinical significance and warrant further 
investigation.  
7.1 Future Directions 
Studies exploring the effects of multidisciplinary rehabilitation for people living with HD are 
only in their infancy (Piira et al., 2013; Thompson et al., 2013; Veenhuizen et al., 2011; Zinzi 
et al., 2007). The present research confirms and expands on previous reports documenting 
significant improvement in clinical aspects of HD (Piira et al., 2013; Thompson et al., 2013; 
Zinzi et al., 2007). This research also provides novel experimental evidence showing that 
multidisciplinary rehabilitation can increase GM volume in the caudate nucleus and DLPFC. 
Finally, this research shows that increases in GM volume are related to performance on 
verbal learning and memory tasks. More work is nevertheless required to explore the clinical, 
neurological and biological effects of multidisciplinary rehabilitation for people with HD. 
Additional research is also required to identify the most therapeutically effective 
rehabilitation components of multidisciplinary treatments for people living with HD. With 
this is mind, the following section outlines future directions that should be undertaken to 
improve the quality of evidence on multidisciplinary rehabilitation as a therapy for HD. 
The work presented in this thesis and previous studies has shown that multidisciplinary 
rehabilitation can improve clinical aspects of HD (Piira et al., 2013; Thompson et al., 2013; 
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Veenhuizen and Tibben, 2009; Zinzi et al., 2007). In particular, significant improvements in 
motor function, body composition, mood, anxiety, physical quality of life and verbal learning 
and memory have been reported after multidisciplinary rehabilitation in patients with HD  
(Piira et al., 2013; Thompson et al., 2013; Zinzi et al., 2007). Methodologically robust studies 
with larger sample sizes, highly sensitive outcome measures, multiple assessment time points 
at baseline, more effective cognitive training exercises, longer duration interventions, and 
adequate follow up periods are nevertheless required to confirm and expand on this. Areas 
that warrant expansion include assessing the effects of multidisciplinary rehabilitation on 
sleep physiology, autonomic function, sexual behaviour, stress reactivity and cardiovascular 
function. These latter physiological and psychological processes are known to be perturbed in 
HD (Aziz et al., 2010a; Goodman et al., 2011; Jhanjee et al., 2011; Kobal et al., 2014; Mo et 
al., 2014; Morton, 2013; Zielonka et al., 2014), and can severely impact on quality of life. 
Observational evidence together with our exploratory findings indicates that lifestyle factors 
influence structural brain changes in a region dependent manner in HD (Bonner-Jackson et 
al., 2013b). Similar findings have been observed in other neurodegenerative disorders after 
cognitive and motor training interventions (Bonzano et al., 2014; Prosperini et al., 2014a; 
Sehm et al., 2014). These findings have significant clinical implications regarding the 
selection and modulation of non-pharmacological treatments for individuals with 
neurodegenerative disorders, particularly those with HD. Future studies should use targeted 
multidisciplinary rehabilitation interventions, encompassing specific rehabilitation 
components, with known benefits on the clinical and/or biological outcomes of interest.  
Significant volume loss can be observed in cortical and subcortical structures many years 
before clinical signs can be detected (Georgiou-Karistianis et al., 2013b; Georgiou-
Karistianis et al., 2013c; Georgiou-Karistianis et al., 2013d). This disconnect between 
structural brain changes and clinical signs have led to the speculation that compensatory 
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neural processes may be present during the early stages of disease (Georgiou-Karistianis et 
al., 2013b). fMRI has the capacity to detect alterations in brain function and may enable 
neural compensation mechanisms to be probed in HD (Gray et al., 2013b; Poudel et al., 2014; 
Poudel et al., 2013). It would be interesting to explore the effects of multidisciplinary 
rehabilitation on compensatory neural processes in individuals with pre-manifest and 
manifest HD.  
Longstanding evidence indicates that neuronal dysfunction precedes neuronal cell loss in HD 
(Georgiou-Karistianis et al., 2013c). Recent advances in imaging methods have enabled the 
quantification of neuronal dysfunction in pre-manifest and manifest HD, using fMRI 
(Georgiou-Karistianis et al., 2013b; Gray et al., 2013b; Poudel et al., 2014; Poudel et al., 
2013). Emerging evidence in other neurodegenerative disorders has shown that cognitive and 
motor training can have profound effects on neuronal function (Bonavita et al., 2014; Cerasa 
et al., 2013; Chiaravalloti, 2012; Filippi et al., 2012; Nombela et al., 2011; Parisi et al., 2014; 
Sastre-Garriga et al., 2011; van Paasschen et al., 2013). Future studies exploring the effects of 
multidisciplinary rehabilitation on neuronal function in individuals at risk or with pre-
manifest HD using fMRI methods would be of clinical interest.   
Recent evidence by our group and others indicates that multidisciplinary rehabilitation exerts 
favourable clinical and neurological benefits in people living with manifest HD (Piira et al., 
2013; Thompson et al., 2013; Veenhuizen et al., 2011; Zinzi et al., 2007). It is possible that 
multidisciplinary rehabilitation exerts these benefits by positively impacting on disease 
biology. Future studies investigating the effects of multidisciplinary rehabilitation on reliable 
biological markers of disease progression, clinical status and brain health are warranted. 
Candidate biological markers that could be utilised to assess the effects of multidisciplinary 
rehabilitation on disease biology include mhtt (Baldo et al., 2012; Weiss et al., 2012), BDNF 
(Zuccato et al., 2010), PGC-1α (Che et al., 2011; Taherzadeh-Fard et al., 2009), cortisol 
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(Shirbin et al., 2013a; Shirbin et al., 2013b; van Duijn et al., 2010), melatonin (Kalliolia et 
al., 2014; van Wamelen et al., 2013) and cholesterol (Karasinska and Hayden, 2011; Leoni 
and Caccia, 2014; Leoni et al., 2011).  
Finally, it is important to identify which components of multidisciplinary rehabilitation 
interventions produce favourable effects in people with HD. From a methodological 
perspective this would involve examining the independent effects of each of the 
multidisciplinary rehabilitation components (exercise [aerobic and resistance], dual task 
training [cued motor training], cognitive training [computerised cognitive training, video 
game playing, paper and pencil cognitive training, bilingual training and sign language 
training], occupational therapy [cooking, planning and social organisation], speech and 
language therapy, respiratory muscle training [inspiratory muscle training and expiratory 
muscle training] and proprioceptive training) in people with HD. Data collected from such 
studies would help optimise multidisciplinary rehabilitation programs for people living with 
HD. 
CHAPTER 8 – GENERAL CONCLUSION 
The work presented in this thesis shows for the first time that multidisciplinary rehabilitation 
can increase GM volume in structures known to degenerate in HD. Moreover, the present 
work shows that multidisciplinary rehabilitation improves muscle strength as well as some 
aspects of motor control, cognitive function and body composition. These findings, while 
preliminary, have significant clinical implications with respect to the treatment of people with 
manifest HD. Multidisciplinary treatment approaches may represent a viable therapeutic 
avenue for people living with HD. Future studies are urgently required to confirm and expand 
on our findings showing that multidisciplinary rehabilitation can have neurorestorative effects 
and improve clinical aspects of HD.  
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APPENDICES 
Appendix 1 Huntington’s Disease Trangenic Mouse Models 
 
Mouse 
Model 
(Strain) 
Genetic 
Characteristics 
Repeat 
Length 
Behavioural Phenotype Neurological Phenotype Survival Ref 
 
R6/2 
 
 
1kb sequence from exon 1 
of the human HTT gene 
 
 
~150 
 
Week 4.5 (wheel running 
deficits) 
 
Weeks 4-6 (hypoactivity; 
open field testing) 
 
Week 5 (morris water maze 
deficits) 
 
Week 6 (rotarod deficits) 
 
11-13 weeks (visual learning 
task deficits) 
Decreased brain weight 
 
Lateral ventricular enlargement 
 
MSN dendrite diameter and 
spine density decreases 
 
NIIs appear by 4 weeks 
10-13 weeks 
 
(Mangiarini et al., 
1996) 
(Carter et al., 1999) 
(Davies et al., 1997) 
(Turmaine et al., 2000) 
 
R6/1 
 
1kb sequence from exon 1 
of the human HTT gene 
 
 
116 
 
Week 13 (horizontal rod 
deficits) 
 
Week 18 (rotarod deficits) 
 
Weeks 14-20 (clasping 
phenotype) 
NIIs appear by 20 weeks 
 
32 weeks dendritic spine 
atrophy 
32-40 weeks 
 
(Mangiarini et al., 
1996) 
(Carter et al., 1999) 
(Davies et al., 1997) 
(Turmaine et al., 2000) 
 
 
N171-82Q 
 
N-terminal fragments of 
the first 171 AA  of human 
HTT (exons 1, 2 and part 
of 3) 
 
82 
12 weeks (rotarod deficits) 
17 weeks striatal degeneration 
ventricular enlargement 
 
24-30 weeks 
(Schilling et al., 1999) 
(Luthi-Carter et al., 
2000) 
HTT, Huntingtin gene, AA, amino acids, NIIs, neuronal intranuclear inclusion, MSN, medium spiny neuron
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Appendix 2 Participant Information Sheet 
Project: The Effects of Environmental Enrichment on Clinical Measures of Disease 
Progression and Quality of Life for Patients with Huntington’s Disease.  
Senior Investigators: Prof Mel Ziman, Dr Jennifer Thompson, Mr Travis Cruickshank, Prof 
Roger Barker, Dr Carmela Connor, Dr Joseph Lee, Prof Anthony Hannan, Dr Sonya Girdler, 
Professor Rob Newton, Dr Stanley Lazic. 
Please take time to read the following information carefully and discuss it with your friends, 
family and clinician if you wish. Ask us any question if some part of the information is not 
clear to you or if you would like more information. Please do this before you sign this consent 
form. 
Who is funding this study and where will it be conducted? 
This study is a joint collaboration between Huntington’s WA (Inc.), Edith Cowan University, 
the Neurosciences Unit, the Howard Florey Institute (Melbourne), the Centre for Brain 
Repair at the University of Cambridge and the Brightwater Group, and it has been funded by 
Lotterywest. It will be conducted at Edith Cowan University. 
Contact persons: 
Should you have any questions about the study you may contact: 
Dr Jennifer Thompson:  Phone 6304 5635   Email  jennifer.thompson@ecu.edu.au  or 
Associate Professor Mel Ziman: Phone 6304 5171   Email m.ziman@ecu.edu.au    
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All study participants will be provided with a copy of the Participant Information Sheet and 
Participant Consent Form for their personal records. 
You may decide to be in the study or not take part at all. If you do decide to take part in this 
study, you may stop at any time or you may withdraw from any one procedure at any time.  
However, before you decide, it is important that you understand why this research is being 
done and what it will involve.  Whatever your decision, this decision will not lead to any 
penalty or affect your regular medical care or any benefit to which you are otherwise entitled. 
The following Information Sheet will explain the study and will include details such as: 
 What is the purpose of the study 
 Why this trial might be suitable for you; 
 The possible risks (side-effects) and benefits of the intervention; 
 The nature of your participation; 
 The type and frequency of any tests or procedures required by the trial; 
 What are the costs to me; 
 Your rights and responsibilities; 
 What if something goes wrong; 
 How will my safety be ensured; 
 Will I find out the results of the study; 
 Who is funding the study. 
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What is the purpose of the study? 
This study is a research project in which we are investigating the effects of mental and 
physical stimulation (environmental enrichment) on the progression of Huntington’s disease. 
This research project intends to implement a therapeutic intervention strategy for patients 
with Huntington’s disease which is centred on mental and physical stimulation as a method 
for reducing symptoms of the disease and improving quality of life for patients.   
Why is this study suitable for me? 
You have been invited to participate in this study because you have been diagnosed with 
Huntington’s disease, and you currently display symptoms of the disease. 
What are the possible benefits of taking part in this research study? 
The results of this study may be of interest to you and your family, and you may decide on 
whether or not the information may be disclosed to your family. You may experience an 
improvement in the symptoms of your disease.  Also, your participation in this research study 
may assist researchers and health care providers to provide better treatment for people with 
Huntington’s disease in the future. 
How long will I be in this study and how will I participate? 
If you agree to participate you will be randomly assigned to a research group with either a 
therapeutic intervention strategy or no therapeutic intervention strategy, and you will 
participate in a number of tests throughout the study to assess changes in the progression of 
the disease. You will be asked to wear an Actiwatch throughout the study which measures 
your physical activity, and provide blood/saliva samples at various stages of the research 
study. Instigation of the study: Tests such as clinical assessment, questionnaires and 
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MRI/DEXA (X-ray) scans will be performed at the beginning of the study as a baseline 
measure of the status of the disease. You will be asked to provide a blood/saliva sample at 
this stage.   
6 months: You will be asked to undergo the same tests as above and provide a blood/saliva 
sample.   
6-18 months: Depending on the research group to which you are assigned, you may or may 
not be treated for 12 months with an environmental enrichment intervention strategy which 
will entail performing a number of physical and mental stimulation strategies each week. At 
the end of a six month period, you will undergo clinical assessment and questionnaires. At 
the end of the full intervention/no intervention period of 12 months, you will be asked to 
undergo the final clinical assessment, questionnaires and MRI/DEXA (X-ray) scans, and 
provide a blood/saliva sample.  
Overall, participants will be involved for a period of 18 months. Participation will require 
about 9 hours per week for the intervention strategy, and about 2 half days every six months 
for the assessments. If you have a carer, they will also be asked to participate in this research 
study. 
What will happen if I decide to be in this study? 
The study will be conducted over a 2 year period, with participants involved over 18 months. 
Participants who are assigned to the intervention group will perform mental and physical 
stimulation tasks over a 12 month period. These will be performed at Edith Cowan University 
and at home. During this time, you will receive phone calls or visits from a trained scientist to 
monitor your progress and participation in the research program. 
As detailed above, you will take part in a variety of assessments throughout the study:- 
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 Clinical assessments will be performed by a neurologist to assess the status of the 
disease. These assessments will be conducted at 0, 6, 12 and 18 months. These 
assessments are mostly the same as the normal assessments you currently receive. 
These assessments may be videorecorded for further analysis. 
 You will complete questionnaires assisted by a trained scientist at 0, 6, 12 and 18 
months. These questionnaires are mostly the same as the normal questionnaires you 
currently participate in. If you have a carer, they will be asked to answer two 
questionnaires at these times. 
 MRI and DEXA (X-ray) scans will be performed at 0, 6 and 18 months. 
 You will perform balance tests at 0, 6 and 18 months. 
 Blood/saliva samples will be taken at 0, 6 and 18 months for physiological 
assessment. The amount of blood taken will be small (20mls per visit). Blood will be 
drawn into two tubes. You will be required to chew swabs a couple of times 
throughout one day for saliva samples. Because your blood/saliva samples will only 
be identifiable by a coded number, the researchers performing the tests will not know 
which sample is yours. Samples will be analysed immediately and will not be stored 
during the research study. 
You may choose to attend voluntary workshops to be updated on the progress of the study 
and to discuss with the research scientists any problems you or your family/carers may be 
experiencing with the research study. You may contact the researchers at any time during the 
study if you require any further general information. 
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Are there any reasons I should not be in this study? 
The clinical staff collaborating in this research study will discuss these with you in detail and 
will ensure that this trial is both safe and appropriate for you. 
What are the costs to me? 
There will be no additional costs to you for participating in this research study. Blood 
samples will be taken at Edith Cowan University when you visit for your assessments. All 
transportation costs will be reimbursed by Edith Cowan University, or taxi vouchers will be 
provided for travel to and from the University where necessary. 
What are the possible benefits of taking part in this research project? 
The results of this study may be of interest to you as the carer of a person with Huntington’s 
disease. By participating in this research, you may be assisting patients to obtain an 
improvement in the symptoms of their disease. Also, your participation in this research study 
may assist researchers and health care providers to provide better treatment for people with 
Huntington’s disease in the future. 
How will my safety be ensured? 
In this study, the sample that you provide is a blood or saliva sample and there is very little 
risk to you in this procedure as only a small volume of blood or saliva is required for the test.  
Exercise treatments will be supervised by an experienced exercise physiologist, and you will 
be instructed on the correct warming up and cooling down procedures to minimise any 
discomfort from the exercise regime. All occupational therapy tasks will be supervised by an 
experienced occupational therapist. Scans will be performed by appropriately qualified health 
care professionals.  However, please do not hesitate to contact the study co-ordinator or your 
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doctor in relation to any adverse effects you think you are experiencing. If the effects are 
severe enough, your doctor may stop your participation in the study. 
What alternatives do I have to going on this study? 
Your participation in this research study is voluntary. This study will not affect your 
treatment. Your treatment will continue in the same manner whether you decide to participate 
in the study or not. 
You may wish to discuss with your doctor or the researchers how the test will benefit patient 
treatment in the future. 
What are the possible side effects, risks and discomforts of taking part? 
In this study, only a small volume of blood is taken (20 mls) at three different intervals 
throughout the study. There is very little risk to you in this procedure as only a small volume 
of blood is required. You may suffer a small amount of discomfort when you donate the 
blood sample, like the feeling of a pinprick. The likelihood of side effects from donating 
blood is small, around 1 in 100. However, should you suffer any side effects or experience 
any new or unusual symptoms, please tell your doctor immediately. 
There are minor risks associated with MRI and DEXA scans; the use of appropriately 
qualified personnel reduces these risks. These risks will be discussed with you by a doctor. 
You may experience minor discomfort during the performance of the physical exercises if 
you participate in the intervention strategy. Should you experience excessive discomfort 
during the performance of the physical exercises, or you do not feel comfortable, please 
inform the exercise physiologist immediately.   
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You may experience general body soreness if you participate in the exercise therapy. This is 
normal after performing physical exercises that you are not used to. Should you suffer 
excessive discomfort or experience any new or unusual symptoms, please tell your doctor 
immediately.   
The researchers acknowledge that should this intervention therapy prove to be unsuccessful, 
or you do not experience as good a benefit as you anticipate you are going to achieve, that 
you may feel depressed or unhappy. Throughout this project, levels of depression will be 
assessed by a clinician and will be treated as the clinician deems necessary. 
What if new information comes along during the study? 
Sometimes, new information about an intervention or disease becomes available as a study 
progresses. You will be told about any information that could be important to you and to your 
decision to continue in the study. If you then want to continue in the trial, you may be asked 
to sign a revised consent form. 
Stopping the study early: 
Sometimes a trial needs to be stopped early because of safety concerns, because the trial is 
not effective enough, or for other reasons. If this occurs, the reasons will be explained to you 
and your treatment will continue as it would have without the test. Your treatment will not be 
influenced by participating in the research study in anyway. 
What if something goes wrong? 
You will receive the best medical care available during and after the intervention and/or tests. 
However, unexpected results may be obtained. In the unlikely event of risks to your health 
being identified, then you will be provided with the necessary care. 
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Medical treatment will be provided at no cost to you for research-related harm. The term 
“research-related harm” means both physical and mental injury caused by the product or 
procedures that are required by this trial. 
Your participation in this study does not prejudice any right to compensation which you may 
have under statute or common law. 
Will my taking part in this study be kept confidential? 
The researchers will need to collect personal data about you, which may be sensitive, such as 
your relevant health information. The researchers may also need to get some of your health 
information from other health service providers, eg another hospital, pathology laboratory, 
radiographer, GP or other medical specialist. 
Any personal or health information will be kept private and confidential. It will be stored 
securely and only authorised persons, who understand it must be kept confidential, will have 
access to it. Your study details will be given a number so that your identity will not be 
apparent. The trial records will be kept at the School of Exercise, Biomedical and Health 
Science at Edith Cowan University during the study and in a locked archive for at least 5 
years and for a maximum of 15 years from the time the study is closed, and may be destroyed 
at any time thereafter. 
Authorised representatives of the researchers, the investigating doctors, or University Human 
Research Ethics Committees, and other regulatory bodies may require access to your study 
records to verify study procedures and/or data. In all cases, when dealing with your 
information these people are required to comply with privacy laws that protect you. 
The results of the research will be made available to other doctors through medical journals 
or meetings, but you will not be identifiable in these communications.  By taking part in this 
176 
 
study, you agree not to restrict the use of any data even if you withdraw. Your rights under 
any applicable data protection laws are not affected. 
Will I find out the results of the study? 
The value of the research is not known at this time. You will be notified of the results of the 
research in general terms at your request and the outcomes of the research as a whole may be 
provided to you upon completion of the project. 
What happens at the end of the study? 
At the end of the study your visits to your doctor will continue and your treatment will not be 
compromised in any way by participating in this research study. Your doctor may adjust your 
medication as he/she feels appropriate depending on the outcome of the study. 
Who has reviewed the study? 
The Edith Cowan University Human Research Ethics Committee and the North Metropolitan 
Area Mental Health Service Human Research Ethics Committee have reviewed this study and 
have given approval for the conduct of this research trial. In doing so, this study conforms to 
the principles set out by the National Statement on Ethical Conduct in Human Research and 
according to the Good Clinical Practice Guidelines.  
If you have any questions or require any further information about the research project, 
please contact: 
Dr Jennifer Thompson:  Phone 6304 5635    Email jennifer.thompson@ecu.edu.au  or 
Associate Professor Mel Ziman:  Phone 6304 5171   Email m.ziman@ecu.ed.au     
If you have any concerns or complaints about the research project and wish to talk to an 
independent person, you may contact: 
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Research Ethics Officer, 
  Edith Cowan University, 
270 Joondalup Drive, 
JOONDALUP  WA  6027 
Phone (08) 6304 2170 
Email: research.ethics@ecu.edu.au 
OR The Secretary, 
North Metropolitan Area Mental Health Service Human Research Ethics 
Committee, 
Private Bag No 1, 
CLAREMONT  WA  6910 
Phone (08) 9347 6618 
 
All study participants will be provided with a copy of the Participant Information Sheet 
and Participant Consent Form for their personal records. 
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Appendix 3: Participant Consent Form                                             PLEASE TICK  
1. I have read and understood the ‘Participant Information Sheet’ for this 
study. 
2. The nature and possible effects of the study have been explained to me. 
3. I understand that the study involves the following procedures: 
a. I will be required to obtain medical approval to undertake the study 
before any measures or training can take place. 
b. I will be randomly assigned to one of the following two groups:  
(1) Therapeutic intervention group (including occupational therapy and 
exercise tasks) or  
(2) no therapeutic intervention group (no occupational therapy or 
exercise tasks). 
c. I will be required to have my cerebral volume (MRI scan), height, 
weight, body composition (DEXA scan), and blood/saliva analysis 
(insulin/c-peptide, glucose, cortisol) assessed before, during and after 
the study period (at 0, 6 and 18 months).  
d. I understand that as a measure of physical function, my balance ability 
will be assessed before, during and after the study (at 0, 6 and 18 
months).  
e. I will be required to complete quality of life questionnaires and undergo 
cognitive testing before, during and after the study period (at 0, 6, 12 
and 18 months).  I understand that most of these tests are performed as 
Y         N 
Y         N
Y         N 
Y         N 
Y         N 
Y         N 
Y         N 
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part of my normal medical care, and if I participate in this research 
study without participating in the intervention, these tests will be 
undertaken as per my normal care regime. I understand that some of the 
cognitive tests may be videorecorded for analysis purposes. 
4. I understand that I will be required to wear an Actiwatch throughout the 
timeframe of the research study. 
5. I agree to my carer participating in this research project by completing 
questionnaires about my health status, and give permission for them to do so. 
This study has been approved by the Human Research Ethics Committees at 
Edith Cowan University and the North Metropolitan Area Mental Health 
Service. Should there be any concerns relating to the project, you can contact 
the Edith Cowan University Ethics Officer at (08) 6304 2170 or Email: 
research.ethics@ecu.edu.au or the Secretary, North Metropolitan Area Mental 
Health Service Human Research Ethics Committee at (08) 9347 6618 or by 
mail to Private Mail Bag No. 1, Clarement WA 6910. 
Any questions concerning the project entitled “The effects of environmental 
enrichment on clinical measures of disease progression and quality of life for 
patients with Huntington’s disease” can be directed to Dr Jennifer Thompson 
(Postdoctoral Research Fellow) Phone 6304 5635 or Email 
jennifer.thompson@ecu.edu.au, or Associate Professor Mel Ziman (Principal  
Investigator) Phone 6304 5171 or Email m.ziman@ecu.edu.au of the School of 
Exercise, Biomedical and Health Sciences, Edith Cowan University, 
Joondalup.   
Y         N 
Y         N 
Y         N 
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Appendix 4: Statement of Informed Consent 
I (the participant) have read the information above and any questions I have 
asked have been answered to my satisfaction. I agree to participate in this 
activity, realizing that I may withdraw at any time. 
I agree the research data gathered for this study may be published provided my 
name is not used. 
I understand that the information I provide will be kept in the strictest 
confidence by the researchers, unless obliged to release by law. 
Name (please print) _______________________________________________ 
Signed______________________________             Date_________________ 
                 
 Participant or Authorised Representative 
 
Contact Phone Number________________________________________________________ 
Are you currently participating in any other research project?  
Investigator (Name, please print)________________________________________________ 
Signed _________________________________________ Date ____________________  
 
 
Y         N 
Y         N 
Y         N 
Y         N 
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Appendix 5: Carer Information Sheet 
Project: The Effects of Environmental Enrichment on Clinical Measures of Disease 
Progression and Quality of Life for Patients with Huntington’s Disease.  
Senior Investigators: Prof Mel Ziman, Dr Jennifer Thompson, Mr Travis Cruickshank, Prof 
Roger Barker, Dr Carmela Connor, Dr Joseph Lee, Prof Anthony Hannan, Dr Sonya Girdler, 
Professor Rob Newton, Dr Stanley Lazic. 
Please take time to read the following information carefully and discuss it with your friends, 
family and clinician if you wish. Ask us any question if some part of the information is not 
clear to you or if you would like more information. Please do this before you sign this consent 
form. 
Who is funding this study and where will it be conducted? 
This study is a joint collaboration between Huntington’s WA (Inc.), Edith Cowan University, 
the Neurosciences Unit, the Howard Florey Institute (Melbourne), the Centre for Brain 
Repair at the University of Cambridge and the Brightwater Group, and it has been funded by 
Lotterywest.  It will be conducted at Edith Cowan University. 
Contact persons: 
Should you have any questions about the study you may contact: 
Dr Jennifer Thompson:  Phone 6304 5635   Email  jennifer.thompson@ecu.edu.au  or 
Associate Professor Mel Ziman: Phone 6304 5171   Email m.ziman@ecu.edu.au    
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All study participants will be provided with a copy of the Participant Information Sheet and 
Participant Consent Form for their personal records. 
You may decide to be in the study or not take part at all.  If you do decide to take part in this 
study, you may stop at any time or you may withdraw from any one procedure at any time. 
However, before you decide, it is important that you understand why this research is being 
done and what it will involve. Whatever your decision, this decision will not lead to any 
penalty or affect your regular medical care or any benefit to which you are otherwise entitled. 
.The following Information Sheet will explain the study and will include details such as: 
 Why this trial might be suitable for you; 
 The possible benefits of taking part in this research study; 
 The nature of your participation; 
 The type and frequency of any assistance you may be required to give; 
 What are the costs to me; 
 Your rights and responsibilities; 
 Will I find out the results of the study; 
 Will my taking part in this study be kept confidential; 
 Who is funding the study; 
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What is the purpose of the study? 
This study is a research project in which we are investigating the effects of mental and 
physical stimulation (environmental enrichment) on the progression of Huntington’s disease. 
This research project intends to implement a therapeutic intervention strategy for patients 
with Huntington’s disease which is centred on mental and physical stimulation as a method 
for reducing symptoms of the disease and improving quality of life for patients.   
Why is this study suitable for me? 
You have been invited to participate in this study because you are the carer of a patient that 
has been diagnosed with Huntington’s disease that currently displays symptoms of the 
disease. 
How long will I be in this study and how will I participate? 
If you agree to participate, you will be asked to assist the research participant to take part in 
an intervention strategy (if they are assigned to the intervention group) by attending exercise 
and occupational therapy classes and assisting the participant to perform these tasks at home 
during the week. You may be asked to assist the research participant to attend a number of 
tests and scans throughout the study to assess changes in the progression of the disease. You 
will be asked to assist the participant to comply with wearing an Actiwatch throughout the 
study which measures their physical activity, and you will be asked to complete two 
questionnaires at each timeframe before, during and after the study. Instigation of the study: 
Tests such as clinical assessment, questionnaires, MRI/DEXA (X-ray) scans and blood/saliva 
tests will be performed at the beginning of the study as a baseline measure of the status of the 
disease. You will be asked to complete the questionnaires and assist the participant to attend 
appointments at this stage.   
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6 months: You will be asked to participate in the same manner as above.   
6-18 months: If the participant is assigned to the intervention group, they will perform a 
number of physical and mental stimulation strategies each week for a 12 month period. At the 
end of a six month period (at 12 months), whether they have participated in the intervention 
strategy or not, the participant will undergo clinical assessment and questionnaires. At the 
end of the full period of 12 months (at 18 months), they will be asked to undergo the final 
clinical assessment, questionnaires, MRI/DEXA (X-ray) scans and blood/saliva tests. You 
will assist the participant in their performance of these tasks at home, and you may attend 
classes and appointments for tests and scans. You will also be required to complete two 
questionnaires each at 12 months and 18 months. 
Overall, participants will be involved for a period of 18 months. Participation will require 
about 9 hours per week for the intervention strategy, and about 2 half days every six months 
for the assessments. 
What are the possible benefits of taking part in this research study? 
The results of this study may be of interest to you as the carer of a person with Huntington’s 
disease. By participating in this research, you may be assisting patients to obtain an 
improvement in the symptoms of their disease. Also, your participation in this research study 
may assist researchers and health care providers to provide better treatment for people with 
Huntington’s disease in the future. 
What will happen if I decide to be in this study? 
The study will be conducted over a 2 year period, with participants involved over 18 months. 
Participants who are assigned to the intervention group will perform mental and physical 
stimulation tasks over a 12 month period. These will be performed at Edith Cowan University 
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and at home. During this time, you will assist the participant to perform these tasks and attend 
appointments and you will receive phone calls or visits from a trained scientist to monitor the 
progress and participation in the research program. 
As detailed above, you will assist in a variety of assessments throughout the study:- 
 Clinical assessments will be performed by a neurologist to assess the status of the 
disease.  These assessments will be conducted at 0, 6, 12 and 18 months.  These 
assessments are mostly the same as the normal assessments the participant currently 
receives.  You may be required to assist the participant to attend these assessments. 
 You will complete two questionnaires assisted by a trained scientist at 0, 6, 12 and 18 
months.   
 MRI and DEXA (X-ray) scans will be performed at 0, 6 and 18 months. You may 
assist the participant to attend these scans. 
 The participant will perform balance tests and have blood/saliva samples taken at 0, 6 
and 18 months.  You may assist the participant to attend these tests. 
You may choose to attend voluntary workshops to be updated on the progress of the study 
and to discuss with the research scientists any problems the participant or you may be 
experiencing with the research study. You may contact the researchers at any time during the 
study if you require any further general information. 
What are the costs to me? 
There will be no additional costs to you for participating in this research study. All 
transportation costs will be reimbursed by Edith Cowan University, or taxi vouchers will be 
provided for travel to and from the University where necessary. 
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What alternatives do I have to going on this study? 
Your participation in this research study is voluntary. This study will not affect the 
participant’s treatment, which will continue in the same manner whether you decide to 
participate in the study or not. 
You may wish to discuss with your doctor or the researchers how the test will benefit patient 
treatment in the future. 
What if new information comes along during the study? 
Sometimes, new information about an intervention or disease becomes available as a study 
progresses. You will be told about any information that could be important to you and the 
participant, and to your decision to continue in the study. If you then want to continue in the 
trial, you may be asked to sign a revised consent form. 
Stopping the study early: 
Sometimes a trial needs to be stopped early because of safety concerns, because the trial is 
not effective enough, or for other reasons. If this occurs, the reasons will be explained to you 
and the participant’s treatment will continue as it would have without the test. The treatment 
will not be influenced by the research study in anyway. 
Will my taking part in this study be kept confidential? 
Any information that you provide will be kept private and confidential. It will be stored 
securely and only authorised persons, who understand it must be kept confidential, will have 
access to it. The participant’s details will be given a number so that their or your identity will 
not be apparent. The trial records will be kept at the School of Exercise, Biomedical and 
Health Science at Edith Cowan University during the study and in a locked archive for at 
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least 5 years and for a maximum of 15 years from the time the study is closed, and may be 
destroyed at any time thereafter. 
Authorised representatives of the researchers, the investigating doctors, or University Human 
Research Ethics Committees, and other regulatory bodies may require access to the study 
records to verify study procedures and/or data. In all cases, when dealing with the 
information you provide, these people are required to comply with privacy laws that protect 
you. 
The results of the research will be made available to other doctors through medical journals 
or meetings, but you or the participant will not be identifiable in these communications. By 
taking part in this study, you agree not to restrict the use of any data even if you withdraw.  
Your rights under any applicable data protection laws are not affected. 
Will I find out the results of the study? 
The value of the research is not known at this time. You will be notified of the results of the 
research in general terms at your request and the outcomes of the research as a whole may be 
provided to you upon completion of the project. 
Who has reviewed the study? 
The Edith Cowan University Human Research Ethics Committee and the North Metropolitan 
Area Mental Health Service Human Research Ethics Committee have reviewed this study and 
have given approval for the conduct of this research trial. In doing so, this study conforms to 
the principles set out by the National Statement on Ethical Conduct in Human Research and 
according to the Good Clinical Practice Guidelines.  
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If you have any questions or require any further information about the research project, 
please contact: 
Dr Jennifer Thompson:  Phone 6304 5635    Email jennifer.thompson@ecu.edu.au  or 
Associate Professor Mel Ziman:  Phone 6304 5171   Email m.ziman@ecu.ed.au     
If you have any concerns or complaints about the research project and wish to talk to an 
independent person, you may contact: 
  Research Ethics Officer, 
  Edith Cowan University, 
270 Joondalup Drive, 
JOONDALUP  WA  6027 
Phone (08) 6304 2170 
Email: research.ethics@ecu.edu.au 
 
OR The Secretary, 
North Metropolitan Area Mental Health Service Human Research Ethics 
Committee, 
Private Bag No 1, 
CLAREMONT  WA  6910 
Phone (08) 9347 6618 
 
All carer participants will be provided with a copy of the Carer Information Sheet and 
Carer Consent Form for their personal records. 
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Appendix 6: Carer Consent form                                                      PLEASE TICK 
1. I have read and understood the ‘Carer Information Sheet’ for this study. 
2. The nature and possible effects of the study have been explained to me. 
3. I understand that the study involves the following procedures: 
a. I will be required to complete quality of life questionnaires before, during 
and after the study period (at 0, 6, 12 and 18 months). 
b. I may be required to attend appointments for tests and scans with the 
participant before, during and after the study period (at 0, 6 and 18 months).  
c. If the participant is assigned to the intervention group, I may be required 
to attend the exercise and occupational therapy classes.   
d. If the participant is assigned to the intervention group, I will be required 
to assist the participant in performing exercise and occupational therapy tasks 
at home.  I understand that I will be instructed on how to assist the participant. 
4. I understand that the participant will be required to wear an Actiwatch 
throughout the timeframe of the research study, and I may be required to assist 
with compliance in this regard. 
This study has been approved by the Human Research Ethics Committees at 
Edith Cowan University and the North Metropolitan Area Mental Health 
Service. Should there be any concerns relating to the project, you can contact 
the Edith Cowan University Ethics Officer at (08) 6304 2170 or Email: 
research.ethics@ecu.edu.au or the Secretary, North Metropolitan Area Mental 
Y         N 
Y         N 
Y         N 
Y         N 
Y         N 
Y         N 
Y         N 
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Health Service Human Research Ethics Committee at (08) 9347 6618 or by 
mail to Private Mail Bag No. 1, Clarement WA 6910. 
Any questions concerning the project entitled “The effects of environmental 
enrichment on clinical measures of disease progression and quality of life for 
patients with Huntington’s disease” can be directed to Dr Jennifer Thompson 
(Postdoctoral Research Fellow) Phone 6304 5635 or Email 
jennifer.thompson@ecu.edu.au, or Associate Professor Mel Ziman (Principal  
Investigator) Phone 6304 5171 or Email m.ziman@ecu.edu.au of the School of 
Exercise, Biomedical and Health Sciences, Edith Cowan University, 
Joondalup.   
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Appendix 7: Statement of Informed Consent 
I (the carer) have read the information above and any questions I have asked have been 
answered to my satisfaction. I agree to participate in this activity with the participant’s 
consent, realizing that I may withdraw at any time. 
I understand that the information I provide will be kept in the strictest confidence by the 
researchers, unless obliged to release by law. 
I agree to participate in this research study by completing quality of life questionnaires and 
assisting the study participant to take part in this research project. 
Name of Carer (please print)  _________________________________________________ 
Signed _____________________________________________ Date _______________ 
Contact Phone Number ______________________________________________________ 
 
Investigator (Name, please print)_______________________________________________ 
Signed _____________________________________________ Date _______________ 
 
 
 
Y         N 
Y         N
Y         N 
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Appendix 8 Example page of the exercise diary 
 
Week  
Date 
Exercises 
Comments 
 
 
Day 
Leg 
Extension 
Leg 
Flexion 
Calve 
Raise 
Leg 
Abduction 
Leg 
Adduction 
Theraband 
Row 
(e.g. experienced pain, fatiguing, 
easy to perform, hard to 
perform) 
 
Monday 
         
Tuesday 
         
Wednesday 
         
Thursday 
         
Friday 
         
Saturday 
         
Sunday 
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Appendix 9 Statement of Contribution by Others (Study 2) 
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Appendix 10 Statement of Contribution by Others (Study 3) 
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